WO2015197919A1 - Antibody drug conjugates binding to high-mannose n-glycan - Google Patents
Antibody drug conjugates binding to high-mannose n-glycan Download PDFInfo
- Publication number
- WO2015197919A1 WO2015197919A1 PCT/FI2015/050466 FI2015050466W WO2015197919A1 WO 2015197919 A1 WO2015197919 A1 WO 2015197919A1 FI 2015050466 W FI2015050466 W FI 2015050466W WO 2015197919 A1 WO2015197919 A1 WO 2015197919A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- binding agent
- binding
- group
- sequence
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 211
- 229940049595 antibody-drug conjugate Drugs 0.000 title description 10
- 239000000611 antibody drug conjugate Substances 0.000 title description 9
- 239000011230 binding agent Substances 0.000 claims abstract description 166
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims abstract description 67
- 210000004027 cell Anatomy 0.000 claims description 145
- 230000004988 N-glycosylation Effects 0.000 claims description 86
- 238000006467 substitution reaction Methods 0.000 claims description 78
- 206010028980 Neoplasm Diseases 0.000 claims description 51
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 201000011510 cancer Diseases 0.000 claims description 42
- 125000000539 amino acid group Chemical group 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 229940024606 amino acid Drugs 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 231100000331 toxic Toxicity 0.000 claims description 31
- 230000002588 toxic effect Effects 0.000 claims description 31
- -1 maytansinoid Chemical compound 0.000 claims description 30
- 229960005395 cetuximab Drugs 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 27
- 241000282414 Homo sapiens Species 0.000 claims description 25
- 125000005647 linker group Chemical group 0.000 claims description 24
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 23
- 150000001412 amines Chemical class 0.000 claims description 23
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 21
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 20
- 239000013604 expression vector Substances 0.000 claims description 20
- 235000018102 proteins Nutrition 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 229960005501 duocarmycin Drugs 0.000 claims description 14
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 14
- 229930184221 duocarmycin Natural products 0.000 claims description 14
- 150000001720 carbohydrates Chemical group 0.000 claims description 13
- 125000000524 functional group Chemical group 0.000 claims description 13
- 229950005646 imgatuzumab Drugs 0.000 claims description 13
- 229950008001 matuzumab Drugs 0.000 claims description 13
- 229960000513 necitumumab Drugs 0.000 claims description 13
- 229950010203 nimotuzumab Drugs 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 229950008250 zalutumumab Drugs 0.000 claims description 13
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 12
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 12
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 150000001345 alkine derivatives Chemical class 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 229960001972 panitumumab Drugs 0.000 claims description 12
- 238000003259 recombinant expression Methods 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 11
- 102220633168 Hexokinase-4_I19N_mutation Human genes 0.000 claims description 11
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 11
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 11
- 229930188854 dolastatin Natural products 0.000 claims description 11
- 230000000087 stabilizing effect Effects 0.000 claims description 11
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 10
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 10
- 229960001230 asparagine Drugs 0.000 claims description 10
- 235000009582 asparagine Nutrition 0.000 claims description 10
- 150000001540 azides Chemical class 0.000 claims description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 10
- 150000003573 thiols Chemical class 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims description 9
- 150000001299 aldehydes Chemical class 0.000 claims description 9
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 9
- 150000002576 ketones Chemical class 0.000 claims description 9
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 8
- 150000001336 alkenes Chemical class 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 102220427208 c.233T>C Human genes 0.000 claims description 7
- 229950003135 margetuximab Drugs 0.000 claims description 7
- 229960002087 pertuzumab Drugs 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 229960000575 trastuzumab Drugs 0.000 claims description 7
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 6
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 6
- 239000005864 Sulphur Substances 0.000 claims description 6
- 229960001904 epirubicin Drugs 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 150000002482 oligosaccharides Polymers 0.000 claims description 6
- 150000002923 oximes Chemical class 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
- 206010057644 Testis cancer Diseases 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 229950008579 ertumaxomab Drugs 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 201000003120 testicular cancer Diseases 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 239000002262 Schiff base Substances 0.000 claims description 4
- 150000004753 Schiff bases Chemical class 0.000 claims description 4
- 238000005865 alkene metathesis reaction Methods 0.000 claims description 4
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 4
- 150000007857 hydrazones Chemical class 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- 150000003512 tertiary amines Chemical class 0.000 claims description 4
- 150000007970 thio esters Chemical class 0.000 claims description 4
- 150000003568 thioethers Chemical class 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 102220569061 Mitochondrial Rho GTPase 2_T18N_mutation Human genes 0.000 claims description 3
- 102220468936 Protein unc-13 homolog A_E80N_mutation Human genes 0.000 claims description 3
- 108010044540 auristatin Proteins 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 102100026608 Aldehyde dehydrogenase family 3 member A2 Human genes 0.000 claims description 2
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 2
- 102000051957 human ERBB2 Human genes 0.000 claims description 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 45
- 239000000562 conjugate Substances 0.000 description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 230000000875 corresponding effect Effects 0.000 description 21
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 16
- 229910001868 water Inorganic materials 0.000 description 15
- 239000012071 phase Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000002285 radioactive effect Effects 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000001268 conjugating effect Effects 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 150000003335 secondary amines Chemical group 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 6
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 125000003277 amino group Chemical group 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 6
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 6
- 229960005558 mertansine Drugs 0.000 description 6
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- HEYJIJWKSGKYTQ-DPYQTVNSSA-N (2r,3s,4s,5r)-6-azido-2,3,4,5-tetrahydroxyhexanal Chemical compound [N-]=[N+]=NC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O HEYJIJWKSGKYTQ-DPYQTVNSSA-N 0.000 description 5
- LQKSHSFQQRCAFW-UHFFFAOYSA-N Dolastatin 15 Natural products COC1=CC(=O)N(C(=O)C(OC(=O)C2N(CCC2)C(=O)C2N(CCC2)C(=O)C(C(C)C)N(C)C(=O)C(NC(=O)C(C(C)C)N(C)C)C(C)C)C(C)C)C1CC1=CC=CC=C1 LQKSHSFQQRCAFW-UHFFFAOYSA-N 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- LQKSHSFQQRCAFW-CCVNJFHASA-N [(2s)-1-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-3-methyl-1-oxobutan-2-yl] (2s)-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H]1N(C(=O)C=C1OC)C(=O)[C@@H](OC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](C(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C)C(C)C)C(C)C)C1=CC=CC=C1 LQKSHSFQQRCAFW-CCVNJFHASA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 229940125782 compound 2 Drugs 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000010474 transient expression Effects 0.000 description 5
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
- 239000005695 Ammonium acetate Substances 0.000 description 4
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 235000019257 ammonium acetate Nutrition 0.000 description 4
- 229940043376 ammonium acetate Drugs 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 4
- 108010045552 dolastatin 15 Proteins 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 102200081893 rs137854510 Human genes 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical group CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 3
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 3
- 0 *[C@]([C@](*)O[C@](*)(C1)C(O)=O)[C@@]1O Chemical compound *[C@]([C@](*)O[C@](*)(C1)C(O)=O)[C@@]1O 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- OFDNQWIFNXBECV-UHFFFAOYSA-N Dolastatin 10 Natural products CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)CC)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 239000012743 FreeStyle Max reagent Substances 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 239000012515 MabSelect SuRe Substances 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101100395824 Solanum lycopersicum HSC-2 gene Proteins 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 101710120037 Toxin CcdB Proteins 0.000 description 3
- HSCJRCZFDFQWRP-ABVWGUQPSA-N UDP-alpha-D-galactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-ABVWGUQPSA-N 0.000 description 3
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 3
- 229940072107 ascorbate Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012650 click reaction Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 108010045524 dolastatin 10 Proteins 0.000 description 3
- OFDNQWIFNXBECV-VFSYNPLYSA-N dolastatin 10 Chemical group CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 OFDNQWIFNXBECV-VFSYNPLYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 229960004198 guanidine Drugs 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 230000009450 sialylation Effects 0.000 description 3
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 3
- 235000010378 sodium ascorbate Nutrition 0.000 description 3
- 229960005055 sodium ascorbate Drugs 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ITQZDWPQQZDNAZ-KDXUFGMBSA-N (2r,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-prop-2-ynoxyhexanal Chemical compound C#CCOC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O ITQZDWPQQZDNAZ-KDXUFGMBSA-N 0.000 description 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 2
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 2
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 2
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 2
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 description 2
- QBXODCKYUZNZCY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]oxyacetic acid Chemical compound CC(C)(C)OC(=O)NOCC(O)=O QBXODCKYUZNZCY-UHFFFAOYSA-N 0.000 description 2
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 229960005532 CC-1065 Drugs 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- YINZYTTZHLPWBO-UHFFFAOYSA-N Kifunensine Natural products COC1C(O)C(O)C(O)C2NC(=O)C(=O)N12 YINZYTTZHLPWBO-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 239000007993 MOPS buffer Substances 0.000 description 2
- 229930126263 Maytansine Natural products 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102100030859 Tissue factor Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 229950004955 adozelesin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229950006844 bizelesin Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 229930195731 calicheamicin Natural products 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- 229950007509 carzelesin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- XCEBOJWFQSQZKR-UHFFFAOYSA-N dbco-nhs Chemical compound C1C2=CC=CC=C2C#CC2=CC=CC=C2N1C(=O)CCC(=O)ON1C(=O)CCC1=O XCEBOJWFQSQZKR-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229950003913 detorubicin Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 2
- 229950002017 esorubicin Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 150000002243 furanoses Chemical class 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- OIURYJWYVIAOCW-VFUOTHLCSA-N kifunensine Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2NC(=O)C(=O)N12 OIURYJWYVIAOCW-VFUOTHLCSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- QRMNENFZDDYDEF-GOSISDBHSA-N methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate Chemical compound C1([C@H](CBr)CN(C1=C1)C(=O)C=2NC3=C(OC)C(OC)=C(OC)C=C3C=2)=C2C(C(=O)OC)=C(C)NC2=C1OC(=O)N1CCN(C)CC1 QRMNENFZDDYDEF-GOSISDBHSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- ZHOBJWVNWMQMLF-UHFFFAOYSA-N n,n-bis(prop-2-ynyl)prop-2-yn-1-amine Chemical compound C#CCN(CC#C)CC#C ZHOBJWVNWMQMLF-UHFFFAOYSA-N 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229960001221 pirarubicin Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 150000003214 pyranose derivatives Chemical class 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229950004892 rodorubicin Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 2
- 229960000641 zorubicin Drugs 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- XSAKVDNHFRWJKS-IIZANFQQSA-N (2s)-n-benzyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC=2C=CC=CC=2)CCC1 XSAKVDNHFRWJKS-IIZANFQQSA-N 0.000 description 1
- QMCOCIWNMHBIIA-LROMGURASA-N (2s)-n-tert-butyl-1-[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC(C)(C)C)CCC1 QMCOCIWNMHBIIA-LROMGURASA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- TVIRNGFXQVMMGB-OFWIHYRESA-N (3s,6r,10r,13e,16s)-16-[(2r,3r,4s)-4-chloro-3-hydroxy-4-phenylbutan-2-yl]-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H](O)[C@@H](Cl)C=2C=CC=CC=2)C/C=C/C(=O)N1 TVIRNGFXQVMMGB-OFWIHYRESA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 101100330723 Arabidopsis thaliana DAR2 gene Proteins 0.000 description 1
- 101100330725 Arabidopsis thaliana DAR4 gene Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000937413 Axia Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 101100285903 Drosophila melanogaster Hsc70-2 gene Proteins 0.000 description 1
- AZVARJHZBXHUSO-UHFFFAOYSA-N Duocarmycin A Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC(C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-UHFFFAOYSA-N 0.000 description 1
- WKODMLPZIYVYIR-UHFFFAOYSA-N Duocarmycin C2 Natural products COC(=O)C1(C)NC2=C(C3C(CCl)CN(C(=O)c4cc5cc(OC)c(OC)c(OC)c5[nH]4)C3=CC2=O)C1=O WKODMLPZIYVYIR-UHFFFAOYSA-N 0.000 description 1
- VQNATVDKACXKTF-UHFFFAOYSA-N Duocarmycin SA Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C(C64CC6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-UHFFFAOYSA-N 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930189413 Esperamicin Natural products 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 description 1
- 101001009079 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Proteins 0.000 description 1
- 101001009082 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 Proteins 0.000 description 1
- 101001032038 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010041012 Integrin alpha4 Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 description 1
- 102100027391 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 Human genes 0.000 description 1
- 102100027390 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3 Human genes 0.000 description 1
- 102100038718 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 Human genes 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 101710096655 Probable acetoacetate decarboxylase 1 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 102000003838 Sialyltransferases Human genes 0.000 description 1
- 108090000141 Sialyltransferases Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
- ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- USMYACISHVPTHK-PXLJZGITSA-N [4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl (4-nitrophenyl) carbonate Chemical compound O=C([C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(C)C)NC(C=C1)=CC=C1COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 USMYACISHVPTHK-PXLJZGITSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- 108091022873 acetoacetate decarboxylase Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- GLEIMNFBCWCWPW-QOTBAUSGSA-N alpha-D-Man-(1->2)-alpha-D-Man-(1->2)-alpha-D-Man-(1->3)-[alpha-D-Man-(1->3)-[alpha-D-Man-(1->6)]-alpha-D-Man-(1->6)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 GLEIMNFBCWCWPW-QOTBAUSGSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 239000013059 antihormonal agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229950011321 azaserine Drugs 0.000 description 1
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- XSBPYGDBXQXSCU-UHFFFAOYSA-N but-3-yn-1-amine Chemical compound NCCC#C XSBPYGDBXQXSCU-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 108700002839 cactinomycin Proteins 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010047060 carzinophilin Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 108010046713 cemadotin Proteins 0.000 description 1
- 229950009017 cemadotin Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 108010089438 cryptophycin 1 Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- WPJRFCZKZXBUNI-HCWXCVPCSA-N daunosamine Chemical group C[C@H](O)[C@@H](O)[C@@H](N)CC=O WPJRFCZKZXBUNI-HCWXCVPCSA-N 0.000 description 1
- OCCYFTDHSHTFER-UHFFFAOYSA-N dbco-amine Chemical compound NCCC(=O)N1CC2=CC=CC=C2C#CC2=CC=CC=C12 OCCYFTDHSHTFER-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229960005519 duocarmycin A Drugs 0.000 description 1
- 229960005514 duocarmycin B2 Drugs 0.000 description 1
- UQPQXFUURNIVNJ-UHFFFAOYSA-N duocarmycin B2 Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3CC(CBr)C=4C5=C(C(=CC=43)O)NC(C5=O)(C)C(=O)OC)=CC2=C1 UQPQXFUURNIVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960005511 duocarmycin C2 Drugs 0.000 description 1
- 229960005518 duocarmycin D Drugs 0.000 description 1
- OXYZQOYSQSPFMI-UHFFFAOYSA-N duocarmycin D Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3C=C(CO)C=4C5=C(C(=CC=43)O)NC(C5=O)(C)C(=O)OC)=CC2=C1 OXYZQOYSQSPFMI-UHFFFAOYSA-N 0.000 description 1
- 229960005510 duocarmycin SA Drugs 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229940015043 glyoxal Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
- 229950008097 improsulfan Drugs 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 108010021315 integrin beta7 Proteins 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 108010032768 isodolastatin H Proteins 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 239000002603 mannosidase inhibitor Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- AZVARJHZBXHUSO-DZQVEHCYSA-N methyl (1R,4R,12S)-4-methyl-3,7-dioxo-10-(5,6,7-trimethoxy-1H-indole-2-carbonyl)-5,10-diazatetracyclo[7.4.0.01,12.02,6]trideca-2(6),8-diene-4-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 AZVARJHZBXHUSO-DZQVEHCYSA-N 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- OXYZQOYSQSPFMI-AREMUKBSSA-N methyl (2r)-4-hydroxy-8-(hydroxymethyl)-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-3h-pyrrolo[3,2-e]indole-2-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C=C(CO)C=4C5=C(C(=CC=43)O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 OXYZQOYSQSPFMI-AREMUKBSSA-N 0.000 description 1
- UQPQXFUURNIVNJ-MZHQLVBMSA-N methyl (2r,8s)-8-(bromomethyl)-4-hydroxy-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-2-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C[C@@H](CBr)C=4C5=C(C(=CC=43)O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 UQPQXFUURNIVNJ-MZHQLVBMSA-N 0.000 description 1
- BOGFADYROAVVTF-MZHQLVBMSA-N methyl (2r,8s)-8-(chloromethyl)-4-hydroxy-2-methyl-1-oxo-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-2-carboxylate Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C[C@@H](CCl)C=4C5=C(C(=CC=43)O)N[C@@](C5=O)(C)C(=O)OC)=CC2=C1 BOGFADYROAVVTF-MZHQLVBMSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 108010059074 monomethylauristatin F Proteins 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- IPZJNJPAVPZHJM-UHFFFAOYSA-N n-[(2,2-dimethylchromen-6-yl)methyl]-3,4-dimethoxy-n-phenylbenzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)N(C=1C=CC=CC=1)CC1=CC=C(OC(C)(C)C=C2)C2=C1 IPZJNJPAVPZHJM-UHFFFAOYSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 125000006412 propinylene group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- BOGFADYROAVVTF-UHFFFAOYSA-N pyrindamycin A Natural products COC1=C(OC)C(OC)=C2NC(C(=O)N3CC(CCl)C=4C5=C(C(=CC=43)O)NC(C5=O)(C)C(=O)OC)=CC2=C1 BOGFADYROAVVTF-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108010029464 tasidotin Proteins 0.000 description 1
- 229950010740 tasidotin Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940053867 xeloda Drugs 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Definitions
- the invention relates to a binding agent, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, a host cell, a method of treating cancer, autoimmune disease, inflammatory disorder or infection, a method of modulating growth of a cell population and a method for treating and/or modulating the growth and/or prophylaxis of tumor cells in humans or animals.
- Binding agents such as antibodies and antibody-drug conjugates (antibodies conjugated to a drug payload molecule) provide targeted therapeutics with improved potential over traditional chemotherapy. Binding agents with improved specificity, internalization into target cells, cytotoxicity in the target cells and other beneficial properties are thus in demand.
- the binding agent according to the present invention is characterized by what is presented in claim 1.
- the binding agent according to the present invention is characterized by what is presented in claim 2.
- composition according to the present invention is characterized by what is presented in claim 35.
- the isolated nucleic acid according to the present invention is characterized by what is presented in claim 36.
- the recombinant expression vector according to the present invention is characterized by what is presented in claim 37.
- the host cell according to the present invention is characterized by what is presented in claim 38.
- the binding agent or the pharmaceutical composition for use as a medicament according to the present invention is characterized by what is presented in claim 39.
- the binding agent or the pharmaceutical composition for use in the treatment of cancer, autoimmune disease, inflammatory disorder or infection according to the present invention is characterized by what is presented in claim 40.
- the method of treating cancer, autoimmune disease, inflammatory disorder or infection according to the present invention is characterized by what is presented in claim 41.
- the method of modulating growth of a cell population according to the present invention is characterized by what is presented in claim 43.
- the method for treating and/or modulating the growth and/or prophylaxis of tumor cells in humans or animals according to the present invention is characterized by what is presented in claim 45.
- the binding agent according to the present invention is characterized by what is presented in claim 47.
- the binding agent according to the present invention is characterized by what is presented in claim 48.
- composition according to the present invention is characterized by what is presented in claim 50.
- Figure 1 shows MALDI-TOF MS image of N-glycans released from GCM014.
- FIG. 2 shows MALDI-TOF MS image of LC's of GCM014.
- Figure 3 shows SDS-PAGE of GCM023 ran in reduced (lane 1) and non-reduced (lane 2) conditions. The locations of the molecular weight markers are shown by the arrows.
- Figure 4 shows MALDI-TOF MS image of N-glycans released from GCM023.
- Figure 5 shows MALDI-TOF MS image of LC's of GCM023.
- Figure 6 shows MALDI-TOF MS image of double charged Fc's of GCM023.
- Figure 7 GCM005 binds to cell surface (HSC-2) at 4°C.
- Figure 8 shows heavy and light chain amino acid sequences of the 2G12 antibody.
- Figure 9 shows heavy and light chain amino acid sequences of the cetuximab and imgatuzumab antibodies.
- Figure 10 shows heavy and light chain amino acid sequences of the matuzumab and nimotuzumab antibodies.
- Figure 11 shows heavy and light chain amino acid sequences of the necitumumab and zalutumumab antibodies.
- Figure 12 shows heavy and light chain amino acid sequences of the trastuzumab, margetuximab, and pertuzumab antibodies.
- a binding agent comprising a payload molecule and a first binding component comprising the complementarity determining regions of an antibody, wherein said antibody is capable of binding a high-mannose N-glycan.
- a binding agent comprising a first binding component comprising the complementarity determining regions of an antibody, wherein said antibody is capable of binding a high- mannose N-glycan; and a second binding component capable of binding an antigen other than the antigen which the first binding component is capable of binding.
- High-mannose N-glycans typically comprise 5-9 or 6-9 mannose residues attached to two GlcNAc residues.
- said antibody is capable of binding an oligosaccharide structure comprising the structure according to formula I Formula !
- the high-mannose N-glycan comprises the structure according to formula I.
- binding agent should be understood as any molecule that is capable of binding an antigen, i.e. specifically recognises an antigen.
- the antigen may be a high-mannose N-glycan, or it may be e.g. another antigen present on the surface of a tumor cell or a cancer cell.
- the binding agent is capable of binding or capable of specifically binding a high-mannose N-glycan.
- glycan should be understood to refer to homo- or heteropolymers of sugar residues, which may be linear or branched.
- glycan should also be understood to encompass a glycan component of a glycoconjugate, i.e. a molecule wherein a sugar moiety is covalently linked to at least one moiety, e.g. a glycoprotein, glycolipid, or proteoglycan.
- N-glycan a term also well known in the art, refers to a glycan conjugated by a ⁇ - ⁇ -linkage (nitrogen linkage through a ⁇ -glycosidic bond) to an asparagine (Asn) residue of a protein.
- N-glycans exist in various forms, but typically comprise two W-acetylglucosamine residues to which three or more mannose residues are attached.
- Glycolipid and carbohydrate nomenclature is essentially according to recommendations by the IUPAC-IUB Commission on Biochemical Nomenclature (e.g. Carbohydrate Res. 1998, 312, 167; Carbohydrate Res. 1997, 297, 1; Eur. J. Biochem. 1998, 257, 293) .
- oligosaccharide structure refers to such glycan structures or portions thereof, which comprise sugar residues.
- sugar residues may comprise e.g. mannose, N- acetylglucosamine, glucose, or fucose linked to each other through glycosidic bonds in a particular configuration.
- Man should be understood as mannose; and “GlcNAc” refers to N- acetylglucosamine .
- cancer should be understood as meaning “tumor” or “cancer cells”.
- tumor is to be understood as meaning solid multicellular tumor tissues, including premalignant tissue, which is developing to a solid tumor and has cancer specific characteristics.
- Man 2Man should be understood as meaning two mannose residues linked by a covalent linkage between the first carbon atom of the first mannose residue to the second carbon atom of the second mannose residue linked by an oxygen atom in the alpha configuration.
- Man8GlcNAc2 should be understood as meaning a structure comprising eight mannose residues linked to two W-acetylglucosamine residues.
- binding agent a binding agent, a first or second binding component or an antibody to discriminate between a specific antigen and any other antigen to the extent that, from a pool of a plurality of different antigens as potential binding partners, only the specific antigen is bound or significantly bound.
- specific binding and/or kinetic measurements may be assayed by e.g. by utilizing surface plasmon resonance-based methods on a Biacore apparatus, by immunological methods such as ELISA or by e.g. protein or carbohydrate microarrays.
- the generation of a binding agent according to the first or second aspect may be done using standard techniques well known in the art.
- phage display based on standard procedures may be used as disclosed in e.g. "Phage Display: A Laboratory Manual”; Ed. Barbas, Burton, Scott & Silverman; Cold Spring Harbor Laboratory Press, 2001. Standard procedures of recombinant antibody technologies may also be used to produce the binding agent.
- first binding component should not be interpreted so that the binding agent would always comprise more than one binding component.
- the binding agent may comprise only the first binding component but no other binding components .
- the binding agent may also comprise more than two binding components, for instance a third binding component.
- binding component may comprise or consist of one or more domains.
- a binding component may also comprise or consist of one or more polypeptides.
- a binding component may comprise a single domain, or it may be an antibody comprising one or more polypeptides, each of which in turn may comprise one or more domains .
- the high-mannose N-glycan is selected from the group consisting of a Man6GlcNAc2 N-glycan, a Man7GlcNAc2 N-glycan, a Man8GlcNAc2 N-glycan, and a Man9GlcNAc2 N-glycan .
- the first binding component is capable of binding a high-mannose N-glycan.
- the antibody or the first binding component is capable of specifically binding a high-mannose N- glycan .
- the antibody is PGT125, PGT126, PGT127, PGT128, PGT130 or TM10 or a modification or derivative thereof .
- the antibodies PGT125, PGT126, PGT127, PGT128 and PGT130 should be understood as referring to the antibodies described in Walker et al. 2011, Nature 477:466-471.
- the antibody TM10 should be understood as referring to the antibody described in Newsom-Davis et al . 2009, Cancer Res. 69:2018-25.
- the antibody is an antibody selected from the group consisting of PGT125, PGT126, PGT127, PGT128, PGT130 and TM10.
- the antibody is 2G12 or a modification or derivative thereof.
- the term "2G12" is to be understood as meaning the domain exchanged human monoclonal IgGl antibody produced from the hybridoma cell line CL2 (described in e.g. US 5,911,989; Buchacher et al. 1994, AIDS Research and Human Retroviruses, 10(4), 359-369; and Trkola et al. 1996, Journal of Virology, 70(2), 1100-1108), and any synthetically, e.g.
- the first binding component comprises the heavy chain complementarity determining regions 1-3 having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity as compared to the heavy chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10, and the light chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10 or light chain complementarity determining regions 1-3 having at least about 80 90 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity as compared to light chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10.
- the first binding component comprises heavy chain complementarity determining regions 1-3 and/or light chain complementarity determining regions having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NOs: 1 - 4, amino acid sequence KAS and SEQ ID NO: 6.
- the first binding component comprises the heavy chain complementarity determining regions HCDR1 (SEQ ID NO: 1), HCDR2 (SEQ ID NO: 2) and HCDR3 (SEQ ID NO: 3) and the light chain complementarity determining regions LCDR1 (SEQ ID NO: 4), LCDR2 (amino acid sequence KAS) and LCDR3 (SEQ ID NO: 6) of the antibody 2G12.
- LCDR2 of the antibody 2G12 has the amino acid sequence
- KAS i.e. Lys Ala Ser
- the first binding component is a scFv, a single domain antibody, an Fv, a VHH antibody, a diabody, a tandem diabody, a Fab, a Fab', or a F(ab)2.
- the first binding component may be e.g. an scFv, a single domain antibody, an Fv, a VHH antibody, a diabody, a tandem diabody, a Fab, a Fab', a F(ab')2, a Db, a dAb-Fc, a taFv, a scDb, a dAb 2 , a DVD-Ig, a Bs (scFv) 4 -IgG, a taFv-Fc, a scFv-Fc- scFv, a Db-Fc, a scDb-Fc, a scDb-C H 3, or a dAb-Fc-dAb.
- the second binding component may be e.g. an scFv, a single domain antibody, an Fv, a VHH antibody, a diabody, a tandem diabody, a Fab, a Fab', a F(ab')2 / a Db, a dAb-Fc, a taFv, a scDb, a dAb 2 , a DVD-Ig, a Bs (scFv) 4 -IgG, a taFv-Fc, a scFv-Fc- scFv, a Db-Fc, a scDb-Fc, a scDb-C H 3, or a dAb-Fc-dAb.
- the binding agent may be present in monovalent monospecific, multivalent monospecific, bivalent monospecific, or multivalent multispecific forms.
- the first binding component is a human antibody or a humanized antibody.
- the second binding component is a human antibody or a humanized antibody.
- human antibody as it is commonly used in the art, is to be understood as meaning antibodies having variable regions in which both the framework and complementarity determining regions (CDRs) are derived from sequences of human origin.
- CDRs complementarity determining regions
- humanized antibody as it is commonly used in the art, is to be understood as meaning antibodies wherein residues from a CDR of an antibody of human origin are replaced by residues from a CDR of a nonhuman species (such as mouse, rat or rabbit) having the desired specificity, affinity and capacity.
- the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 7 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 7.
- the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 8 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 8.
- the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 9 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 9.
- the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 10 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 10.
- the scFv comprising the sequence set forth in SEQ ID NO: 7, 8, 9 or 10, or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to the SEQ ID NO: 7, 8, 9 or 10 is capable of binding a high-mannose N-glycan.
- the first binding component comprises a heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11.
- the heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11 is capable of binding a high-mannose N-glycan.
- the first binding component comprises a light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 12.
- the light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO:
- SEQ ID NO: 12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 12 is capable of binding a high-mannose N-glycan .
- the first binding component comprises a heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11 and light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to the SEQ ID NO: 12, and optionally the light chain constant domain of the antibody 2G12 and/or one or more heavy chain constant domains of the antibody 2G12 selected from the group consisting of CHI, CH2 and CH3 of the antibody 2G12.
- the first binding component or the antibody 2G12 comprises a heavy chain variable region comprising a sequence set forth in SEQ ID NO: 11 and a light chain variable region comprising a sequence set forth in SEQ ID NO: 12.
- the first binding component comprises the light chain constant domain of the antibody 2G12 and/or one or more heavy chain constant domains of the antibody 2G12 selected from the group consisting of CHI, CH2 and CH3 of the antibody 2G12.
- the first binding component comprises one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the light chain of an Ig molecule; and/or one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the heavy chain of an Ig molecule; wherein the first binding component comprises one or more introduced N- glycosylation sites in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the light chain; and/or one or more introduced N-glycosylation sites in any region or domain in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the heavy chain.
- the first binding component comprises the antibody 2G12.
- the first binding component is or consists of the antibody 2G12.
- one or more amino acid residues of the first binding component are substituted by substitutions selected from the group consisting of I19N, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 13.
- the first binding component comprises the 2G12 heavy chain having a sequence set forth in SEQ ID NO: 13, wherein one or more amino acid residues are substituted by substitutions selected from the group consisting of I19N, F78S, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 13.
- substitution I19N should be understood as referring to a substitution of the amino acid residue I at the position 19 of the sequence set forth in SEQ ID NO: 13 to the amino acid residue N. Other substitutions described in this specification are indicated in the same manner. If the first binding component comprises a portion but not the full sequence of e.g. the heavy chain set forth in SEQ ID NO: 13, a skilled person is capable of determining a corresponding amino acid residue in the first binding component and making a corresponding substitution.
- substitutions may provide improved properties to the binding agent.
- the substitution I19N and/or F78S may improve the solubility of the binding agent, render the production of the binding agent easier and/or improve the yield of the binding agent.
- One or more of the substitutions may introduce an additional N-glycosylation site.
- the additional N-glycosylation sites may be utilized by incorporating therein e.g. N-glycans having beneficial properties or additional payload molecules.
- one or more amino acid residues of the first binding component are substituted by substitutions selected from the group consisting of T18N, L154S, Q160N S174N and T180N as compared to SEQ ID NO: 14.
- the first binding component comprises the 2G12 light chain having a sequence set forth in in SEQ ID NO: 14, wherein one or more amino acid residues are substituted by substitutions selected from the group consisting of T18N, L154S, Q160N S174N and T180N as compared to SEQ ID NO: 14.
- the first binding component comprises the sequences set forth in SEQ ID NOs : 15 and SEQ ID NO: 12.
- the first binding component comprises the sequences set forth in SEQ ID NOs: 15 and SEQ ID NO: 14.
- the first binding component comprises the sequences set forth in SEQ ID NOs: 16 and SEQ ID NO: 12.
- the first binding component comprises the sequences set forth in SEQ ID NOs: 16 and SEQ ID NO: 14.
- the first binding component comprises the sequences set forth in SEQ ID NOs: 17 and SEQ ID NO: 12. In an embodiment, the first binding component comprises the sequences set forth in SEQ ID NOs : 17 and SEQ ID NO: 14.
- the binding agent comprises a detection-enabling molecule.
- detection-enabling molecules are molecules conveying affinity such as biotin or a
- His tag comprising at least five histidine (His) residues; molecules that have enzymatic activity such as horseradish peroxidase (HRP) or alkaline phosphatase (AP) ; various fluorescent molecules such as FITC, TRITC, and the Alexa and Cy dyes; gold; radioactive atoms or molecules comprising such; chemiluminescent or chromogenic molecules and the like, which molecules provide a signal for visualization or quantitation.
- HRP horseradish peroxidase
- AP alkaline phosphatase
- various fluorescent molecules such as FITC, TRITC, and the Alexa and Cy dyes
- gold radioactive atoms or molecules comprising such; chemiluminescent or chromogenic molecules and the like, which molecules provide a signal for visualization or quantitation.
- the detection-enabling molecule may be covalently bound to the binding agent, to the first binding component and/or to the second binding component, or it may be bound indirectly thereto e.g. via a suitable linker group.
- the linker group may be e.g. any linker described in this specification.
- the binding agent comprises a second binding component capable of binding an antigen other than the antigen which the first binding component is capable of binding.
- the second binding component is capable of binding an antigen that is different or other than the antigen which the first binding component is capable of binding.
- the second binding component may thus have a different binding specificity than the first binding component.
- the antigen that the second binding component is capable of binding may be e.g. an antigen present on the surface of a tumor cell or cancer cell .
- the second binding component is capable of binding an antigen other than a high-mannose N- glycan .
- the second binding component is capable of binding a cell surface antigen.
- the cell surface antigen is a tumor antigen and/or a cancer antigen.
- the tumor antigen/a cancer antigen may include, but is not limited to, CD2, CD3, CD4, CD5, CD6, CD11, CD8, CDlla, CD19, CD20, CD22, CD25, CD26, CD30, CD33, CD34, CD37, CD38, CD40, CD44, CD46, CD52, CD56, CD79, CD105, and CD138; members of the ErbB receptor family, such as epidermal growth factor receptor 1 (EGFR) , epidermal growth factor receptor 2 (HER2/neu), HER3 or HER4 receptor; cell adhesion molecules, such as LFA-1, Macl, pl50.95, VLA-4, ICAM-1, VCAM, EpCAM, alpha4/beta7 integrin, and alpha v/beta3 integrin including either alpha or beta subunits thereof; growth factors, such as VEGF; tissue factor (TF) ; tumor necrosis
- the binding agent according to the first or second aspect may be a bispecific binding agent, such as a bispecific antibody molecule.
- a bispecific binding agent contains both the first binding component and the second binding component and is thus capable of binding to two different antigens or epitopes.
- the binding agent may also be a multispecific binding agent, such as a multispecific antibody molecule.
- bispecific binding agent such as bispecific antibodies
- a protein moiety thereof may comprise e.g.
- bispecific IgG 2 IgG, IgG, IgGscFv, scFv-IgG, F(ab')2, F (ab' ) 2-scFv, diabody, dual-affinity re-targeted antibody (DART) , tandem scFv, Fab-scFv, taFv, scDb, dAb 2 , DVD-Ig, Bs (scFv) 4 -IgG, taFv-Fc, scFv-Fc-scFv, db-Fc, scDb-Fc, scDb-C H 3, or dAb-Fc-dAb.
- the binding agent comprises IgG 2 .
- additional N-glycosylation sites are introduced into the heavy chain of the IgG 2 .
- additional N-glycosylation sites are introduced into the light chain of the IgG 2 .
- additional N-glycosylation sites are introduced into the heavy chain of the IgG 2 .
- additional N-glycosylation sites are introduced into the light chain of the IgG 2 .
- additional N- glycosylation sites are introduced into the heavy chains and light chains of the IgG 2 .
- the binding agent comprises a bispecific IgG.
- additional N-glycosylation sites are introduced into the heavy chain of the bispecific IgG.
- additional N-glycosylation sites are introduced into the light chain of the bispecific IgG.
- additional N-glycosylation sites are introduced into the heavy chain of the bispecific IgG.
- additional N-glycosylation sites are introduced into the light chain of the bispecific IgG.
- additional N- glycosylation sites are introduced into the heavy chains and light chains of the bispecific IgG.
- the binding agent comprises an IgG- scFv.
- additional N-glycosylation sites are introduced into the heavy chain of the IgG-scFv.
- additional N-glycosylation sites are introduced into the light chain of the IgG-scFv.
- additional N- glycosylation sites are introduced into the heavy chain of the IgG-scFv.
- additional N-glycosylation sites are introduced into the light chain of the IgG-scFv.
- additional N-glycosylation sites are introduced into the heavy chains and light chains of the IgG-scFv.
- the binding agent comprises an scFv- IgG.
- additional N-glycosylation sites are introduced into the heavy chain of the scFv-IgG.
- additional N-glycosylation sites are introduced into the light chain of the scFv-IgG.
- additional N- glycosylation sites are introduced into the heavy chain of the scFv-IgG.
- additional N-glycosylation sites are introduced into the light chain of the scFv-IgG.
- additional N- glycosylation sites are introduced into the heavy chains and light chains of the scFv- IgG.
- the binding agent comprises a bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N- glycosylation sites are introduced into the heavy chains and light chains of the bispecific F(ab' )2- In an embodiment, the binding agent comprises an
- additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N- glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chains and light chains of the bispecific F(ab' )2-
- the binding agent comprises a diabody.
- additional N-glycosylation sites are introduced into the heavy chain of the diabody.
- additional N-glycosylation sites are introduced into light chain of the diabody.
- additional N- glycosylation sites are introduced into the heavy chain of the diabody.
- additional N-glycosylation sites are introduced into the light chain of the diabody.
- additional N-glycosylation sites are introduced into the heavy chains and light chains of the diabody.
- the binding agent comprises a dual- affinity re-targeted antibody (DART) .
- DART dual- affinity re-targeted antibody
- additional N-glycosylation sites are introduced into the heavy chain of the DART.
- additional N-glycosylation sites are introduced into the light chain of the DART.
- additional N-glycosylation sites are introduced into the heavy chain of the DART.
- additional N- glycosylation sites are introduced into the light chain of the DART.
- additional N-glycosylation sites are introduced into the heavy chains and light chains of the DART.
- the binding agent comprises a tandem scFv.
- additional N-glycosylation sites are introduced into the heavy chain of the tandem scFv.
- additional N-glycosylation sites are introduced into the light chain of the tandem scFv.
- additional N-glycosylation sites are introduced into the heavy chain of the tandem scFv.
- additional N-glycosylation sites are introduced into the light chain of the tandem scFv.
- additional N-glycosylation sites are introduced into the heavy chains and light chains of the tandem scFv.
- the binding agent comprises a Fab- scFv.
- additional N-glycosylation sites are introduced into the heavy chain of the Fab-scFv.
- additional N-glycosylation sites are introduced into the light chain of the Fab-scFv.
- additional N- glycosylation sites are introduced into the heavy chain of the Fab-scFv.
- additional N-glycosylation sites are introduced into the light chain of the Fab-scFv.
- additional N-glycosylation sites are introduced into the heavy chains and light chains of the Fab-scFv.
- the first binding component and the second binding component may be functionally linked e.g. by chemical coupling, fusion, or non-covalent association.
- the first binding component and the second binding component are fused.
- the binding agent thus comprises a fusion polypeptide, wherein the fusion polypeptide comprises both the first binding component and the second binding component.
- the C-terminus of the first binding component may be fused to the N-terminus of the second binding component, or the C-terminus of the second binding component may be fused to the N-terminus of the first binding component.
- the first binding component and the second binding component may be fused directly or indirectly, e.g. via a linker sequence.
- first binding component and the second binding component are chemically cross-linked. They may be chemically crosslinked e.g. via a suitable linker group.
- the length of the linker group may be selected based on the first and second binding component to be joined.
- Suitable linker groups may be, for example, m-maleimidobenzoyl-N- hydroxysuccinimide ester or disuccinimidyl suberate.
- the second binding component is capable of binding human EGFRl .
- the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR, and LCDR3 of an anti-EGFRl antibody .
- the first binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 of 2G12 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of 2G12
- the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of an anti-EGFRl antibody.
- the second binding component is an anti-EGFRl antibody or an EGFRl binding fragment thereof.
- the second binding component comprises a heavy chain variable region and a light chain variable region of an anti-EGFRl antibody.
- the anti-EGFRl antibody is selected from the group consisting of cetuximab, imgatuzumab, matuzumab, nimotuzumab, necitumumab, panitumumab, and zalutumumab.
- the anti-EGFRl antibody is cetuximab.
- cetuximab comprises the sequences set forth in SEQ ID NO:s 18 and 19.
- additional N-glycosylation sites are introduced into the cetuximab heavy chain.
- the cetuximab heavy chain comprises one or more substitutions selected from the group consisting of G161S, Q177N, L184N, S192N, and L195N as compared to SEQ ID NO: 18.
- cetuximab light chain comprises one or more substitutions selected from the group consisting of R18N, L154S, Q160N, S174N, and T180N as compared to SEQ ID NO: 19.
- the anti-EGFRl antibody is imgatuzumab .
- imgatuzumab comprises the sequences set forth in SEQ ID NO:s 20 and 21.
- additional N-glycosylation sites are introduced into the imgatuzumab heavy chain.
- the imgatuzumab heavy chain comprises one or more substitutions selected from the group consisting of E80N, G164S, Q178N, L185N, S193N, and L196N as compared to SEQ ID NO: 20.
- additional N-glycosylation sites are introduced into imgatuzumab light chain.
- imgatuzumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 21.
- the anti-EGFRl antibody is matuzumab.
- matuzumab comprises the sequences set forth in SEQ ID NO:s 22 and 23.
- additional N-glycosylation sites are introduced into the matuzumab heavy chain.
- the matuzumab heavy chain comprises one or more substitutions selected from the group consisting of E89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 22.
- additional N-glycosylation sites are introduced into the matuzumab light chain.
- the matuzumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N and T185N as compared to SEQ ID NO: 23.
- nimotuzumab comprises the sequences set forth in SEQ ID NO:s 24 and 25.
- additional N-glycosylation sites are introduced into the nimotuzumab heavy chain.
- the nimotuzumab heavy chain comprises one or more substitutions selected from the group consisting of E74N, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 24.
- additional N-glycosylation sites are introduced into the nimotuzumab light chain.
- the nimotuzumab light chain comprises one or more substitutions selected from the group of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 25.
- the anti-EGFRl antibody is necitumumab.
- necitumumab comprises the sequences set forth in SEQ ID NO:s 26 and 27.
- additional N-glycosylation sites are introduced into the necitumumab heavy chain.
- the necitumumab heavy chain comprises one or more substitutions selected from the group consisting of A89N, G165S, Q179N, L186N, S194N and L197N as compared to SEQ ID NO: 26.
- additional N-glycosylation sites are introduced into the necitumumab light chain.
- the necitumumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 27.
- the antibody is panitumumab.
- additional N-glycosylation sites can be introduced into heavy and/or light chains of panitumumab, and any other antibody herein, as described in, for example, W097/34632 and/or W095/15769.
- additional N-glycosylation sites may be those of depicted in Fig 12 and corresponding to HCN1, HCN2, HCN3, HCN4, and/or HCN5 for heavy chain, and KCN1, KCN2, KCN3, and/or KCN4 for kappa light chain.
- An additional N-glycosylation site in an antibody may mean one or more non-Asn297 N-glycosylation sites.
- the non- Asn297 N-glycosylation sites can be present in or be introduced into a heavy and/or a light chain.
- the anti-EGFRl antibody is zalutumumab .
- zalutumumab comprises the sequences set forth in SEQ ID NO:s 28 and 29.
- additional N-glycosylation sites are introduced into the zalutumumab heavy chain.
- the zalutumumab heavy chain comprises one or more substitutions selected from the group consisting of E89N, G169S, Q183N, L190N, S198N, and L201N as compared to SEQ ID NO: 28.
- additional N-glycosylation sites are introduced into the zalutumumab light chain.
- the zalutumumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 29.
- the anti-EGFRl antibody or its EGFR1 binding fragment comprises one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the light chain of an anti-EGFRl Ig molecule; and/or one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of sequence corresponding to the heavy chain of an anti-EGFRl Ig molecule; wherein the anti-EGFRl antibody or its EGFR1 binding fragment comprises one or more introduced N-glycosylation sites in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the light chain; and/or one or more introduced N-glycosylation sites in any region or domain in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the heavy chain.
- the first binding component is a scFv derived from 2G12
- the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 of an anti-EGFRl antibody.
- the scFv derived from 2G12 is a scFv comprising the heavy chain complementarity determining regions HCDR1 (SEQ ID NO: 1), HCDR2 (SEQ ID NO: 2) and HCDR3 (SEQ ID NO: 3) and the light chain complementarity determining regions LCDR1 (SEQ ID NO: 4), LCDR2 (amino acid sequence KAS) and LCDR3 (SEQ ID NO: 6) of 2G12.
- the scFv derived from 2G12 comprises the sequence set forth in SEQ ID NO: 7.
- the scFv derived from 2G12 comprises a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs : 7 - 10.
- the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 7, and the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 of an anti-EGFRl antibody.
- the first binding component is a scFv comprising a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs: 7 - 10, and the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 of an anti-EGFRl antibody.
- the scFv derived from 2G12 is fused to the C-terminus of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
- the scFv derived from 2G12 is fused to the C-terminus of the heavy chain of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
- the scFv derived from 2G12 is fused to the N-terminus of the heavy chain of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
- the scFv derived from 2G12 is fused to the N-terminus of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
- the second binding component comprises at least one of the following:
- cetuximab heavy chain having a sequence set forth in SEQ ID NO: 18, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of G161S, Q177N, L184N, S192N and L195N as compared to SEQ ID NO: 18;
- imgatuzumab heavy chain having a sequence set forth in SEQ ID NO: 20, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E80N, G164S, Q178N, L185N, S193N, and L196N as compared to SEQ ID NO: 20;
- matuzumab heavy chain having a sequence set forth in SEQ ID NO: 22, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 22;
- nimotuzumab heavy chain having a sequence set forth in SEQ ID NO: 24, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E74N, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 24;
- necitumumab heavy chain having a sequence set forth in SEQ ID NO: 26, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of A89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 26;
- panitumumab heavy chain wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E to N substitution at about amino acid 91, G to S substitution at about amino acid 161 (in sequence NSG) , Q to N at about amino acid 177 (in sequence QSS), L to N at about amino acid 184 (in sequence LSS), S to N at about amino acid 192 (in sequence SSS) , and L to N at about amino acid 195 (in sequence LGT) as compared to the panitumumab heavy chain sequence; or
- zalutumumab heavy chain having a sequence set forth in in SEQ ID NO: 28, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E89N, G169S, Q183N, L190N, S198N, and L201N as compared to SEQ ID NO: 28.
- the second binding component comprises at least one of the following:
- cetuximab light chain having a sequence set forth in in SEQ ID NO: 19, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L154S, Q160N, S174N, and T180N as compared to SEQ ID NO: 19;
- the imgatuzumab light chain having a sequence set forth in in SEQ ID NO: 21, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 21;
- the matuzumab light chain having a sequence set forth in in SEQ ID NO: 23, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 23;
- the nimotuzumab light chain having a sequence set forth in in SEQ ID NO: 25 comprises one or more substitutions selected from the group of: R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 25;
- panitumumab light chain wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R to N substitution at about amino acid 18, L to S substitution at about amino acid 154 (in sequence NAL) , Q to N substitution at about amino acid 160 (in sequence QES) , S to N substitution at about amino acid 174 (sequence SLS -> NLS) , and T to N substitution at about amino acid 180 (in sequence TLS) as compared to the panitumumab light chain sequence; or
- the second binding component is capable of binding human ERBB2/HER2.
- the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR, and LCDR3 of an anti-ERBB2 /HER2 antibody.
- the first binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 of 2G12 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of 2G12
- the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of an anti-ERBB2 /HER2 antibody.
- the second binding component is an anti- ERBB2/HER2 antibody or an ERBB2/HER2 binding fragment thereof .
- the second binding component comprises a heavy chain variable region and a light chain variable region of an anti-ERBB2 /HER2 antibody.
- the anti-EGFRl antibody is selected from the group consisting of trastuzumab, ertumaxomab, margetuximab, and pertuzumab.
- the anti-ERBB2 /HER2 antibody is trastuzumab.
- trastuzumab comprises the sequences set forth in SEQ ID NO:s 30 and 31.
- additional N-glycosylation sites are introduced into the trastuzumab heavy chain.
- additional N- glycosylation sites are introduced into the trastuzumab light chain .
- the anti-ERBB2 /HER2 antibody is ertumaxomab. In an embodiment, additional N-glycosylation sites are introduced into the ertumaxomab heavy chain. In an embodiment, additional N-glycosylation sites are introduced into the ertumaxomab light chain. In an embodiment, the anti-ERBB2 /HER2 antibody is margetuximab . In an embodiment, margetuximab comprises the sequences set forth in SEQ ID NO:s 32 and 33. In an embodiment, additional N-glycosylation sites are introduced into the margetuximab heavy chain. In an embodiment, additional N- glycosylation sites are introduced into the margetuximab light chain .
- the anti-ERBB2 /HER2 antibody is pertuzumab.
- pertuzumab comprises the sequences set forth in SEQ ID NO:s 34 and 35.
- additional N-glycosylation sites are introduced into the pertuzumab heavy chain.
- additional N-glycosylation sites are introduced into the pertuzumab light chain.
- the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions.
- the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions in the heavy chain.
- the binding agent comprises a fusion polypeptide comprising one or more additional stabilizing amino acid substitutions.
- the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions, such as an additional cysteine residues.
- the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions, such as an additional cysteine residues in the scFv.
- Exemplary stabilizing amino acid substitutions include, but are not limited to, an additional cysteine residue in the heavy chain variable and/or light chain variable domain of an scFv.
- Such an additional cysteine residue may be capable of forming a sulphur bridge with another cysteine residue, for instance another additional cysteine residue in the scFv, and thus stabilize the structure.
- a stabilizing amino acid substitution corresponds to G44C in a heavy chain of an Ig molecule. In an embodiment, a stabilizing amino acid substitution corresponds to G100C in a light chain of an Ig molecule .
- stabilizing amino acid substitutions correspond to G44C in a heavy chain and G100C in a light chain of an Ig molecule.
- a stabilizing amino acid substitution is G44C in a heavy chain of 2G12 (scFv) and G100C in a light chain of 2G12 (scFv) .
- the binding agent comprises a fusion polypeptide comprising the nimotuzumab heavy chain fused to a scFv derived from 2G12.
- the scFv derived from 2G12 may be any scFv derived from 2G12 described in this specification .
- the binding agent comprises a fusion polypeptide having a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs : 36, 37 and 38.
- the binding agent comprises a fusion polypeptide comprising a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs: 36, 37 and 38.
- the binding agent comprises the sequences set forth in SEQ ID NOs: 36 and 39.
- the binding agent comprises the sequences set forth in SEQ ID NOs: 37 and 39.
- the binding agent comprises the sequences set forth in SEQ ID NOs: 38 and 19.
- the binding agent comprises the sequence set forth in SEQ ID NO: 42.
- the payload molecule may be any number of agents, including but not limited to cytotoxic agents or drugs such as chemotherapeutic agents, growth inhibitory agents, toxins (for example, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof) , or a radioactive isotope or a compound comprising a radioactive isotope (that is, a radioconjugate) .
- cytotoxic agents or drugs such as chemotherapeutic agents, growth inhibitory agents, toxins (for example, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof) , or a radioactive isotope or a compound comprising a radioactive isotope (that is, a radioconjugate) .
- the payload molecule is a toxic payload molecule, a fluorescent label molecule or a radioactive molecule.
- the toxic payload molecule may, in principle, be any toxic molecule suitable for conjugation to the binding agent according to the first aspect. It may be any compound that results in the death of a cell, or induces cell death, or in some manner decreases cell viability.
- the toxic payload molecule can be any of many small molecule drugs, including, but not limited to, dolastatins ; auristatins ; epothilones ; daunorubicins and doxorubicins; alkylating agents, such as thiotepa and cyclophosphamide (CYTOXANTM) ; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylene-phosphoramide, triethylenethiophosphaoramide and trimethylolomelamine ; acetogenins (especially bullatacin and bullatacinone) ; camptothecins (including the synthetic analogue topotecan) ; bryostat
- calicheamicins especially calicheamicin ⁇ ; dynemicin, including dynemicin A; esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores ) , aclacinomysins , actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin; chromomycins , dactinomycin, detorubicin, 6-diazo-5-oxo-L- norleucine, other doxorubicin derivatives including morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino- doxorubicin and deoxydoxorubicin, epirubicin, esorubicin, idarubicin,
- paclitaxel TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.J.
- doxetaxel TAXOTERE®, Rhone- Poulenc Rorer, Antony, France
- chlorambucil gemcitabine
- 6- thioguanine mercaptopurine
- methotrexate platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO) ; retinoic acid; capecitabine ; anti-hormonal agents that act to regulate or inhibit hormone action on tumors, such as anti-
- the toxic payload molecule is a dolastatin, auristatin, doxorubicin, maytansinoid, epirubicin, duocarmycin, or any analogue or derivative thereof.
- the toxic payload molecule is dolastatin 10, dolastatin 15 or any derivative thereof.
- the toxic payload molecule is auristatin F or any derivative thereof.
- the toxic payload molecule is dolastatin 10, dolastatin 15, or auristatin F.
- the toxic payload molecule is dolastatin 10.
- the toxic payload molecule is dolastatin 15.
- the toxic payload molecule is auristatin F.
- Dolastatins that can be used in the present invention are well known in the art and can be isolated from natural sources according to known methods or prepared synthetically according to known methods .
- dolastatins examples include monomethyl and desmethyl dolastatins 10, 15, C, D and H, monomethyl and desmethyl isodolastatin H, and analogues and derivatives thereof. These dolastatins contain a primary or secondary amine at the N-terminus. Dolastatins 10 and 15 are the most potent toxic payload molecules among the naturally occurring dolastatins. Monomethyl and desmethyl dolastatins 10 and 15 can be prepared by chemical synthesis according to standard peptide synthesis chemistry.
- Auristatins that can be used in the present invention include (but are not limited to) monomethyl and desmethyl auristatins E, F, EB, EFP, PY, PYE, PE, PHE, TP, 2-AQ and 6-AQ, e.g. described in U.S. Pat. No. 5,635,483; Int. J. Oncol. 15:367-72 (1999); Mol. Cancer Ther. 3:921-32 (2004); U.S. application Ser. No. 11/134,826; U.S. Patent Publication Nos. 20060074008 and 2006022925; and Pettit, G.R., et al . (2011) J. Nat. Prod. 74:962-8.
- the monomethyl or desmethyl dolastatin 15 analogue or derivative is selected from the group consisting of monomethyl and desmethyl dolastatin 15, monomethyl and desmethyl cemadotin, monomethyl and desmethyl tasidotin, and monomethyl and desmethyl P5 (the corresponding dimethyl compounds are described in Bai et al . 2009. Mol. Pharmacol. 75:218-26) .
- the toxic payload molecule may also be daunorubicin or doxorubicin.
- the primary amine group of the daunosamine moiety can be used, or daunorubicin or doxorubicin can be modified to comprise another primary or secondary amine moiety.
- the toxic payload molecule is a maytansinoid .
- the toxic payload molecule is maytansine, an ansamitocin, DM1 or DM4 (also known as DM-4) .
- the toxic payload molecule is DM1.
- DM1 is also known as DM-1 and mertansine.
- the toxic payload molecule is a rubicin.
- Suitable rubicins may be e.g. daunorubicins , doxorubicins, detorubicin, other doxorubicin derivatives including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, idarubicin, rodorubicin, zorubicin, and pirarubicin.
- the toxic payload molecule is epirubicin .
- the toxic payload molecule is duocarmycin.
- Suitable duocarmyxins may be e.g. duocarmycin A, duocarmycin Bl, duocarmycin B2, duocarmycin CI, duocarmycin C2, duocarmycin D, duocarmycin SA, duocarmycin MA, and CC-1065.
- duocarmycin should be understood as referring also to synthetic analogs of duocarmycins , such as adozelesin, bizelesin, carzelesin, KW-2189 and CBI-TMI.
- the duocarmycin is a duocarmycin suitable for conjugating to the binding agent according to the first aspect.
- the duocarmycin comprises an amino group or another suitable chemical group for conjugating the duocarmycin to the binding agent according to the first aspect.
- the amino group is a free amino group.
- the payload molecule is a toxic payload molecule selected from the group consisting of dolastatin, auristatin, doxorubicin, maytansinoid, epirubicin, duocarmycin, and any analogue or derivative thereof.
- fluorescent label molecule may refer to any fluorophore which can re-emit light upon light excitation. Such a fluorescent label molecule may be suitable for detection, visualization and/or quantitation. Suitable fluorescent label molecules may be e.g. FITC, TRITC, and the Alexa and Cy dyes.
- radioactive molecule may refer to any molecule that comprises a radioactive atom.
- radioactive molecule may refer to a radioactive molecule suitable for radiation therapy. It may also refer to a radioactive molecule suitable for detection, visualization and/or quantitation.
- the payload molecule may be selected so that it comprises a functional group that allows for conjugating it to the binding agent according to the first aspect.
- the payload molecule may also be modified prior to reacting it with other components of the binding agent according to the first aspect.
- the payload molecule comprises a primary or secondary amine moiety.
- the payload molecule is modified to comprise a primary or secondary amine moiety.
- the amine-modified payload molecule essentially retains the activity of the original payload molecule after conj ugation .
- the payload molecule is covalently linked to the binding agent.
- the payload molecule is covalently linked to the first binding component.
- the payload molecule is covalently linked to the second binding component.
- the payload molecule may be covalently linked to the binding agent, to the first binding component and/or to the second binding component directly, via a bond, or indirectly, e.g. via a linker or linker group.
- An overview of the technology of covalently linking or conjugating payload molecules to binding agents is provided in Ducry et al . , Bioconjugate Chem. , 21:5-13 (2010), Carter et al . , Cancer J. 14(3) :154 (2008) and Senter, Current Opin. Chem. Biol. 13:235-244 (2009).
- Linkers that may, in principle, be utilised are described e.g. in Dosio et al . , Toxins 2011, 3, 848-883, and Sammet et al . , Pharm. Pat. Analyst 2012, 1(1), 2046-8954.
- the linker may be e.g. a peptide linkage or a linker cleavable by a lysosomal hydrolase.
- the number of payload molecules, i.e. the drug moieties per binding agent may vary.
- the binding agent comprises a molecule represented by formula II [D-L] n -P
- n is at least 1 ;
- L is a linker group covalently joining P to D
- D is the payload molecule
- the binding agent is a molecule represented by formula II.
- the binding agent consists of a molecule represented by formula II.
- n is an integer from 1 to 20. In an embodiment, n is 2-18. In an embodiment, n is 2-16. In an embodiment, n is 2-10. In other embodiments, n is 2-6; 2-5; 2- 4; 2-3; 3-4; or 1, 2, 3 or 4.
- the binding agent comprises a molecule represented by formula III
- P is the first binding component or the second binding component comprising an N-glycan, wherein the N-glycan comprises a GlcNAc residue bound by a ⁇ - ⁇ linkage to an asparagine ;
- n is at least 1;
- D is the payload molecule
- L is a linker group covalently joining G to D
- G is a saccharide structure represented by formula IV
- R is a glycosidic bond to the N-glycan or a glycosidic bond to the GlcNAc residue bound by a ⁇ - ⁇ linkage to an asparagine ;
- X 1 is H or carboxyl
- X 2 , X 3 and X 4 are each independently OH, H, amino, C2-C6 acylamide, phosphate or sulphate ester, or a bond to L;
- X 5 is CH 2 OH, carboxyl, CH 3 , H, C 1 -C3 alkyl or substituted C 1 -C3 alkyl, or a bond to L;
- one substituent selected from X 2 , X 3 , X 4 and X 5 is a bond to L or bonded via a bond to L;
- the binding agent is a molecule represented by formula III.
- the binding agent consists of a molecule represented by formula III.
- These embodiments have the added utility that they comprise a relatively small payload molecule-glycan moiety that is efficiently released inside cells. This may be particularly beneficial when the payload molecule is a toxic payload molecule. Further, the moiety released is relatively small; small toxic payload molecule conjugates tend to be more toxic than large toxic payload molecule conjugates e.g. comprising a complex-type N-glycan core structure.
- the toxic payload molecule-glycan conjugate released from the binding agent in cells is capable of delivering the toxic payload molecule into cells and further into the cytosol, the nucleus or the endoplasmic reticulum.
- the binding agent is also sufficiently stable towards chemical or biochemical degradation during manufacturing or in physiological conditions, e.g. in blood, serum, plasma or tissues, and in reducing conditions, in low pH and inside cells, cellular organelles, endosomes and lysosomes.
- n is an integer from 1 to 20. In an embodiment, n is 2-18. In an embodiment, n is 2-16. In an embodiment, n is 2-10. In other embodiments, n is 2-6; 2-5; 2-4; 2-3; 3-4; or 1, 2, 3 or 4.
- G is a saccharide structure represented by formula V
- R is a glycosidic bond to the N-glycan
- X 4 is OH, H, amino, C 2 _ C6 acylamide, phosphate or sulphate ester, or a bond to L;
- X 5 is C 1 -C3 alkyl or substituted C 1 -C3 alkyl
- X 4 is a bond to L or X 5 is bonded via a bond to L.
- the N-glycan comprises a terminal ⁇ residue and R is a glycosidic bond to the terminal ⁇ residue .
- N-glycan consists of the structure represented by formula VI
- X 1 is H
- X 2 , X 3 and X 4 are each independently OH, H, amino, C2-C6 acylamide, phosphate or sulphate ester, or a bond to L;
- X 5 is CH 2 OH, carboxyl, CH 3 , H, C 1 -C3 alkyl or substituted C 1 -C3 alkyl, or a bond to L;
- one substituent selected from X 2 , X 3 , X 4 and X 5 is a bond to L or bonded via a bond to L;
- R is a glycosidic bond to the GlcNAc residue.
- the linker group is hydrophilic.
- the linker group comprises at least one OH group.
- the linker group comprises at least one moiety derived from one or more saccharide units.
- linker group is represented by formula VII
- Z is a saccharide or absent
- D' is the payload molecule, wherein the payload molecule comprises an amine moiety, through which the payload molecule is bound so as to form a secondary or tertiary amine;
- Ri, R2, R3, R4, R5, R7, 3 ⁇ 4 and R9 are each independently H, OH, amine, C 2 -C6 acylamide, carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
- W is H, CH 2 OH, CH 3 , carboxyl, substituted carboxyl, C 1 -C6 alkyl or substituted C 1 -C6 alkyl;
- a is an integer from 0 to 6;
- b is 0 or 1;
- c and e are each independently an integer from 0 to 7; d is an integer from 1 to 7;
- Q is E'-F'-E, wherein F' is an amine, amide, disulfide, thioether, thioester, hydrazone, Schiff base, oxime, olefin metathesis reaction product, triazole or phosphine group, or other group generated by the reaction of the functional group F- E and the functional group F' , wherein F is a functional group that can react with an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine, and F' is an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine; and E is absent or a polyethyleneoxy unit of formula (CH 2 CH 2 0) P , wherein p is an integer from 2 to about 20; and E and E' are each independently absent or a polyethyleneoxy unit of formula (CH 2 CH 2 0)
- L is a linker group represented formula VIII
- Z is a saccharide or absent
- D' is the payload molecule, wherein the payload molecule comprises an amine moiety, through which the payload molecule is bound so as to form a secondary or tertiary amine;
- Ri, R 2 , R9 and Rio are each independently H, OH, amine,
- C2-C6 acylamide carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
- a is an integer from 0 to 6;
- e is an integer from 0 to 3;
- d and f are integers from 0 to 4 with the proviso that their sum is from 1 to 4;
- Q is E'-F'-E, wherein F' is an amine, amide, disulfide, thioether, thioester, hydrazone, Schiff base, oxime, olefin metathesis reaction product, triazole or phosphine group, or other group generated by the reaction of the functional group F- E and the functional group F' , wherein F is a functional group that can react with an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine, and F' is an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine ; and E is absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and E and E' are each independently absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P
- L is a linker group represented by formula IX
- Z is a saccharide or absent
- D' is the payload molecule, wherein the toxic payload molecule comprises an amine moiety, through which the toxic payload molecule is bound so as to form a secondary or tertiary amine;
- Ri and R 2 are each independently H, OH, amine, C 2 -C6 acylamide, carboxyl, substituted carboxyl, C 1 -C6 alkyl or substituted C1-C6 alkyl;
- a is an integer from 0 to 6;
- c and e are each independently an integer from 0 to 3;
- Q is E'-F'-E, wherein F' is an amine, amide, disulfide, thioether, thioester, hydrazone, Schiff base, oxime, olefin metathesis reaction product, triazole or phosphine group, or other group generated by the reaction of the functional group F- E and the functional group F' , wherein F is a functional group that can react with an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine, and F' is an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine; and E is absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and E and E' are each independently absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P
- F is an amine reacting group, a thiol reactive group, an azide reactive group, an alkyne reactive group, a carbonyl reactive group or a hydroxylamine reactive group.
- F is an amine reacting group, such as (but not limited) to an N- hydroxysuccinmide ester, p-nitrophenyl ester, dinitrophenyl ester, or pentafluorophenyl ester.
- F is a thiol reactive group, such as (but not limited to) pyridyldisulfide, nitropyridyldisulfide, maleimide, haloacetate or carboxylic acid chloride.
- F is an azide reactive group, such as (but not limited to) alkyne.
- F is an alkyne.
- F is CH ⁇ C .
- F is a dibenzocyclooctyl group
- F is an alkyne reactive group, such as (but not limited to) azide.
- F is azide
- F is a carbonyl reactive group, such as (but not limited to) hydroxylamine.
- F is a hydroxylamine reactive group, such as (but not limited to) aldehyde or ketone.
- F is isothiocyanate, isocyanate, sulfonyl chloride, glyoxal, epoxide, oxirane, carbonate, aryl halide, imidoester, carbodiimide, or anhydride.
- Z is absent.
- Z is a saccharide. In an embodiment, Z is an oligosaccharide with a degree of polymerization from 1 to about 20; from 1 to 10; from 1 to 8; from 1 to 6; from 1 to 5; from 1 to 4; from 1 to 3; from 1 to 2; or 1, 2, 3, 4 or 5.
- Z is a monosaccharide, disaccharide or trisaccharide .
- Z is OH
- Z is H.
- a is 1, 2 , 3 , 4 , 5 , or 6.
- a is 1.
- b is 0.
- b is 1.
- c is 0.
- c is 1, 2, 3, 4, 5, 6 or 7.
- d is 1, 2, 3, 4, 5, 6 or 7.
- d is 3, 4 or 5.
- d is 3.
- d is 4.
- d is 5.
- d is 6.
- e 0.
- e is 1, 2, 3, 4, 5, 6 or 7.
- d is 3; and R 7 is H.
- d is 4; and R 7 is H.
- b is 1; and R3 and R4 are each
- a is 1; and Ri and R2 are each
- e is 1; and R8 and R9 are each
- a, b, c , or e is 0.
- a, b, c , and/or e is 0.
- W is H.
- a is 2 or 3; and Ri and R2 are
- Y is oxygen .
- Y is sulphur .
- Y is a peptide
- the binding agent is preferentially internalized by a tumor cell or a cancer cell.
- the binding agent is preferentially internalized by a tumor cell or a cancer cell as compared to a non-tumor cell or a non-cancer cell.
- the present invention further relates to a pharmaceutical composition comprising the binding agent according to one or more embodiments of the first or second aspect .
- the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.
- suitable pharmaceutically acceptable carriers are well known in the art and may include e.g. phosphate buffered saline solutions, water, oil/water emulsions, wetting agents, and liposomes. Compositions comprising such carriers may be formulated by methods well known in the art.
- the pharmaceutical composition may further comprise other components such as vehicles, additives, preservatives, other pharmaceutical compositions administrated concurrently, and the like.
- the pharmaceutical composition comprises an effective amount of the binding agent according to one or more embodiments of the first or second aspect.
- the pharmaceutical composition comprises a therapeutically effective amount of the binding agent according to one or more embodiments of the first or second aspect.
- an "effective amount" of the conjugate should be un-derstood as referring to the dosage regimen for modulating the growth of cancer cells and/or treating a patient's disease.
- the therapeutically effective amount may be selected in accordance with a variety of factors, including the age, weight, sex, diet and medical condition of the patient, the severity of the disease, and pharmacological considerations, such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular conjugate used.
- the therapeutically effective amount can also be determined by reference to standard medical texts, such as the Physicians Desk Reference 2004.
- the patient may be male or female, and may be an infant, child or adult.
- treatment or "treat” is used in the conventional sense and means attending to, caring for and nursing a patient with the aim of combating, reducing, attenuating or alleviating an illness or health abnormality and improving the living conditions impaired by this illness, such as, for example, with a cancer disease.
- the pharmaceutical composition comprises a composition for e.g. oral, parenteral, transdermal, intraluminal, intraarterial, intrathecal and/or intranasal administration or for direct injection into tissue.
- Administration of the pharmaceutical composition may be effected in different ways, e.g. by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration .
- binding agent comprises a sequence selected from the group consisting of SEQ ID NO: 17, 36, 37, and 38.
- binding agent comprises sequences set forth in SEQ ID NOs : 17 and SEQ ID NO: 12; or SEQ ID NOs: 17 and SEQ ID NO: 14; or SEQ ID NOs: 36 and 39; or SEQ ID NOs: 37 and 39; or or SEQ ID NOs: 38 and 19.
- the binding agent comprises a payload molecule.
- the payload molecule may be any payload molecule described in this specification.
- the present invention further relates to a pharmaceutical composition comprising the binding agent according to one or more embodiments of third or fourth aspect.
- the present invention further relates to a nucleic acid encoding the protein moiety of the binding agent according to one or more embodiments of the first, second, third or fourth aspect .
- the present invention further relates to an isolated nucleic acid encoding the protein moiety of the binding agent according to one or more embodiments of the first, second, third or fourth aspect.
- the isolated nucleic acid comprises a nucleotide sequence encoding the protein moiety of a binding agent according to the first, second, third or fourth aspect.
- protein moiety should be understood as referring to at least one polypeptide, wherein the polypeptide comprises the first binding component, the second binding component or both.
- the protein moiety may also be a fusion polypeptide comprising both the first binding component and the second binding component.
- the present invention further relates to a recombinant expression vector comprising the nucleic acid according one or more embodiments of the invention.
- the recombinant expression vector according to one or more embodiments of the present invention may be e.g. a plasmid, phagemid, phage or viral vector, into which a nucleic acid encoding a binding agent according to one or more embodiments of the first, second, third or fourth aspect is inserted.
- the nucleic acid and the recombinant expression vector may be produced by variety of techniques such as chemically synthesized using, for example, synthesizers.
- Recombinant expression vectors of the invention may be capable of expressing the RNA and/or protein products of the nucleic acids (DNA) .
- the recombinant expression vector may further comprise regulatory sequences, including a promoter operably linked to the open reading frame (ORF) .
- the vector may further comprise a selectable marker sequence. Specific initiation and secretory signals also may be included for efficient translation of inserted target gene coding sequences.
- the recombinant expression vector may be advantageously selected and constructed depending upon the use intended for the binding agent being expressed. For example, when a large quantity of a binding agent is to be produced, for the generation of antibodies, for example, vectors which direct the expression of high levels of protein products that are readily purified may be desirable.
- the present invention further relates to a host cell comprising the recombinant expression vector according to one or more embodiments of the invention.
- the host cell is an isolated host cell .
- the host cell can be virtually any cell for which recombinant expression vectors are available. It may be, for example, a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell or a fungal cell, and may be a prokaryotic cell, such as a bacterial cell, for example E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus .
- a higher eukaryotic host cell such as a mammalian cell
- a lower eukaryotic host cell such as a yeast cell or a fungal cell
- a prokaryotic cell such as a bacterial cell, for example E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus .
- the mammalian cell is a CHO cell, cell line CHO-K1 (ATCC CCL-61), cell line DUXB11 (ATCC CRL-9096) and cell line Pro-5 (ATCC CRL-1781) registered at ATCC, CHO-S (Cat # 11619 of Life Technologies)), a BHK cell (ATCC accession no. CCL 10), a NSO cell, NSO cell line (RCB 0213) registered at RIKEN Cell Bank, The Institute of Physical and Chemical Research, a SP2/0 cell, a SP2/0-Agl4 cell, SP2/0-Agl4 cell (ATCC CRL-1581), a YB2/0 cell, a PER cell, a PER .
- Gl 1.16Ag .20 cell including cell lines established from Y3/Agl.2.3 cell (ATCC CRL-1631), YB2/3HL.P2.G11.16Ag.20 cell, YB2 /3HL . P2.
- Gl 1.16Ag .20 cell ATCC CRL-1662
- any sub-lines obtained by naturalizing these cell lines to media in which they can grow, and the like a hybridoma cell, a human leukemic Namalwa cell, or an embryonic stem cell.
- Introduction of the recombinant construct into the host cell can be effected, for example, by calcium phosphate transfection, DEAE, dextran mediated transfection, electroporation or phage infection.
- the present invention further relates to a method for producing the binding agent according to one or more embodiments of the first, second, third or fourth aspect, comprising
- the method comprises conjugating a payload molecule to the protein moiety of the binding agent according to one or more embodiments of the first, second, third or fourth aspect.
- the present invention further relates to the binding agent according one or more embodiments of the first, second, third or fourth aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use as a medicament.
- the present invention further relates to the binding agent according one or more embodiments of the first, second, third or fourth aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use in the treatment of cancer, autoimmune disease, inflammatory disorder or infection.
- the present invention further relates to the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use in the treatment of a disorder selected from the group consisting of cancer, autoimmune disease, inflammatory disorder and infection.
- the present invention further relates to the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use in the treatment of cancer.
- the cancer is a leukemia, lymphoma, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cancer, small-cell lung cancer, head-and-neck cancer, multidrug resistant cancer, glioma, melanoma and testicular cancer.
- the present invention further relates to the use of the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to one or more embodiments of the invention in the manufacture of a medicament .
- the present invention further relates to the use of the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to one or more embodiments of the present invention in the manufacture of a medicament for the treatment of cancer, autoimmune disease, inflammatory disorder or infection.
- the present invention further relates to the use of the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to one or more embodiments of the present invention in the manufacture of a medicament for the treatment of a disorder selected from the group consisting of cancer, autoimmune disease, inflammatory disorder and infection.
- the present invention further relates to a method of treating cancer, autoimmune disease, inflammatory disorder or infection, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human in an effective amount.
- the present invention further relates to a method of treating a disorder selected from the group consisting of cancer, autoimmune disease, inflammatory disorder and infection, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human in an effective amount.
- the present invention further relates to a method of treating cancer, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human in an effective amount.
- the cancer is a leukemia, lymphoma, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cancer, small-cell lung cancer, head-and-neck cancer, multidrug resistant cancer, glioma, melanoma and testicular cancer.
- the present invention further relates to a method for modulating growth of a cell population, wherein the method comprises contacting the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention with the cell population.
- the cell population is a tumor cell population or a cancer cell population.
- the present invention further relates to a method of treating and/or modulating the growth of and/or prophylaxis of tumor cells in humans or animals, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human or animal in an effective amount.
- the tumor cells are selected from the group consisting of leukemia cells, lymphoma cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, head-and-neck cancer cells, multidrug resistant cancer cells, and testicular cancer cells.
- inventions described hereinbefore may be used in any combination with each other. Several of the embodiments may be combined together to form a further embodiment of the invention.
- a product, a use or a method to which the invention is related may comprise at least one of the embodiments of the invention described hereinbefore.
- the binding according to one or more embodiments of the first or second aspect has a number of advantageous properties.
- the binding agent is preferentially internalized by tumor or cancer cells.
- the binding agent has a good internalization efficiency.
- the presence of two binding components improves capability and specificity of the binding of the binding agent to tumor or cancer cells.
- the binding agent according to the first aspect allows for conjugating a relatively large number of payload molecules to the binding agent.
- the binding agent has low immunogenicity; yet it is well soluble in aqueous solutions.
- 2G12-antibody human IgG; Polymun Scientific, Austria
- 2G12-antibody human IgG; Polymun Scientific, Austria
- UDP- galactose UDP- galactose
- CMP- 9-azido-N-acetyl-neuraminic as in Example 5.
- Fc-fragments were released from a small aliquot of reaction mixture with Fabricator enzyme and recovered using Poros Rl tips.
- MALDI-TOF MS analysis of purified Fc revealed major signal at m/z 25873 corresponding to Fc with 9-azido-NeuNAc-G2F .
- 9-azido-sialylated antibody was purified with Protein G as in Example 5 and DM1-DBCO was conjugated to 9-azido- sialylated 2G12 as in Example 5. Fabricator analysis of conjugated antibody was done as described below.
- MALDI-TOF MS of purified Fc revealed major signal at m/z 26927 corresponding to Fc chain carrying DMl-DBCO-9-azido-NeuNAc-G2F.
- a minor signal was detected at m/z 28299 corresponding to (DMl-DBCO-9-azido- NeuNAc) 2-G2F . Based on the peak intensities, approximately 2.3 toxins were conjugated to 2G12 antibody.
- Amicon Ultra centrifugal filter unit (30K, 0.5 ml) . Low molecular weight reagents were then removed by Amicon centrifugal filter with repeated addition of PBS - 5 % mannitol
- the DAR of the 2G12-drug conjugate was estimated to be about 2, by isolating the Fc-fragments and light chains followed by MALDI-TOF MS analysis.
- 2G12 light chain encoding sequence is ordered as a synthetic gene from a supplier and cloned into e.g. a CHO expression vector.
- 2G12 heavy chain variantl is assembled by overlap PCR from two sequences. Sequence encoding amino acids 1-220 is ordered as a synthetic gene from a supplier, sequence encoding amino acids 221-453 is PCR amplified from GCM012 expression vector.
- Heavy chain mutation I19N is generated to 2G12 variantl backbone by PCR overlap, using overlapping oligos containing the mutated site. Full length heavy chain is assembled from two pieces essentially as described for GCM023.
- GCM020 (2G12 variantl+I19N+F78S)
- Heavy chain mutation F78S is generated to 2G12 variantl or 2G12 variant2 heavy chain backbone by PCR overlap, using overlapping oligos containing the mutated site. Full length heavy chain is assembled from two pieces essentially as described for GCM023.
- Cetuximab light chain fragment was amplified by PCR from a plasmid having a CHO codon optimized light chain DNA sequence using primers enabling cloning into the transient expression vector pCEP4.
- Cetuximab heavy chain and 2G12 scFv fragments were PCR amplified separately (cetuximab heavy chain from a plasmid having CHO codon optimized heavy chain; 2G12 scFv from a plasmid having CHO codon optimized 2G12 scFv) .
- PCR fragments were purified from agarose gel and joined by overlap extension PCR. The whole 2220 bp join product was amplified, cut with restriction enzymes, and ligated to transient expression vector pCEP4. All antibodies produced in the Examples used signal peptides of SEQ ID NO: 40 (for heavy chains) or SEQ ID NO: 41 (for light chains) .
- TGTA (3) 33mg of 2 (0.034mmol) was dissolved in 3ml 60% TFA (in H 2 0) and stirred at 50°C for 1.5 hours. The reaction mixture was then diluted with water, concentrated and dried under vacuum to give 3 as a white solid (25mg, quantitative, : ⁇ 2:3) .
- An expression vector with coding sequences for GCM012 heavy- and light chains was constructed to pCHOl .0 backbone. Coding sequence for entire light chain was ordered as a synthetic CHO codon optimized sequence and cloned to pCHOl .0 with AvrII/Bstll07I . Coding sequence for heavy chain was constructed by PCR overlap from two pieces, synthetic sequence for heavy chain variable region and PCR amplified sequence for heavy chain constant region. Full-length PCR product was cloned to the pCHOl.O - GCM012 light chain backbone with EcoRV/PacI. The resulting vector was verified by sequencing and used for transient expression in CHO-S cells.
- GCM012 was produced by transfecting CHO-S cells transiently using FreeStyleTM MAX CHO Expression system (Life technologies) according to the manufacturer's instructions. The transfected cell cultures were grown for four days before the culture supernatants were collected by centrifugating at 350 x g for 5 minutes at RT . GCM012 was purified from culture supernatant by Protein A column (High Trap MAb Select Sure; 5 ml; GE Healthcare) and AKTA purifier instrument (GE
- GCM012 comprises sequences set forth in SEQ ID NOs : 39 and 42.
- EXAMPLE 4 Generation of GCM014 (GCM012 heavy chain fused to 2G12 scFv variant with additional cysteines)
- a vector with CHO optimized coding sequences for GCM014 heavy- and light chain was constructed to a plasmid backbone.
- Sequence encoding the C-terminal part (2G12 scFv) of the GCM014 heavy chain was ordered as a synthetic gene, N- terminal part of the GCM014 heavy chain (GCM012) was made as a PCR fragment from the plasmid described in the previous example. Sequences were combined by overlap PCR into EcoRV/PacI site replacing the GCM012 heavy chain and resulting vector was verified by sequencing and used for transient expression in CHO- S cells.
- the 2G12 scFv part of the GCM014 has two additional cysteines corresponding to G44C in the heavy chain and G100C in the light chain to stabilize the bispecific antibody.
- GCM014 was produced by transfecting CHO-S cells transiently using FreestyleTM MAX CHO Expression system (Life technologies) according to the manufacturer's instructions. The transfected cell cultures were grown for four days before the culture supernatants were collected by centrifugating at 350 x g for 5 minutes at RT .
- N-glycans of GCM014 were analysed from total antibody and Fc fragment.
- N-glycans were released from SDS denatured GCM014 using PNGase F (ProZyme Inc.) in 20 mM sodium phosphate buffer, pH 7.3, in overnight reaction at +37°C.
- the released N- glycans were purified with Hypersep C18 and Hypersep Hypercarb (Thermo Scientific) and analysed with MALDI-TOF MS.
- the domain structure of the antibody was first denatured with guanidine-HCl and the disulphide bonds were reduced with dithiotreitol . Free light chains were then purified with Poros Rl and analyzed by MALDI- TOF.
- MALDI analysis implicated that sialylated N-glycan SFG2 is the most abundant structure (m/z 26171, Figure 2) . 97% of LCs are glycosylated.
- Boc-aminooxyacetic acid (Novabiochem) (0.41 g, 2.1 mmol) was dissolved in 7 ml dry THF (under argon atmosphere) and the mixture was cooled on an ice bath. 0.24 ml (2.1 mmol, 1 equiv.) NMM and 0.28 ml (2.1 mmol, 1 equiv.) IBCF were added and the reaction mixture was stirred for 0.5 h at 0 °C .
- Boc-ABAA was conjugated to N- ( 6-N 3 -Gal ) -MODO by copper (I) catalyzed azide-alkyne cycloaddition reaction: The reaction contained 2.5 ymol N- ( 6-N 3 -Gal ) -MODO, 6,3 ymol Boc-ABAA (2,5 x molar excess to N- ( 6-N 3 -Gal ) -MODO) , 25 ymol Na-ascorbate (10 x molar excess to N- ( 6-N 3 -Gal ) -MODO) and 5 ymol of CuS0 4 (2 x molar excess to N- ( 6-N 3 -Gal ) -MODO) .
- Boc-ABAA and N- ( 6-N 3 -Gal) - MODO were dissolved in DMSO and Na-ascorbate and CuS0 4 in MilliQ- H 2 0 before adding to the reaction. Total volume of the reaction was 117 ⁇ containing 64% DMSO. Reaction was carried out for 1.5 hours at RT . The conjugation was stopped with 40 ⁇ of 0,5M EDTA pH 8 (20 ⁇ EDTA) . Progress of the reaction was analyzed with MALDI-TOF MS using 2 , 5-dihydroxybenzoic acid matrix in the positive ion reflector mode. Major signal was observed at m/ z 1224.6, which corresponds to [M+Na] + ion of the expected click- reaction product Modo-Boc- aminooxybutynylacetamide (Boc-
- Boc-ABAA-MODO was purified by solid-phase extraction on Bond-Elut C18 extraction cartridge. To obtain unprotected aminooxy drug, ABAA-MODO, the Boc-protecting group was removed by incubating in dichloromethane-TFA (12.5:1), and the product MODO-ABAA was isolated by reversed-phase chromatography using Gemini NX C18 column (Phenomenex) using a acetonitrile gradient in 20 mM ammonium acetate, pH 5.6.
- ABAA-MODO was conjugated to 7-aldehydo-NeuNAc-GCM014 in an oxime ligation reaction by incubating 500 yg of antibody with 34 nmol of ABAA-MODO in 0.08M sodium acetate, pH 4.2.
- the conjugate (Scheme 6) was purified by ultrafiltration and light chains were isolated as above to analyze the reaction outcome. MS analysis showed a major signal at m/z 28271, which was assigned to (7- aldehydo-NeuNAc) 2-G2F-LC carrying two oxime linked ABAA-MODO units .
- GCM023 GCM012 heavy chain fused to 2G12 scFv variant [additional cysteines in scFv and I19N and F78S in heavy chain] )
- F78S in 2G12 heavy chain were made by overlapping PCR, amplifying Ascl-Pacl fragment of GCM012 heavy chain as three overlapping parts, and assembling the final plasmid comprising also GCM012 light chain sequence.
- IRES2-eGFP fragment was added to the construct to aid the identification of high-expressing clones.
- IRES2-eGFP sequence was cut from helper plasmid as Eco32I-fragment and cloned into Bstll07I-site right after light chain.
- GCM023 (cloned in an IRES-eGFP vector) was transfected into CHO-S cells to develop stable cell pools for GCM023 production using Freedom CHO-S kit (Life Technologies) according to the manufacturer's instructions. Negative controls (no Freestyle MAX reagent, no DNA) as well as the expression vector (pCHOl.O) alone were included. GCM023 plasmid and the expression vector were linearized using Ndel prior to transfection to improve the transfection efficiency. Two transfections with the GCM023 plasmid were performed. Selecting stable transfectants for GCM023 expression
- Selection phase 1 was conducted after transfection according to the manufacturer's instructions using selection reagents puromycin (Invitrogen) and methotrexate (Sigma) to select the stable transfectants . For each transfection two flasks (125 ml Erlenmeyer flask, Corning) were seeded having different selection reagent concentrations. Negative controls (no Freestyle MAX reagent, no DNA) were discarded on day 14 of selection phase 1 (almost no live cells) . Selection phase 1 was completed when the viability of the samples exceeded 85% and pools of each sample were cryopreserved .
- each sample flask was further divided into two having increased selection reagent concentrations according to the Freedom CHO-S Kit manual. Selection was complete when the viability exceeded 90 % and pools of each sample were again cryopreserved. Analysing the selections phase 2 cell pools for eGFP expression using flow cytometry
- the cell pools were analysed for eGFP expression, which correlated with the level of GCM023 produced.
- the eGFP expression of the cell pools was analysed by flow cytometry (FACSAria II, BD Biosciences) and the data analysis was done by FACSDiva software. About 1 x 10 s cells were taken from each sample, the cells were centrifuged at 200 x g for 5 minutes and the cells were suspended in 0.5 ml Complete CD FortiCHOTM medium (Life technologies) . The cells were filtered through cell strainer caps (35 ym nylon mesh, BD Falcon) and 10 000 events were recorded from each sample. The sample having only the expression vector transfected was used as a negative control in the analysis. The amount of eGFP-positive cells was about 3-100 % in the samples.
- a sample 99.9 % eGFP - positive was chosen to be used in sorting.
- the most eGFP -positive cells (15.5 ⁇ 6 ) were sorted using 2-way purity method aiming to get a cell pool with enhanced GCM023 producing capability.
- the sorted cells were collected into 15 ml Falcon tube having 0.5 ml Complete CD FortiCHOTM medium. About 6.5 x 10 s cells were sorted in total.
- the sorted cells were centrifuged (300 x g, 5 min, RT) and suspended in 20 ml Complete CD FortiCHOTM medium including the selection reagents (50 yg/ml Puromycin; 1000 nM methotrexate) and penicillin/streptomycin.
- Selection reagents 50 yg/ml Puromycin; 1000 nM methotrexate
- penicillin/streptomycin penicillin/streptomycin.
- GCM023 Purification of GCM023 from culture supernatant using Protein A column
- the culture medium was filtered (HPF Millex HV PVDF filter; 0.45 ym) and NaCl was added to the medium to a final concentration of 150 mM.
- the GCM023 antibody was purified using Protein A column (High Trap MAb Select Sure; 5 ml; GE Healthcare) and AKTA purifier instrument (GE Healthcare) .
- the column was equilibrated with 20 mM Na-phosphate - 150 mM NaCl, pH 7.3 before sample application.
- the unbound material was washed with 50 mM Tris - 250 mM arginine-HCl - 1M NaCl, pH 9 and with 20 mM Na-phosphate - 150 mM NaCl, pH 7.3.
- GCM023 was eluted with 0.1M Na-citrate, pH 3.
- GCM023 containing fractions were collected, neutralized with 2M Tris-HCl, pH 9 and pooled.
- the pooled fractions were concentrated using Amicon Ultra-4 Centrifugal filter unit, 30K (Millipore) .
- the GCM023 concentration was determined by using NanoDrop 1000 (Thermo Scientific) .
- GCM023 produced from high expressing cell pool was ran in SDS-PAGE (4-15 % Mini-Protean TGX gel; BioRad) , in the presence of reducing ( Figure 3, lane 1) and non-reducing (Figure 3, lane 2) sample buffer.
- the size of the light chain is about 37 kDa and that of heavy chain about 100 kDa .
- the non-reduced protein moves around the place of the 260 kDa molecular marker.
- N-glycans were released from GCM023 and purified as described above.
- the main glycoform in the GCM023 heavy chain is FG0 (m/z 1485, Figure 4) .
- Terminal galactose-residues in GCM023 N-glycans were sialylated with a-2, 6 sialyltransferase : 100 ⁇ antibody, 30 mM CMP-NeuNAc and 0,05 yg/ ⁇ ST6Gal-l (hum rec, Roche Diagnostics) in 50 mM MOPS pH 7,2 were incubated o/n at +37°C.
- Fc-ScFv-fragments were released from a small aliquot of the reaction mixture with Fabricator enzyme and recovered using reversed-phase extraction on hand ⁇ made Poros Rl tips.
- a minor signal at m/z 27291 (z 2) was also detected corresponding to GOF in Fc-N-glycans and SG2F in ScFv.
- MALDI-TOF MS analysis of purified LC revealed major signal at m/z 26466 corresponding to LC with S2G2F glycan.
- Minor signals at 26012 and 26177 corresponded to LC with SGIF and SG2F.
- Sialylated GCM023 was purified with HiTrap Protein G column (GE Healthcare) using 0.02 M Na-phosphate pH 7.0 as the binding buffer and 0.1 M citric acid pH 2.6 as the elution buffer. Purified antibody was subjected to galactosylation and sialylation using UDP-galactose and CMP- 9-azido-N-acetyl- neuraminic acid as the donor substrates. ⁇ -1,4- galactosyltransferase- and a-2 , 6-sialyltransferase-reactions were done in succession without removal of the galactosylation components.
- DMl-DBCO was purified by reversed-phase chromatography on a column of Gemini-NX-5u C-18 (Phenomenex) .
- DMl-DBCO was conjugated to galactosylated and 9-azido- sialylated GCM023 as follows: 20 ⁇ antibody in 4 "6 mannitol , 0,1 % Tween, PBS was incubated with 400 ⁇ DMl-DBCO in the presence of 20% propylene glycol and 6% DMSO. Reaction was allowed to proceed 16 h at room temperature after which unbound DMl-DBCO was removed by repeated additions of 5 % mannitol, 0,1 % Tween, PBS and centrifugations through Amicon Ultracel 30 k centrifugal filter.
- DMl-DBCO-linked antibody (Scheme 7) was recovered from the concentrator and a small sample was taken for Fc-analysis, which revealed major signals at m/z 28275 and 28815.
- the signal m/z 28275 was assigned to DMl-DBCO-9-azido- NeuNAc-G2F in Fc N-glycans and S2G2F in ScFv N-glycans.
- m/z 28815 was assigned to DMl-DBCO-9-azido-NeuNAc-G2F in Fc N- glycans and DMl-DBCO-9-azido-NeuNAc-SG2F in ScFv N-glycans.
- the antibody-drug- conjugate was thus a mixture of antibodies having either 2 (DAR2) or 4 (DAR4) attached drugs.
- GCM023-PEG4-N3 was prepared as described in Example 2.
- Fmoc removal was carried out by adding 150 ⁇ of diethylamine and by stirring at room temperature overnight.
- MALDI-TOF mass analysis using 2 , 5-dihydroxybenzoic acid matrix showed the generation of expected deprotected product (m/z 1198 [M+Na] + ) .
- Val-Cit-PAB-MODO was purified by Akta purifier (GE).
- MODO-Val-Cit-PAB-DBCO was purified by reversed-phase chromatography as described above.
- GCM023-PEG4-N3 was prepared as described in Example 2.
- To prepare GCM023-drug conjugate (Scheme 9) lOx molar excess per azido group of DBCO-Val-Cit-PAB-MODO in DMSO was added into the solution of GCMO23-PEG 4 -N3. The reaction was performed at room temperature for 2 hours. The conjugated antibody was purified by Amicon centrifugal filter as above.
- MODO-TREA was purified by Akta purifier (GE Healthcare) HPLC instrument with Gemini 5 ⁇ NX-AXIA-C18 reversed phase column (21.2 x 250 mm, 110 A (Phenomenex) ) eluted with ACN gradient in aqueous ammonium acetate.
- MODO-TREA-DBCO was purified by Akta purifier (GE Healthcare) HPLC instrument with Gemini 5 ym NX-AXIA-C18 reversed phase column (21.2 x 250 mm, 110 A (Phenomenex)) eluted with ACN gradient in aqueous ammonium acetate.
- GCM023-PEG4-N 3 was prepared as described in Example 2.
- 7-aldehydo-NeuAc-cetuximab was prepared as described in Example 4, and was conjugated with 300x molar excess of MMAF- AOAA in 0.1 M sodium acetate buffer pH 5.5.
- the Fc-fragment of MMAF-AOAA-Cetuximab conjugate (Scheme 11) was isolated as described in Example 5 and analyzed by MALDI-TOF MS. The spectrum of Fc-fragment showed a major signal at m/z 26614, corresponding to MMAF-AOAA-Cetuximab conj ugate .
- HEK-cells were cultured in the presence of kifunensine (a mannosidase inhibitor) . After 3 days culture with kifunensine (Cayman Chemical) at 12 ⁇ g/ml concentration high-mannose glycans appear on the cell surface. Cetuximab and GCM012 were used as a control.
- HSC-2, FaDu, Skov-3 and HEK cells (2xl0 5 ) were seeded on a 24-well plate and allowed to grow for 24h. Thereafter the cells were incubated 3h either at +37°C or at +4°C in 300 ⁇ 1 media containing 2 yg/ml AlexaFluor488 labeled 2G12, cetuximab, or GCM005. The cells were washed two times with PBS, detached by incubating with ⁇ Trypsin-EDTA, lOmin at +37°C, neutralized with 300 ⁇ media, resuspended in PBS, and analyzed in a flow cytometer (FACS LRS II) .
- FACS LRS II flow cytometer
- Table 2 shows the results of the internalization assay (measured as mean of all fluorescent events) .
- Table 4 shows fold increase of internalization of the bispecific antibody GCM005 compared to its components 2G12 or cetuximab.
- HSC-2 cells (5xl0 4 ) were seeded on a chamber slides and allowed to grow for 24h. Thereafter the cells were incubated 3h either at +37°C or at +4°C in ⁇ media containing 5 yg/ml AlexaFluor488 labeled GCM005. The cells were washed two times with PBS and fixed with 4% paraformaldehyde for 20 min. The cells were mounted (Prolong Gold antifade reagent with DAPI) and photographed with fluorescence microscopy (Zeiss Axio Scope Al) . GCM005 binds to cell surface at 4°C but after incubation at 37°C, antibody was internalized and most staining was seen inside the cells ( Figure 7) .
- ADC antibody drug conjugates
Abstract
The invention relates to a binding agent comprising a payload molecule and a first binding component comprising the complementarity determining regions of an antibody, wherein said antibody is capable of binding a high-mannose N-glycan.
Description
ANTIBODY DRUG CONJUGATES BINDING TO HIGH-MANNOSE N-GLYCAN
FIELD OF THE INVENTION
The invention relates to a binding agent, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, a host cell, a method of treating cancer, autoimmune disease, inflammatory disorder or infection, a method of modulating growth of a cell population and a method for treating and/or modulating the growth and/or prophylaxis of tumor cells in humans or animals.
BACKGROUND OF THE INVENTION
Binding agents, such as antibodies and antibody-drug conjugates (antibodies conjugated to a drug payload molecule) provide targeted therapeutics with improved potential over traditional chemotherapy. Binding agents with improved specificity, internalization into target cells, cytotoxicity in the target cells and other beneficial properties are thus in demand.
SUMMARY
The binding agent according to the present invention is characterized by what is presented in claim 1.
The binding agent according to the present invention is characterized by what is presented in claim 2.
The pharmaceutical composition according to the present invention is characterized by what is presented in claim 35.
The isolated nucleic acid according to the present invention is characterized by what is presented in claim 36.
The recombinant expression vector according to the present invention is characterized by what is presented in claim 37.
The host cell according to the present invention is characterized by what is presented in claim 38.
The binding agent or the pharmaceutical composition for use as a medicament according to the present invention is characterized by what is presented in claim 39.
The binding agent or the pharmaceutical composition for use in the treatment of cancer, autoimmune disease, inflammatory disorder or infection according to the present invention is characterized by what is presented in claim 40.
The method of treating cancer, autoimmune disease, inflammatory disorder or infection according to the present invention is characterized by what is presented in claim 41.
The method of modulating growth of a cell population according to the present invention is characterized by what is presented in claim 43.
The method for treating and/or modulating the growth and/or prophylaxis of tumor cells in humans or animals according to the present invention is characterized by what is presented in claim 45.
The binding agent according to the present invention is characterized by what is presented in claim 47.
The binding agent according to the present invention is characterized by what is presented in claim 48.
The pharmaceutical composition according to the present invention is characterized by what is presented in claim 50.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying drawings, which are included to provide a further understanding of the invention and constitute a part of this specification, illustrate embodiments of the invention and together with the description help to explain the principles of the invention. In the drawings:
Figure 1 shows MALDI-TOF MS image of N-glycans released from GCM014.
Figure 2 shows MALDI-TOF MS image of LC's of GCM014. Figure 3 shows SDS-PAGE of GCM023 ran in reduced (lane 1) and non-reduced (lane 2) conditions. The locations of the molecular weight markers are shown by the arrows.
Figure 4 shows MALDI-TOF MS image of N-glycans released from GCM023.
Figure 5 shows MALDI-TOF MS image of LC's of GCM023. Figure 6 shows MALDI-TOF MS image of double charged Fc's of GCM023.
Figure 7 GCM005 binds to cell surface (HSC-2) at 4°C.
After incubation at 37°C, antibody is internalized and most of the staining is seen inside the cells while only very weak staining could be detected on the cell surface.
Figure 8 shows heavy and light chain amino acid sequences of the 2G12 antibody.
Figure 9 shows heavy and light chain amino acid sequences of the cetuximab and imgatuzumab antibodies.
Figure 10 shows heavy and light chain amino acid sequences of the matuzumab and nimotuzumab antibodies.
Figure 11 shows heavy and light chain amino acid sequences of the necitumumab and zalutumumab antibodies.
Figure 12 shows heavy and light chain amino acid sequences of the trastuzumab, margetuximab, and pertuzumab antibodies.
DETAILED DESCRIPTION OF THE INVENTION According to a first aspect of the invention there is provided a binding agent comprising a payload molecule and a first binding component comprising the complementarity determining regions of an antibody, wherein said antibody is capable of binding a high-mannose N-glycan.
According to a second aspect of the invention there is provided a binding agent comprising a first binding component comprising the complementarity determining regions of an antibody, wherein said antibody is capable of binding a high- mannose N-glycan; and a second binding component capable of binding an antigen other than the antigen which the first binding component is capable of binding.
High-mannose N-glycans typically comprise 5-9 or 6-9 mannose residues attached to two GlcNAc residues.
In an embodiment of the first or second aspect, said antibody is capable of binding an oligosaccharide structure comprising the structure according to formula I
Formula !
wherein
(β-Ν-Asn) = β-Ν linkage to asparagine;
Rl = absent or Man 2nMan 6, wherein n = 0 or 1 ; R2 = absent or Man 2mMan 3, wherein m = 0 or 1 ; R3 = Man 2kMan 3, wherein k = 0, 1 or 2 ; with the proviso that at least two substituent groups selected from the group consisting of Rl, R2 and R3 comprise at least two Man residues.
In an embodiment, the high-mannose N-glycan comprises the structure according to formula I.
In this context, the term "binding agent" should be understood as any molecule that is capable of binding an antigen, i.e. specifically recognises an antigen. The antigen may be a high-mannose N-glycan, or it may be e.g. another antigen present on the surface of a tumor cell or a cancer cell. In an embodiment, the binding agent is capable of binding or capable of specifically binding a high-mannose N-glycan.
As known in the art (see e.g. "Essentials of Glycobiology", 2nd edition, Ed. Varki, Cummings, Esko, Freeze, Stanley, Bertozzi, Hart & Etzler; Cold Spring Harbor Laboratory Press, 2009) and used herein, the term "glycan" should be understood to refer to homo- or heteropolymers of sugar residues, which may be linear or branched. In this context, "glycan" should also be understood to encompass a glycan component of a glycoconjugate, i.e. a molecule wherein a sugar moiety is covalently linked to at least one moiety, e.g. a glycoprotein, glycolipid, or proteoglycan. "N-glycan", a term also well known in the art, refers to a glycan conjugated by a β-Ν-linkage (nitrogen linkage through a β-glycosidic bond) to an asparagine (Asn) residue of a protein. N-glycans exist in various forms, but typically comprise two W-acetylglucosamine residues to which three or more mannose residues are attached.
Glycolipid and carbohydrate nomenclature is essentially according to recommendations by the IUPAC-IUB Commission on
Biochemical Nomenclature (e.g. Carbohydrate Res. 1998, 312, 167; Carbohydrate Res. 1997, 297, 1; Eur. J. Biochem. 1998, 257, 293) .
The term "oligosaccharide structure" refers to such glycan structures or portions thereof, which comprise sugar residues. Such sugar residues may comprise e.g. mannose, N- acetylglucosamine, glucose, or fucose linked to each other through glycosidic bonds in a particular configuration.
In this context, the abbreviation "Man" should be understood as mannose; and "GlcNAc" refers to N- acetylglucosamine .
In this context, the term "cancer" should be understood as meaning "tumor" or "cancer cells". The term "tumor" is to be understood as meaning solid multicellular tumor tissues, including premalignant tissue, which is developing to a solid tumor and has cancer specific characteristics.
The notation of the oligosaccharide structure and the glycosidic bonds between the sugar residues comprised therein follows that commonly used in the art, e.g. "Man 2Man" should be understood as meaning two mannose residues linked by a covalent linkage between the first carbon atom of the first mannose residue to the second carbon atom of the second mannose residue linked by an oxygen atom in the alpha configuration. Furthermore, in this context, the notation of the oligosaccharide structure "Man8GlcNAc2" should be understood as meaning a structure comprising eight mannose residues linked to two W-acetylglucosamine residues.
The term "specifically binding" or any related expression as used herein refers to the ability of a binding agent, a first or second binding component or an antibody to discriminate between a specific antigen and any other antigen to the extent that, from a pool of a plurality of different antigens as potential binding partners, only the specific antigen is bound or significantly bound. As examples only, specific binding and/or kinetic measurements may be assayed by e.g. by utilizing surface plasmon resonance-based methods on a Biacore apparatus, by immunological methods such as ELISA or by e.g. protein or carbohydrate microarrays.
The generation of a binding agent according to the first or second aspect may be done using standard techniques well known in the art. For instance, to select a binding agent or a binding component having a desired binding capability and specificity, phage display based on standard procedures may be used as disclosed in e.g. "Phage Display: A Laboratory Manual"; Ed. Barbas, Burton, Scott & Silverman; Cold Spring Harbor Laboratory Press, 2001. Standard procedures of recombinant antibody technologies may also be used to produce the binding agent.
In the context of the first aspect of the invention, the term "first binding component" should not be interpreted so that the binding agent would always comprise more than one binding component. In other words, in some embodiments according to the first aspect of the invention, the binding agent may comprise only the first binding component but no other binding components .
The binding agent may also comprise more than two binding components, for instance a third binding component.
A skilled person will understand that a binding component (first binding component, second binding component or both) may comprise or consist of one or more domains. A binding component may also comprise or consist of one or more polypeptides. For instance, a binding component may comprise a single domain, or it may be an antibody comprising one or more polypeptides, each of which in turn may comprise one or more domains .
The features of the embodiments described below may be combined with the first aspect of the invention as well as with the second aspect of the invention.
In an embodiment, the high-mannose N-glycan is selected from the group consisting of a Man6GlcNAc2 N-glycan, a Man7GlcNAc2 N-glycan, a Man8GlcNAc2 N-glycan, and a Man9GlcNAc2 N-glycan .
In an embodiment, the first binding component is capable of binding a high-mannose N-glycan.
In an embodiment, the antibody or the first binding component is capable of specifically binding a high-mannose N- glycan .
In an embodiment, the antibody is PGT125, PGT126, PGT127, PGT128, PGT130 or TM10 or a modification or derivative thereof .
In the context of the first and second aspect, the antibodies PGT125, PGT126, PGT127, PGT128 and PGT130 should be understood as referring to the antibodies described in Walker et al. 2011, Nature 477:466-471.
In the context of the first and second aspect, the antibody TM10 should be understood as referring to the antibody described in Newsom-Davis et al . 2009, Cancer Res. 69:2018-25.
In an embodiment, the antibody is an antibody selected from the group consisting of PGT125, PGT126, PGT127, PGT128, PGT130 and TM10.
In an embodiment, the antibody is 2G12 or a modification or derivative thereof.
In the context of the first and second aspect, the term "2G12" is to be understood as meaning the domain exchanged human monoclonal IgGl antibody produced from the hybridoma cell line CL2 (described in e.g. US 5,911,989; Buchacher et al. 1994, AIDS Research and Human Retroviruses, 10(4), 359-369; and Trkola et al. 1996, Journal of Virology, 70(2), 1100-1108), and any synthetically, e.g. recombinantly, produced antibody having an identical sequence of amino acids, including any antibody fragment thereof having at least the antigen-binding portions of the heavy and light chain variable region domains to the full- length antibody, such as the 2G12 domain exchanged Fab fragment (described in e.g. US 20050003347; Calarese et al. 2003, Science, 300, 2065-2071), or a modification or derivative thereof .
In an embodiment, the first binding component comprises the heavy chain complementarity determining regions 1-3 having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity as compared to the heavy chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10, and the light chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10 or light chain complementarity determining regions 1-3 having at least about 80 90 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity
as compared to light chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10.
In an embodiment, the first binding component comprises heavy chain complementarity determining regions 1-3 and/or light chain complementarity determining regions having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NOs: 1 - 4, amino acid sequence KAS and SEQ ID NO: 6.
In an embodiment, the first binding component comprises the heavy chain complementarity determining regions HCDR1 (SEQ ID NO: 1), HCDR2 (SEQ ID NO: 2) and HCDR3 (SEQ ID NO: 3) and the light chain complementarity determining regions LCDR1 (SEQ ID NO: 4), LCDR2 (amino acid sequence KAS) and LCDR3 (SEQ ID NO: 6) of the antibody 2G12.
LCDR2 of the antibody 2G12 has the amino acid sequence
KAS (i.e. Lys Ala Ser) .
In an embodiment, the first binding component is a scFv, a single domain antibody, an Fv, a VHH antibody, a diabody, a tandem diabody, a Fab, a Fab', or a F(ab)2.
The first binding component may be e.g. an scFv, a single domain antibody, an Fv, a VHH antibody, a diabody, a tandem diabody, a Fab, a Fab', a F(ab')2, a Db, a dAb-Fc, a taFv, a scDb, a dAb2, a DVD-Ig, a Bs (scFv) 4-IgG, a taFv-Fc, a scFv-Fc- scFv, a Db-Fc, a scDb-Fc, a scDb-CH3, or a dAb-Fc-dAb.
The second binding component may be e.g. an scFv, a single domain antibody, an Fv, a VHH antibody, a diabody, a tandem diabody, a Fab, a Fab', a F(ab')2/ a Db, a dAb-Fc, a taFv, a scDb, a dAb2, a DVD-Ig, a Bs (scFv) 4-IgG, a taFv-Fc, a scFv-Fc- scFv, a Db-Fc, a scDb-Fc, a scDb-CH3, or a dAb-Fc-dAb.
The binding agent may be present in monovalent monospecific, multivalent monospecific, bivalent monospecific, or multivalent multispecific forms.
In an embodiment, the first binding component is a human antibody or a humanized antibody. In an embodiment, the second binding component is a human antibody or a humanized antibody. In this context, the term "human antibody", as it is commonly used in the art, is to be understood as meaning antibodies having variable regions in which both the framework and complementarity determining regions (CDRs) are derived from
sequences of human origin. In this context, the term
"humanized antibody", as it is commonly used in the art, is to be understood as meaning antibodies wherein residues from a CDR of an antibody of human origin are replaced by residues from a CDR of a nonhuman species (such as mouse, rat or rabbit) having the desired specificity, affinity and capacity.
In an embodiment, the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 7 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 7.
In an embodiment, the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 8 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 8.
In an embodiment, the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 9 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 9.
In an embodiment, the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 10 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 10.
In an embodiment, the scFv comprising the sequence set forth in SEQ ID NO: 7, 8, 9 or 10, or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to the SEQ ID NO: 7, 8, 9 or 10 is capable of binding a high-mannose N-glycan.
In an embodiment, the first binding component comprises a heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11.
In an embodiment, the heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO:
11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11 is capable of binding a high-mannose N-glycan.
In an embodiment, the first binding component comprises a light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 12.
In an embodiment, the light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO:
12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 12 is capable of binding a high-mannose N-glycan .
In an embodiment, the first binding component comprises a heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11 and light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to the SEQ ID NO: 12, and optionally the light chain constant domain of the antibody 2G12 and/or one or more heavy chain constant domains of the antibody 2G12 selected from the group consisting of CHI, CH2 and CH3 of the antibody 2G12.
In an embodiment, the heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11 and/or the light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 12 is capable of binding a high-mannose N-glycan.
In an embodiment, the first binding component or the antibody 2G12 comprises a heavy chain variable region comprising a sequence set forth in SEQ ID NO: 11 and a light chain variable region comprising a sequence set forth in SEQ ID NO: 12.
In an embodiment, the first binding component comprises the light chain constant domain of the antibody 2G12 and/or one or more heavy chain constant domains of the antibody 2G12 selected from the group consisting of CHI, CH2 and CH3 of the antibody 2G12.
In an embodiment, the first binding component comprises one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the light chain of an Ig molecule; and/or one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the heavy chain of an Ig molecule; wherein the first binding component comprises one or more introduced N- glycosylation sites in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the light chain; and/or one or more introduced N-glycosylation sites in any region or domain in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the heavy chain.
In an embodiment, the first binding component comprises the antibody 2G12.
In an embodiment, the first binding component is or consists of the antibody 2G12.
In an embodiment, one or more amino acid residues of the first binding component are substituted by substitutions selected from the group consisting of I19N, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 13.
In an embodiment, the first binding component comprises the 2G12 heavy chain having a sequence set forth in SEQ ID NO: 13, wherein one or more amino acid residues are substituted by substitutions selected from the group consisting of I19N, F78S,
E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 13.
The substitution I19N should be understood as referring to a substitution of the amino acid residue I at the position 19 of the sequence set forth in SEQ ID NO: 13 to the amino acid residue N. Other substitutions described in this specification are indicated in the same manner. If the first binding component comprises a portion but not the full sequence of e.g. the heavy chain set forth in SEQ ID NO: 13, a skilled person is capable of determining a corresponding amino acid residue in the first binding component and making a corresponding substitution.
One or more of the substitutions may provide improved properties to the binding agent. For instance, the substitution I19N and/or F78S may improve the solubility of the binding agent, render the production of the binding agent easier and/or improve the yield of the binding agent. One or more of the substitutions may introduce an additional N-glycosylation site. The additional N-glycosylation sites may be utilized by incorporating therein e.g. N-glycans having beneficial properties or additional payload molecules.
In an embodiment, one or more amino acid residues of the first binding component are substituted by substitutions selected from the group consisting of T18N, L154S, Q160N S174N and T180N as compared to SEQ ID NO: 14.
In an embodiment, the first binding component comprises the 2G12 light chain having a sequence set forth in in SEQ ID NO: 14, wherein one or more amino acid residues are substituted by substitutions selected from the group consisting of T18N, L154S, Q160N S174N and T180N as compared to SEQ ID NO: 14.
In an embodiment, the first binding component comprises the sequences set forth in SEQ ID NOs : 15 and SEQ ID NO: 12.
In an embodiment, the first binding component comprises the sequences set forth in SEQ ID NOs: 15 and SEQ ID NO: 14.
In an embodiment, the first binding component comprises the sequences set forth in SEQ ID NOs: 16 and SEQ ID NO: 12.
In an embodiment, the first binding component comprises the sequences set forth in SEQ ID NOs: 16 and SEQ ID NO: 14.
In an embodiment, the first binding component comprises the sequences set forth in SEQ ID NOs: 17 and SEQ ID NO: 12.
In an embodiment, the first binding component comprises the sequences set forth in SEQ ID NOs : 17 and SEQ ID NO: 14.
In an embodiment, the binding agent comprises a detection-enabling molecule. Examples of detection-enabling molecules are molecules conveying affinity such as biotin or a
His tag comprising at least five histidine (His) residues; molecules that have enzymatic activity such as horseradish peroxidase (HRP) or alkaline phosphatase (AP) ; various fluorescent molecules such as FITC, TRITC, and the Alexa and Cy dyes; gold; radioactive atoms or molecules comprising such; chemiluminescent or chromogenic molecules and the like, which molecules provide a signal for visualization or quantitation.
The detection-enabling molecule may be covalently bound to the binding agent, to the first binding component and/or to the second binding component, or it may be bound indirectly thereto e.g. via a suitable linker group. The linker group may be e.g. any linker described in this specification.
In an embodiment according to the first aspect, the binding agent comprises a second binding component capable of binding an antigen other than the antigen which the first binding component is capable of binding.
In the context of both the first aspect and the second aspect of the invention, the second binding component is capable of binding an antigen that is different or other than the antigen which the first binding component is capable of binding.
The second binding component may thus have a different binding specificity than the first binding component. The antigen that the second binding component is capable of binding may be e.g. an antigen present on the surface of a tumor cell or cancer cell .
In an embodiment, the second binding component is capable of binding an antigen other than a high-mannose N- glycan .
In an embodiment, the second binding component is capable of binding a cell surface antigen.
In an embodiment, the cell surface antigen is a tumor antigen and/or a cancer antigen.
In an embodiment, the tumor antigen/a cancer antigen may include, but is not limited to, CD2, CD3, CD4, CD5, CD6, CD11, CD8, CDlla, CD19, CD20, CD22, CD25, CD26, CD30, CD33, CD34, CD37, CD38, CD40, CD44, CD46, CD52, CD56, CD79, CD105, and CD138; members of the ErbB receptor family, such as epidermal growth factor receptor 1 (EGFR) , epidermal growth factor receptor 2 (HER2/neu), HER3 or HER4 receptor; cell adhesion molecules, such as LFA-1, Macl, pl50.95, VLA-4, ICAM-1, VCAM, EpCAM, alpha4/beta7 integrin, and alpha v/beta3 integrin including either alpha or beta subunits thereof; growth factors, such as VEGF; tissue factor (TF) ; tumor necrosis factor alpha (TNF- ) ; human vascular endothelial growth factor (VEGF) ; glycoprotein Ilb/IIIa; TGF-beta; alpha interferon (alpha-IFN) ; an interleukin, such as IL-8; an interleukin receptor, such as IL-2 receptor; cancer-associated high-mannose type N-glycans; blood group antigens Apo2, death receptor; flk2/flt3 receptor; CTLA-4; transferrin receptor; or a cancer-associated glycan structure, such as Lewis y or GD3.
The features of the embodiments described below may be combined with the first aspect of the invention as well as with the second aspect of the invention.
The binding agent according to the first or second aspect may be a bispecific binding agent, such as a bispecific antibody molecule. A bispecific binding agent contains both the first binding component and the second binding component and is thus capable of binding to two different antigens or epitopes. The binding agent may also be a multispecific binding agent, such as a multispecific antibody molecule.
A skilled person is well aware that there are a number of ways to create a bispecific or a multispecific binding agent e.g. by recombinant technology. Various formats of bispecific binding agents, such as bispecific antibodies, are described e.g. in Kontermann RE (2012) Dual targeting strategies with bispecific antibodies, mAbs 4:182-197. The bispecific binding agent or a protein moiety thereof may comprise e.g. a bispecific IgG2, IgG, IgG, IgGscFv, scFv-IgG, F(ab')2, F (ab' ) 2-scFv, diabody, dual-affinity re-targeted antibody (DART) , tandem scFv, Fab-scFv, taFv, scDb, dAb2, DVD-Ig, Bs (scFv) 4-IgG, taFv-Fc, scFv-Fc-scFv, db-Fc, scDb-Fc, scDb-CH3, or dAb-Fc-dAb.
In an embodiment, the binding agent comprises IgG2. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the IgG2. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the IgG2. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the IgG2. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the IgG2. In an embodiment, additional N- glycosylation sites are introduced into the heavy chains and light chains of the IgG2.
In an embodiment, the binding agent comprises a bispecific IgG. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific IgG. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific IgG. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific IgG. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific IgG. In an embodiment, additional N- glycosylation sites are introduced into the heavy chains and light chains of the bispecific IgG.
In an embodiment, the binding agent comprises an IgG- scFv. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the IgG-scFv. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the IgG-scFv. In an embodiment, additional N- glycosylation sites are introduced into the heavy chain of the IgG-scFv. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the IgG-scFv. In an embodiment, additional N-glycosylation sites are introduced into the heavy chains and light chains of the IgG-scFv.
In an embodiment, the binding agent comprises an scFv- IgG. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the scFv-IgG. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the scFv-IgG. In an embodiment, additional N- glycosylation sites are introduced into the heavy chain of the scFv-IgG. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the scFv-IgG. In an
embodiment, additional N- glycosylation sites are introduced into the heavy chains and light chains of the scFv- IgG.
In an embodiment, the binding agent comprises a bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N- glycosylation sites are introduced into the heavy chains and light chains of the bispecific F(ab' )2- In an embodiment, the binding agent comprises an
F (ab' ) 2~scFv . In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the bispecific F(ab' )2- In an embodiment, additional N- glycosylation sites are introduced into the light chain of the bispecific F(ab' )2- In an embodiment, additional N-glycosylation sites are introduced into the heavy chains and light chains of the bispecific F(ab' )2-
In an embodiment, the binding agent comprises a diabody. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the diabody. In an embodiment, additional N-glycosylation sites are introduced into light chain of the diabody. In an embodiment, additional N- glycosylation sites are introduced into the heavy chain of the diabody. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the diabody. In an embodiment, additional N-glycosylation sites are introduced into the heavy chains and light chains of the diabody.
In an embodiment, the binding agent comprises a dual- affinity re-targeted antibody (DART) . In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the DART. In an embodiment, additional N-glycosylation
sites are introduced into the light chain of the DART. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the DART. In an embodiment, additional N- glycosylation sites are introduced into the light chain of the DART. In an embodiment, additional N-glycosylation sites are introduced into the heavy chains and light chains of the DART.
In an embodiment, the binding agent comprises a tandem scFv. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the tandem scFv. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the tandem scFv. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the tandem scFv. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the tandem scFv. In an embodiment, additional N-glycosylation sites are introduced into the heavy chains and light chains of the tandem scFv.
In an embodiment, the binding agent comprises a Fab- scFv. In an embodiment, additional N-glycosylation sites are introduced into the heavy chain of the Fab-scFv. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the Fab-scFv. In an embodiment, additional N- glycosylation sites are introduced into the heavy chain of the Fab-scFv. In an embodiment, additional N-glycosylation sites are introduced into the light chain of the Fab-scFv. In an embodiment, additional N-glycosylation sites are introduced into the heavy chains and light chains of the Fab-scFv.
The first binding component and the second binding component may be functionally linked e.g. by chemical coupling, fusion, or non-covalent association.
In an embodiment, the first binding component and the second binding component are fused. The binding agent thus comprises a fusion polypeptide, wherein the fusion polypeptide comprises both the first binding component and the second binding component. A skilled person is well aware of a number of methods of producing fusion polypeptides. The C-terminus of the first binding component may be fused to the N-terminus of the second binding component, or the C-terminus of the second binding component may be fused to the N-terminus of the first binding component. The first binding component and the second
binding component may be fused directly or indirectly, e.g. via a linker sequence.
In an embodiment, the first binding component and the second binding component are chemically cross-linked. They may be chemically crosslinked e.g. via a suitable linker group. The length of the linker group may be selected based on the first and second binding component to be joined. Suitable linker groups may be, for example, m-maleimidobenzoyl-N- hydroxysuccinimide ester or disuccinimidyl suberate.
In an embodiment, the second binding component is capable of binding human EGFRl .
In an embodiment, the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR, and LCDR3 of an anti-EGFRl antibody .
In an embodiment, the first binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 of 2G12 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of 2G12, and the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of an anti-EGFRl antibody.
In an embodiment, the second binding component is an anti-EGFRl antibody or an EGFRl binding fragment thereof.
In an embodiment, the second binding component comprises a heavy chain variable region and a light chain variable region of an anti-EGFRl antibody.
In an embodiment, the anti-EGFRl antibody is selected from the group consisting of cetuximab, imgatuzumab, matuzumab, nimotuzumab, necitumumab, panitumumab, and zalutumumab.
In an embodiment, the anti-EGFRl antibody is cetuximab.
In an embodiment, cetuximab comprises the sequences set forth in SEQ ID NO:s 18 and 19.
In one embodiment, additional N-glycosylation sites are introduced into the cetuximab heavy chain. In one embodiment, the cetuximab heavy chain comprises one or more substitutions
selected from the group consisting of G161S, Q177N, L184N, S192N, and L195N as compared to SEQ ID NO: 18.
In one embodiment, additional N-glycosylation sites are introduced into the cetuximab light chain. In one embodiment, cetuximab light chain comprises one or more substitutions selected from the group consisting of R18N, L154S, Q160N, S174N, and T180N as compared to SEQ ID NO: 19.
In an embodiment, the anti-EGFRl antibody is imgatuzumab .
In an embodiment, imgatuzumab comprises the sequences set forth in SEQ ID NO:s 20 and 21.
In an embodiment, additional N-glycosylation sites are introduced into the imgatuzumab heavy chain.
In an embodiment, the imgatuzumab heavy chain comprises one or more substitutions selected from the group consisting of E80N, G164S, Q178N, L185N, S193N, and L196N as compared to SEQ ID NO: 20.
In an embodiment, additional N-glycosylation sites are introduced into imgatuzumab light chain.
In an embodiment, imgatuzumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 21.
In an embodiment, the anti-EGFRl antibody is matuzumab. In an embodiment, matuzumab comprises the sequences set forth in SEQ ID NO:s 22 and 23.
In an embodiment, additional N-glycosylation sites are introduced into the matuzumab heavy chain.
In an embodiment, the matuzumab heavy chain comprises one or more substitutions selected from the group consisting of E89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 22.
In an embodiment, additional N-glycosylation sites are introduced into the matuzumab light chain.
In an embodiment, the matuzumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N and T185N as compared to SEQ ID NO: 23.
In an embodiment, nimotuzumab comprises the sequences set forth in SEQ ID NO:s 24 and 25.
In an embodiment, additional N-glycosylation sites are introduced into the nimotuzumab heavy chain. In an embodiment, the nimotuzumab heavy chain comprises one or more substitutions selected from the group consisting of E74N, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 24.
In an embodiment, additional N-glycosylation sites are introduced into the nimotuzumab light chain.
In one embodiment, the nimotuzumab light chain comprises one or more substitutions selected from the group of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 25.
In an embodiment, the anti-EGFRl antibody is necitumumab. In an embodiment, necitumumab comprises the sequences set forth in SEQ ID NO:s 26 and 27.
In an embodiment, additional N-glycosylation sites are introduced into the necitumumab heavy chain.
In an embodiment, the necitumumab heavy chain comprises one or more substitutions selected from the group consisting of A89N, G165S, Q179N, L186N, S194N and L197N as compared to SEQ ID NO: 26.
In an embodiment, additional N-glycosylation sites are introduced into the necitumumab light chain.
In an embodiment, the necitumumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 27.
In an embodiment, the antibody is panitumumab. In one embodiment, additional N-glycosylation sites can be introduced into heavy and/or light chains of panitumumab, and any other antibody herein, as described in, for example, W097/34632 and/or W095/15769. As described in W097/34632, additional N-glycosylation sites may be those of depicted in Fig 12 and corresponding to HCN1, HCN2, HCN3, HCN4, and/or HCN5 for heavy chain, and KCN1, KCN2, KCN3, and/or KCN4 for kappa light chain. An additional N-glycosylation site in an antibody may mean one or more non-Asn297 N-glycosylation sites. The non-
Asn297 N-glycosylation sites can be present in or be introduced into a heavy and/or a light chain.
In an embodiment, the anti-EGFRl antibody is zalutumumab .
In an embodiment, zalutumumab comprises the sequences set forth in SEQ ID NO:s 28 and 29.
In an embodiment, additional N-glycosylation sites are introduced into the zalutumumab heavy chain.
In an embodiment, the zalutumumab heavy chain comprises one or more substitutions selected from the group consisting of E89N, G169S, Q183N, L190N, S198N, and L201N as compared to SEQ ID NO: 28.
In an embodiment, additional N-glycosylation sites are introduced into the zalutumumab light chain.
In an embodiment, the zalutumumab light chain comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 29.
In an embodiment, the anti-EGFRl antibody or its EGFR1 binding fragment comprises one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the light chain of an anti-EGFRl Ig molecule; and/or one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of sequence corresponding to the heavy chain of an anti-EGFRl Ig molecule; wherein the anti-EGFRl antibody or its EGFR1 binding fragment comprises one or more introduced N-glycosylation sites in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the light chain; and/or one or more introduced N-glycosylation sites in any region or domain in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the heavy chain.
In an embodiment, the first binding component is a scFv derived from 2G12, and the second binding component comprises
the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 of an anti-EGFRl antibody.
In an embodiment, the scFv derived from 2G12 is a scFv comprising the heavy chain complementarity determining regions HCDR1 (SEQ ID NO: 1), HCDR2 (SEQ ID NO: 2) and HCDR3 (SEQ ID NO: 3) and the light chain complementarity determining regions LCDR1 (SEQ ID NO: 4), LCDR2 (amino acid sequence KAS) and LCDR3 (SEQ ID NO: 6) of 2G12.
In an embodiment, the scFv derived from 2G12 comprises the sequence set forth in SEQ ID NO: 7.
In an embodiment, the scFv derived from 2G12 comprises a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs : 7 - 10.
In an embodiment, the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 7, and the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 of an anti-EGFRl antibody.
In an embodiment, the first binding component is a scFv comprising a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs: 7 - 10, and the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2 and LCDR3 of an anti-EGFRl antibody.
In an embodiment, the scFv derived from 2G12 is fused to the C-terminus of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
In an embodiment, the scFv derived from 2G12 is fused to the C-terminus of the heavy chain of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
In an embodiment, the scFv derived from 2G12 is fused to the N-terminus of the heavy chain of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
In an embodiment, the scFv derived from 2G12 is fused to the N-terminus of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
In an embodiment, the second binding component comprises at least one of the following:
(i) the cetuximab heavy chain having a sequence set forth in SEQ ID NO: 18, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of G161S, Q177N, L184N, S192N and L195N as compared to SEQ ID NO: 18;
(ii) imgatuzumab heavy chain having a sequence set forth in SEQ ID NO: 20, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E80N, G164S, Q178N, L185N, S193N, and L196N as compared to SEQ ID NO: 20;
(iii) matuzumab heavy chain having a sequence set forth in SEQ ID NO: 22, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 22;
(iv) nimotuzumab heavy chain having a sequence set forth in SEQ ID NO: 24, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E74N, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 24;
(v) necitumumab heavy chain having a sequence set forth in SEQ ID NO: 26, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of A89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 26;
(vi) panitumumab heavy chain, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E to N substitution at about amino acid 91, G to S substitution at about amino acid 161 (in sequence NSG) , Q to N at about amino acid 177 (in sequence QSS), L to N at about amino acid 184 (in sequence LSS), S to N at about amino acid 192 (in sequence SSS) , and L to N at about amino acid 195 (in sequence LGT) as compared to the panitumumab heavy chain sequence; or
(vii) zalutumumab heavy chain having a sequence set forth in in SEQ ID NO: 28, wherein one or more amino acid residues are substituted by a substitution selected from the
group consisting of E89N, G169S, Q183N, L190N, S198N, and L201N as compared to SEQ ID NO: 28.
In an embodiment, the second binding component comprises at least one of the following:
(i) the cetuximab light chain having a sequence set forth in in SEQ ID NO: 19, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L154S, Q160N, S174N, and T180N as compared to SEQ ID NO: 19;
(ii) the imgatuzumab light chain having a sequence set forth in in SEQ ID NO: 21, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 21;
(iii) the matuzumab light chain having a sequence set forth in in SEQ ID NO: 23, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 23;
(iv) the nimotuzumab light chain having a sequence set forth in in SEQ ID NO: 25, comprises one or more substitutions selected from the group of: R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 25;
(v) the necitumumab light chain having a sequence set forth in in SEQ ID NO: 27, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 27;
(vi) the panitumumab light chain wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R to N substitution at about amino acid 18, L to S substitution at about amino acid 154 (in sequence NAL) , Q to N substitution at about amino acid 160 (in sequence QES) , S to N substitution at about amino acid 174 (sequence SLS -> NLS) , and T to N substitution at about amino acid 180 (in sequence TLS) as compared to the panitumumab light chain sequence; or
(vii) the zalutumumab light chain having a sequence set forth in in SEQ ID NO: 29, wherein one or more amino acid
residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 29.
In an embodiment, the second binding component is capable of binding human ERBB2/HER2.
In an embodiment, the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR, and LCDR3 of an anti-ERBB2 /HER2 antibody.
In an embodiment, the first binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 of 2G12 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of 2G12, and the second binding component comprises the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of an anti-ERBB2 /HER2 antibody.
In an embodiment, the second binding component is an anti- ERBB2/HER2 antibody or an ERBB2/HER2 binding fragment thereof .
In an embodiment, the second binding component comprises a heavy chain variable region and a light chain variable region of an anti-ERBB2 /HER2 antibody.
In an embodiment, the anti-EGFRl antibody is selected from the group consisting of trastuzumab, ertumaxomab, margetuximab, and pertuzumab.
In an embodiment, the anti-ERBB2 /HER2 antibody is trastuzumab. In an embodiment, trastuzumab comprises the sequences set forth in SEQ ID NO:s 30 and 31. In an embodiment, additional N-glycosylation sites are introduced into the trastuzumab heavy chain. In an embodiment, additional N- glycosylation sites are introduced into the trastuzumab light chain .
In an embodiment, the anti-ERBB2 /HER2 antibody is ertumaxomab. In an embodiment, additional N-glycosylation sites are introduced into the ertumaxomab heavy chain. In an embodiment, additional N-glycosylation sites are introduced into the ertumaxomab light chain.
In an embodiment, the anti-ERBB2 /HER2 antibody is margetuximab . In an embodiment, margetuximab comprises the sequences set forth in SEQ ID NO:s 32 and 33. In an embodiment, additional N-glycosylation sites are introduced into the margetuximab heavy chain. In an embodiment, additional N- glycosylation sites are introduced into the margetuximab light chain .
In an embodiment, the anti-ERBB2 /HER2 antibody is pertuzumab. In an embodiment, pertuzumab comprises the sequences set forth in SEQ ID NO:s 34 and 35. In an embodiment, additional N-glycosylation sites are introduced into the pertuzumab heavy chain. In an embodiment, additional N-glycosylation sites are introduced into the pertuzumab light chain.
In an embodiment, the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions.
In an embodiment, the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions in the heavy chain.
In an embodiment, the binding agent comprises a fusion polypeptide comprising one or more additional stabilizing amino acid substitutions.
In an embodiment, the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions, such as an additional cysteine residues.
In an embodiment, the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions, such as an additional cysteine residues in the scFv.
Exemplary stabilizing amino acid substitutions include, but are not limited to, an additional cysteine residue in the heavy chain variable and/or light chain variable domain of an scFv. Such an additional cysteine residue may be capable of forming a sulphur bridge with another cysteine residue, for instance another additional cysteine residue in the scFv, and thus stabilize the structure.
In an embodiment, a stabilizing amino acid substitution corresponds to G44C in a heavy chain of an Ig molecule.
In an embodiment, a stabilizing amino acid substitution corresponds to G100C in a light chain of an Ig molecule .
In an embodiment, stabilizing amino acid substitutions correspond to G44C in a heavy chain and G100C in a light chain of an Ig molecule. In an embodiment, a stabilizing amino acid substitution is G44C in a heavy chain of 2G12 (scFv) and G100C in a light chain of 2G12 (scFv) .
In an embodiment, the binding agent comprises a fusion polypeptide comprising the nimotuzumab heavy chain fused to a scFv derived from 2G12. In this context, the scFv derived from 2G12 may be any scFv derived from 2G12 described in this specification .
In an embodiment, the binding agent comprises a fusion polypeptide having a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs : 36, 37 and 38.
In an embodiment, the binding agent comprises a fusion polypeptide comprising a sequence selected from the group consisting of the sequences set forth in SEQ ID NOs: 36, 37 and 38.
In an embodiment, the binding agent comprises the sequences set forth in SEQ ID NOs: 36 and 39.
In an embodiment, the binding agent comprises the sequences set forth in SEQ ID NOs: 37 and 39.
In an embodiment, the binding agent comprises the sequences set forth in SEQ ID NOs: 38 and 19.
In an embodiment, the binding agent comprises the sequence set forth in SEQ ID NO: 42.
According to the first aspect, the payload molecule may be any number of agents, including but not limited to cytotoxic agents or drugs such as chemotherapeutic agents, growth inhibitory agents, toxins (for example, an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof) , or a radioactive isotope or a compound comprising a radioactive isotope (that is, a radioconjugate) .
In an embodiment according to the first aspect, the payload molecule is a toxic payload molecule, a fluorescent label molecule or a radioactive molecule.
The toxic payload molecule may, in principle, be any toxic molecule suitable for conjugation to the binding agent according to the first aspect. It may be any compound that results in the death of a cell, or induces cell death, or in some manner decreases cell viability. The toxic payload molecule can be any of many small molecule drugs, including, but not limited to, dolastatins ; auristatins ; epothilones ; daunorubicins and doxorubicins; alkylating agents, such as thiotepa and cyclophosphamide (CYTOXAN™) ; alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines, such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylene-phosphoramide, triethylenethiophosphaoramide and trimethylolomelamine ; acetogenins (especially bullatacin and bullatacinone) ; camptothecins (including the synthetic analogue topotecan) ; bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues) ; cryptophycins (particularly cryptophycin 1 and cryptophycin 8); duocarmycin (including the synthetic analogues, KW-2189 and CBI- TMI); eleutherobin; pancratistatin; sarcodictyins ; spongistatin; nitrogen mustards such as chlorambucil, chlomaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics, such as the enediyne antibiotics (e.g. calicheamicins , especially calicheamicin γΐ ; dynemicin, including dynemicin A; esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antiobiotic chromomophores ) , aclacinomysins , actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, caminomycin, carzinophilin; chromomycins , dactinomycin, detorubicin, 6-diazo-5-oxo-L- norleucine, other doxorubicin derivatives including morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino- doxorubicin and deoxydoxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, nitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin,
tubercidin, ubenimex, zinostatin, zorubicin; antimetabolites, such as methotrexate and 5-fluorouracil (5-FU) ; folic acid analogues, such as denopterin, methotrexate, pteropterin, trimetrexate ; purine analogs, such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine ; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-fluorouracil ; androgens, such as calusterone, dromostanolone propionate, epitiostanol , mepitiostane, testolactone ; anti-adrenals, such as aminoglutethimide, mitotane, trilostane; folic acid replenisher, such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids , such as maytansine, ansamitocins , DM- 1, DM-4; mitoguazone; mitoxantrone ; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2- ethylhydrazide ; procarbazine; PSK®; razoxane; rhizoxin; sizofuran; spirogermanium; tenuazonic acid; triaziquone; 2 , 2 2 "-trichlorotriethylamine ; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine) ; urethan; vindesine; dacarbazine; mannomustine ; mitobronitol ; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C") ; cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.J.) and doxetaxel (TAXOTERE®, Rhone- Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6- thioguanine; mercaptopurine ; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO) ; retinoic acid; capecitabine ; anti-hormonal agents that act to regulate or inhibit hormone action on tumors, such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4 ( 5 ) -imidazoles , 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston) ; and anti-androgens , such as flutamide, nilutamide, bicalutamide,
leuprolide, and goserelin; siRNA; and pharmaceutically acceptable salts, acids or derivatives of any of the above as well as analogues and derivatives thereof, some of which are described below.
In an embodiment, the toxic payload molecule is a dolastatin, auristatin, doxorubicin, maytansinoid, epirubicin, duocarmycin, or any analogue or derivative thereof.
In an embodiment, the toxic payload molecule is dolastatin 10, dolastatin 15 or any derivative thereof.
In an embodiment, the toxic payload molecule is auristatin F or any derivative thereof.
In an embodiment, the toxic payload molecule is dolastatin 10, dolastatin 15, or auristatin F.
In an embodiment, the toxic payload molecule is dolastatin 10.
In an embodiment, the toxic payload molecule is dolastatin 15.
In an embodiment, the toxic payload molecule is auristatin F.
Dolastatins that can be used in the present invention are well known in the art and can be isolated from natural sources according to known methods or prepared synthetically according to known methods .
Examples of suitable dolastatins include monomethyl and desmethyl dolastatins 10, 15, C, D and H, monomethyl and desmethyl isodolastatin H, and analogues and derivatives thereof. These dolastatins contain a primary or secondary amine at the N-terminus. Dolastatins 10 and 15 are the most potent toxic payload molecules among the naturally occurring dolastatins. Monomethyl and desmethyl dolastatins 10 and 15 can be prepared by chemical synthesis according to standard peptide synthesis chemistry.
Auristatins that can be used in the present invention include (but are not limited to) monomethyl and desmethyl auristatins E, F, EB, EFP, PY, PYE, PE, PHE, TP, 2-AQ and 6-AQ, e.g. described in U.S. Pat. No. 5,635,483; Int. J. Oncol. 15:367-72 (1999); Mol. Cancer Ther. 3:921-32 (2004); U.S. application Ser. No. 11/134,826; U.S. Patent Publication Nos.
20060074008 and 2006022925; and Pettit, G.R., et al . (2011) J. Nat. Prod. 74:962-8.
In an embodiment, the monomethyl or desmethyl dolastatin 15 analogue or derivative is selected from the group consisting of monomethyl and desmethyl dolastatin 15, monomethyl and desmethyl cemadotin, monomethyl and desmethyl tasidotin, and monomethyl and desmethyl P5 (the corresponding dimethyl compounds are described in Bai et al . 2009. Mol. Pharmacol. 75:218-26) .
The toxic payload molecule may also be daunorubicin or doxorubicin. The primary amine group of the daunosamine moiety can be used, or daunorubicin or doxorubicin can be modified to comprise another primary or secondary amine moiety.
In an embodiment, the toxic payload molecule is a maytansinoid .
In an embodiment, the toxic payload molecule is maytansine, an ansamitocin, DM1 or DM4 (also known as DM-4) .
In an embodiment, the toxic payload molecule is DM1. DM1 is also known as DM-1 and mertansine.
In an embodiment, the toxic payload molecule is a rubicin. Suitable rubicins may be e.g. daunorubicins , doxorubicins, detorubicin, other doxorubicin derivatives including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, deoxydoxorubicin, epirubicin, esorubicin, idarubicin, rodorubicin, zorubicin, and pirarubicin.
In an embodiment, the toxic payload molecule is epirubicin .
In an embodiment, the toxic payload molecule is duocarmycin. Suitable duocarmyxins may be e.g. duocarmycin A, duocarmycin Bl, duocarmycin B2, duocarmycin CI, duocarmycin C2, duocarmycin D, duocarmycin SA, duocarmycin MA, and CC-1065. The term "duocarmycin" should be understood as referring also to synthetic analogs of duocarmycins , such as adozelesin, bizelesin, carzelesin, KW-2189 and CBI-TMI.
In an embodiment, the duocarmycin is a duocarmycin suitable for conjugating to the binding agent according to the first aspect. In an embodiment, the duocarmycin comprises an amino group or another suitable chemical group for conjugating
the duocarmycin to the binding agent according to the first aspect. In an embodiment, the amino group is a free amino group.
One skilled in the art of payload molecules will readily understand that each of the payload molecules described in this specification can be modified in such a manner that the resulting compound still retains the specificity and/or activity of the starting compound. The skilled person will also understand that many of these compounds can be used in place of the toxic payload molecules described herein. Thus, the toxic payload molecules of the present invention should be understood as including any analogues and derivatives of the compounds described herein.
In an embodiment, the payload molecule is a toxic payload molecule selected from the group consisting of dolastatin, auristatin, doxorubicin, maytansinoid, epirubicin, duocarmycin, and any analogue or derivative thereof.
In this context, the term "fluorescent label molecule" may refer to any fluorophore which can re-emit light upon light excitation. Such a fluorescent label molecule may be suitable for detection, visualization and/or quantitation. Suitable fluorescent label molecules may be e.g. FITC, TRITC, and the Alexa and Cy dyes.
In this context, the term "radioactive molecule" may refer to any molecule that comprises a radioactive atom. The term "radioactive molecule" may refer to a radioactive molecule suitable for radiation therapy. It may also refer to a radioactive molecule suitable for detection, visualization and/or quantitation.
The payload molecule may be selected so that it comprises a functional group that allows for conjugating it to the binding agent according to the first aspect. The payload molecule may also be modified prior to reacting it with other components of the binding agent according to the first aspect. In an embodiment, the payload molecule comprises a primary or secondary amine moiety. In an embodiment, the payload molecule is modified to comprise a primary or secondary amine moiety. In an embodiment, the amine-modified payload molecule essentially retains the activity of the original payload molecule after conj ugation .
In an embodiment, the payload molecule is covalently linked to the binding agent.
In an embodiment, the payload molecule is covalently linked to the first binding component.
In an embodiment, the payload molecule is covalently linked to the second binding component.
The payload molecule may be covalently linked to the binding agent, to the first binding component and/or to the second binding component directly, via a bond, or indirectly, e.g. via a linker or linker group. An overview of the technology of covalently linking or conjugating payload molecules to binding agents is provided in Ducry et al . , Bioconjugate Chem. , 21:5-13 (2010), Carter et al . , Cancer J. 14(3) :154 (2008) and Senter, Current Opin. Chem. Biol. 13:235-244 (2009). Linkers that may, in principle, be utilised are described e.g. in Dosio et al . , Toxins 2011, 3, 848-883, and Sammet et al . , Pharm. Pat. Analyst 2012, 1(1), 2046-8954.
The linker may be e.g. a peptide linkage or a linker cleavable by a lysosomal hydrolase. As will be appreciated by those in the art, the number of payload molecules, i.e. the drug moieties per binding agent may vary.
In an embodiment, the binding agent comprises a molecule represented by formula II [D-L]n-P
Formula II wherein P is the first binding component or the second binding component;
n is at least 1 ;
L is a linker group covalently joining P to D; and
D is the payload molecule.
In an embodiment, the binding agent is a molecule represented by formula II.
In an embodiment, the binding agent consists of a molecule represented by formula II.
In an embodiment, n is an integer from 1 to 20. In an embodiment, n is 2-18. In an embodiment, n is 2-16. In an
embodiment, n is 2-10. In other embodiments, n is 2-6; 2-5; 2- 4; 2-3; 3-4; or 1, 2, 3 or 4.
In an embodiment, the binding agent comprises a molecule represented by formula III
[D-L-G]n-P
Formula III wherein P is the first binding component or the second binding component comprising an N-glycan, wherein the N-glycan comprises a GlcNAc residue bound by a β-Ν linkage to an asparagine ;
n is at least 1;
D is the payload molecule;
L is a linker group covalently joining G to D; and
G is a saccharide structure represented by formula IV
Formula IV wherein
R is a glycosidic bond to the N-glycan or a glycosidic bond to the GlcNAc residue bound by a β-Ν linkage to an asparagine ;
X1 is H or carboxyl;
X2, X3 and X4 are each independently OH, H, amino, C2-C6 acylamide, phosphate or sulphate ester, or a bond to L;
X5 is CH2OH, carboxyl, CH3, H, C1-C3 alkyl or substituted C1-C3 alkyl, or a bond to L;
with the proviso that one substituent selected from X2, X3, X4 and X5 is a bond to L or bonded via a bond to L; and
with the proviso that when X1 is carboxyl, then X2 is H, X3 is OH, X5 is C1-C3 alkyl or substituted C1-C3 alkyl; R is a glycosidic bond to the N-glycan; and X4 is a bond to L or X5 is bonded via a bond to L; or
when X1 is H, then R is a glycosidic bond to the N- glycan or to the GlcNAc residue bound by a β-Ν linkage to an asparagine .
In an embodiment, the binding agent is a molecule represented by formula III.
In an embodiment, the binding agent consists of a molecule represented by formula III.
These embodiments have the added utility that they comprise a relatively small payload molecule-glycan moiety that is efficiently released inside cells. This may be particularly beneficial when the payload molecule is a toxic payload molecule. Further, the moiety released is relatively small; small toxic payload molecule conjugates tend to be more toxic than large toxic payload molecule conjugates e.g. comprising a complex-type N-glycan core structure. The toxic payload molecule-glycan conjugate released from the binding agent in cells is capable of delivering the toxic payload molecule into cells and further into the cytosol, the nucleus or the endoplasmic reticulum. The binding agent is also sufficiently stable towards chemical or biochemical degradation during manufacturing or in physiological conditions, e.g. in blood, serum, plasma or tissues, and in reducing conditions, in low pH and inside cells, cellular organelles, endosomes and lysosomes.
In an embodiment, n is an integer from 1 to 20. In an embodiment, n is 2-18. In an embodiment, n is 2-16. In an embodiment, n is 2-10. In other embodiments, n is 2-6; 2-5; 2-4; 2-3; 3-4; or 1, 2, 3 or 4.
In an embodiment, G is a saccharide structure represented by formula V
Formula V wherein
R is a glycosidic bond to the N-glycan;
X4 is OH, H, amino, C2 _ C6 acylamide, phosphate or sulphate ester, or a bond to L;
X5 is C1-C3 alkyl or substituted C1-C3 alkyl;
and X4 is a bond to L or X5 is bonded via a bond to L.
In an embodiment, the N-glycan comprises a terminal Θβΐβ residue and R is a glycosidic bond to the terminal Θβΐβ residue .
In an embodiment, the N-glycan consists of the structure represented by formula VI
(Fuc 6),
\
GicNAc{i5-N-Asn)
Formula VI wherein (β-Ν-Asn) is a β-Ν linkage to an asparagine and y is 0 or 1;
X1 is H;
X2, X3 and X4 are each independently OH, H, amino, C2-C6 acylamide, phosphate or sulphate ester, or a bond to L;
X5 is CH2OH, carboxyl, CH3, H, C1-C3 alkyl or substituted C1-C3 alkyl, or a bond to L;
with the proviso that one substituent selected from X2, X3, X4 and X5 is a bond to L or bonded via a bond to L; and
R is a glycosidic bond to the GlcNAc residue.
In an embodiment, the linker group is hydrophilic.
In an embodiment, the linker group comprises at least one OH group.
In an embodiment, the linker group comprises at least one moiety derived from one or more saccharide units.
In an embodiment, the linker group is represented by formula VII
Formula VII
wherein
Y is an oxygen, sulphur, amine, amide, peptide or absent, wherein the peptide is an E1-P-E2 unit in which Ei and E2 are independently C=0, 0 or NRP, wherein Rp is H, C1-C6 alkyl or substituted C1-C6 alkyl, P is a peptide unit from 2 to 5 amino acids in length, and Ei and E2 can independently be linked to the peptide through the terminal nitrogen, terminal carbon or through a side chain of one of the amino acids of the peptide;
Z is a saccharide or absent;
D' is the payload molecule, wherein the payload molecule comprises an amine moiety, through which the payload molecule is bound so as to form a secondary or tertiary amine;
Ri, R2, R3, R4, R5,
R7, ¾ and R9 are each independently H, OH, amine, C2-C6 acylamide, carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
W is H, CH2OH, CH3, carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
a is an integer from 0 to 6;
b is 0 or 1;
c and e are each independently an integer from 0 to 7; d is an integer from 1 to 7;
Q is E'-F'-E, wherein F' is an amine, amide, disulfide, thioether, thioester, hydrazone, Schiff base, oxime, olefin metathesis reaction product, triazole or phosphine group, or other group generated by the reaction of the functional group F- E and the functional group F' , wherein F is a functional group that can react with an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine, and F' is an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine; and E is absent or a polyethyleneoxy unit of formula (CH2CH20)P, wherein p is an integer from 2 to about 20; and E and E' are each independently absent or a polyethyleneoxy unit of formula (CH2CH20)P, wherein p is an integer from 2 to about 20; and
Q is bound via a bond to G.
This embodiment has the added utility that the linker group conveys good solubility in aqueous solutions.
In an embodiment, L is a linker group represented formula VIII
Y is an oxygen, sulphur, amine, amide, peptide or absent, wherein the peptide is an E1-P-E2 unit in which Ei and E2 are independently C=0, 0 or NRP, wherein Rp is H, C1-C6 alkyl or substituted C1-C6 alkyl, P is a peptide unit from 2 to 5 amino acids in length, and Ei and E2 can independently be linked to the peptide through the terminal nitrogen, terminal carbon or through a side chain of one of the amino acids of the peptide;
Z is a saccharide or absent;
D' is the payload molecule, wherein the payload molecule comprises an amine moiety, through which the payload molecule is bound so as to form a secondary or tertiary amine;
Ri, R2, R9 and Rio are each independently H, OH, amine,
C2-C6 acylamide, carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
a is an integer from 0 to 6;
e is an integer from 0 to 3;
d and f are integers from 0 to 4 with the proviso that their sum is from 1 to 4;
Q is E'-F'-E, wherein F' is an amine, amide, disulfide, thioether, thioester, hydrazone, Schiff base, oxime, olefin metathesis reaction product, triazole or phosphine group, or other group generated by the reaction of the functional group F- E and the functional group F' , wherein F is a functional group that can react with an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine, and F' is an amine, thiol, azide, alkene, alkyne, aldehyde, ketone,
carboxylic acid or hydroxylamine ; and E is absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and E and E' are each independently absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and
Q is bound via a bond to G.
In an embodiment, L is a linker group represented by formula IX
Formula IX wherein
Y is an oxygen, sulphur, amine, amide, peptide or absent, wherein the peptide is an E1-P-E2 unit in which Ei and E2 are independently C=0, 0 or NRP, wherein Rp is H, C1-C6 alkyl or substituted C1-C6 alkyl, P is a peptide unit from 2 to 5 amino acids in length, and Ei and E2 can independently be linked to the peptide through the terminal nitrogen, terminal carbon or through a side chain of one of the amino acids of the peptide;
Z is a saccharide or absent;
D' is the payload molecule, wherein the toxic payload molecule comprises an amine moiety, through which the toxic payload molecule is bound so as to form a secondary or tertiary amine;
Ri and R2 are each independently H, OH, amine, C2-C6 acylamide, carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
a is an integer from 0 to 6;
c and e are each independently an integer from 0 to 3;
Q is E'-F'-E, wherein F' is an amine, amide, disulfide, thioether, thioester, hydrazone, Schiff base, oxime, olefin metathesis reaction product, triazole or phosphine group, or other group generated by the reaction of the functional group F- E and the functional group F' , wherein F is a functional group that can react with an amine, thiol, azide, alkene, alkyne,
aldehyde, ketone, carboxylic acid or hydroxylamine, and F' is an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine; and E is absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and E and E' are each independently absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and
Q is bound via a bond to G.
In an embodiment of the invention, F is an amine reacting group, a thiol reactive group, an azide reactive group, an alkyne reactive group, a carbonyl reactive group or a hydroxylamine reactive group.
In an embodiment of the invention, F is an amine reacting group, such as (but not limited) to an N- hydroxysuccinmide ester, p-nitrophenyl ester, dinitrophenyl ester, or pentafluorophenyl ester.
In an embodiment of the invention, F is a thiol reactive group, such as (but not limited to) pyridyldisulfide, nitropyridyldisulfide, maleimide, haloacetate or carboxylic acid chloride.
In an embodiment of the invention, F is an azide reactive group, such as (but not limited to) alkyne.
In an embodiment, F is an alkyne.
In an embodiment, F is CH≡C .
In an embodiment, F is a dibenzocyclooctyl group
(DBCO) .
In an embodiment of the invention, F is an alkyne reactive group, such as (but not limited to) azide.
In an embodiment, F is azide.
In an embodiment of the invention, F is a carbonyl reactive group, such as (but not limited to) hydroxylamine.
In an embodiment of the invention, F is a hydroxylamine reactive group, such as (but not limited to) aldehyde or ketone.
In an embodiment of the invention, F is isothiocyanate, isocyanate, sulfonyl chloride, glyoxal, epoxide, oxirane, carbonate, aryl halide, imidoester, carbodiimide, or anhydride.
In an embodiment, Z is absent.
In an embodiment, Z is a saccharide.
In an embodiment, Z is an oligosaccharide with a degree of polymerization from 1 to about 20; from 1 to 10; from 1 to 8; from 1 to 6; from 1 to 5; from 1 to 4; from 1 to 3; from 1 to 2; or 1, 2, 3, 4 or 5.
In an embodiment, Z is a monosaccharide, disaccharide or trisaccharide .
In an embodiment, Z is OH
In an embodiment, Z is H.
In an embodiment, a is 1, 2 , 3 , 4 , 5 , or 6.
In an embodiment, a is 1.
In an embodiment, b is 0.
In an embodiment, b is 1.
In an embodiment, c is 0.
In an embodiment, c is 1, 2, 3, 4, 5, 6 or 7.
In an embodiment, d is 1, 2, 3, 4, 5, 6 or 7.
In an embodiment, d is 3, 4 or 5.
In an embodiment, d is 3.
In an embodiment, d is 4.
In an embodiment, d is 5.
In an embodiment, d is 6.
In an embodiment, e is 0.
In an embodiment, e is 1, 2, 3, 4, 5, 6 or 7.
In an embodiment, d is 3; and R7 is H.
In an embodiment, d is 4; and R7 is H.
In an embodiment, b is 1; and R3 and R4 are each
In an embodiment, a is 1; and Ri and R2 are each
In an embodiment, e is 1; and R8 and R9 are each
In an embodiment, a, b, c , or e is 0.
In an embodiment, a, b, c , and/or e is 0.
In an embodiment, W is H.
In an embodiment, a is 2 or 3; and Ri and R2 are
In an embodiment, Y is oxygen .
In an embodiment, Y is sulphur .
In an embodiment, Y is a peptide .
In ar embodiment according to the first or second aspect, the binding agent is preferentially internalized by a tumor cell or a cancer cell.
In an embodiment, the binding agent is preferentially internalized by a tumor cell or a cancer cell as compared to a non-tumor cell or a non-cancer cell.
The present invention further relates to a pharmaceutical composition comprising the binding agent according to one or more embodiments of the first or second aspect .
The pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier. Examples of suitable pharmaceutically acceptable carriers are well known in the art and may include e.g. phosphate buffered saline solutions, water, oil/water emulsions, wetting agents, and liposomes. Compositions comprising such carriers may be formulated by methods well known in the art. The pharmaceutical composition may further comprise other components such as vehicles, additives, preservatives, other pharmaceutical compositions administrated concurrently, and the like.
In an embodiment, the pharmaceutical composition comprises an effective amount of the binding agent according to one or more embodiments of the first or second aspect.
In an embodiment, the pharmaceutical composition comprises a therapeutically effective amount of the binding agent according to one or more embodiments of the first or second aspect.
The term "therapeutically effective amount" or
"effective amount" of the conjugate should be un-derstood as referring to the dosage regimen for modulating the growth of cancer cells and/or treating a patient's disease. The therapeutically effective amount may be selected in accordance with a variety of factors, including the age, weight, sex, diet and medical condition of the patient, the severity of the disease, and pharmacological considerations, such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular conjugate used. The therapeutically effective amount can also be determined by reference to standard medical texts, such as the Physicians Desk Reference 2004. The patient may be male or female, and may be an infant, child or adult.
The term "treatment" or "treat" is used in the conventional sense and means attending to, caring for and
nursing a patient with the aim of combating, reducing, attenuating or alleviating an illness or health abnormality and improving the living conditions impaired by this illness, such as, for example, with a cancer disease.
In an embodiment, the pharmaceutical composition comprises a composition for e.g. oral, parenteral, transdermal, intraluminal, intraarterial, intrathecal and/or intranasal administration or for direct injection into tissue. Administration of the pharmaceutical composition may be effected in different ways, e.g. by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration .
According to a third aspect of the invention there is provided a binding agent, wherein the binding agent comprises a sequence selected from the group consisting of SEQ ID NO: 17, 36, 37, and 38.
According to a fourth aspect of the invention there is provided a binding agent, wherein the binding agent comprises sequences set forth in SEQ ID NOs : 17 and SEQ ID NO: 12; or SEQ ID NOs: 17 and SEQ ID NO: 14; or SEQ ID NOs: 36 and 39; or SEQ ID NOs: 37 and 39; or or SEQ ID NOs: 38 and 19.
In an embodiment according to the third or fourth aspect, the binding agent comprises a payload molecule. In the context of this aspect, the payload molecule may be any payload molecule described in this specification.
The present invention further relates to a pharmaceutical composition comprising the binding agent according to one or more embodiments of third or fourth aspect.
The present invention further relates to a nucleic acid encoding the protein moiety of the binding agent according to one or more embodiments of the first, second, third or fourth aspect .
The present invention further relates to an isolated nucleic acid encoding the protein moiety of the binding agent according to one or more embodiments of the first, second, third or fourth aspect.
The isolated nucleic acid comprises a nucleotide sequence encoding the protein moiety of a binding agent according to the first, second, third or fourth aspect.
In the context of this specification, the term
"protein moiety" should be understood as referring to at least one polypeptide, wherein the polypeptide comprises the first binding component, the second binding component or both. The protein moiety may also be a fusion polypeptide comprising both the first binding component and the second binding component.
The present invention further relates to a recombinant expression vector comprising the nucleic acid according one or more embodiments of the invention.
The recombinant expression vector according to one or more embodiments of the present invention may be e.g. a plasmid, phagemid, phage or viral vector, into which a nucleic acid encoding a binding agent according to one or more embodiments of the first, second, third or fourth aspect is inserted.
The nucleic acid and the recombinant expression vector may be produced by variety of techniques such as chemically synthesized using, for example, synthesizers. Recombinant expression vectors of the invention may be capable of expressing the RNA and/or protein products of the nucleic acids (DNA) . The recombinant expression vector may further comprise regulatory sequences, including a promoter operably linked to the open reading frame (ORF) . The vector may further comprise a selectable marker sequence. Specific initiation and secretory signals also may be included for efficient translation of inserted target gene coding sequences.
The recombinant expression vector may be advantageously selected and constructed depending upon the use intended for the binding agent being expressed. For example, when a large quantity of a binding agent is to be produced, for the generation of antibodies, for example, vectors which direct the expression of high levels of protein products that are readily purified may be desirable.
The present invention further relates to a host cell comprising the recombinant expression vector according to one or more embodiments of the invention.
In an embodiment, the host cell is an isolated host cell .
The host cell can be virtually any cell for which recombinant expression vectors are available. It may be, for
example, a higher eukaryotic host cell, such as a mammalian cell, a lower eukaryotic host cell, such as a yeast cell or a fungal cell, and may be a prokaryotic cell, such as a bacterial cell, for example E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus .
In an embodiment, the mammalian cell is a CHO cell, cell line CHO-K1 (ATCC CCL-61), cell line DUXB11 (ATCC CRL-9096) and cell line Pro-5 (ATCC CRL-1781) registered at ATCC, CHO-S (Cat # 11619 of Life Technologies)), a BHK cell (ATCC accession no. CCL 10), a NSO cell, NSO cell line (RCB 0213) registered at RIKEN Cell Bank, The Institute of Physical and Chemical Research, a SP2/0 cell, a SP2/0-Agl4 cell, SP2/0-Agl4 cell (ATCC CRL-1581), a YB2/0 cell, a PER cell, a PER . C6 cell, a rat myeloma cell line YB2 /3HL . P2. Gl 1.16Ag .20 cell (including cell lines established from Y3/Agl.2.3 cell (ATCC CRL-1631), YB2/3HL.P2.G11.16Ag.20 cell, YB2 /3HL . P2. Gl 1.16Ag .20 cell (ATCC CRL-1662), and any sub-lines obtained by naturalizing these cell lines to media in which they can grow, and the like) , a hybridoma cell, a human leukemic Namalwa cell, or an embryonic stem cell. Introduction of the recombinant construct into the host cell can be effected, for example, by calcium phosphate transfection, DEAE, dextran mediated transfection, electroporation or phage infection.
The present invention further relates to a method for producing the binding agent according to one or more embodiments of the first, second, third or fourth aspect, comprising
culturing the host cell according to one or more embodiments of the invention under conditions suitable for expression of the nucleic acid encoding the protein moiety of a binding agent according to one or more embodiments of the first, second, third or fourth aspect to produce the protein moiety of the binding agent; and
isolating the protein moiety of the binding agent from the culture.
In an embodiment according to the first aspect, the method comprises conjugating a payload molecule to the protein moiety of the binding agent according to one or more embodiments of the first, second, third or fourth aspect.
The present invention further relates to the binding agent according one or more embodiments of the first, second, third or fourth aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use as a medicament.
The present invention further relates to the binding agent according one or more embodiments of the first, second, third or fourth aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use in the treatment of cancer, autoimmune disease, inflammatory disorder or infection.
The present invention further relates to the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use in the treatment of a disorder selected from the group consisting of cancer, autoimmune disease, inflammatory disorder and infection.
The present invention further relates to the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention for use in the treatment of cancer.
In an embodiment, the cancer is a leukemia, lymphoma, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cancer, small-cell lung cancer, head-and-neck cancer, multidrug resistant cancer, glioma, melanoma and testicular cancer.
The present invention further relates to the use of the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to one or more embodiments of the invention in the manufacture of a medicament .
The present invention further relates to the use of the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to one or more embodiments of the present invention in the manufacture of a medicament for the treatment of cancer, autoimmune disease, inflammatory disorder or infection.
The present invention further relates to the use of the binding agent according one or more embodiments of the first or second aspect or the pharmaceutical composition according to one or more embodiments of the present invention in the manufacture of a medicament for the treatment of a disorder selected from the group consisting of cancer, autoimmune disease, inflammatory disorder and infection.
The present invention further relates to a method of treating cancer, autoimmune disease, inflammatory disorder or infection, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human in an effective amount.
The present invention further relates to a method of treating a disorder selected from the group consisting of cancer, autoimmune disease, inflammatory disorder and infection, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human in an effective amount.
The present invention further relates to a method of treating cancer, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human in an effective amount.
In an embodiment, the cancer is a leukemia, lymphoma, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous cancer, small-cell lung cancer, head-and-neck cancer, multidrug resistant cancer, glioma, melanoma and testicular cancer.
The present invention further relates to a method for modulating growth of a cell population, wherein the method comprises contacting the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention with the cell population.
In an embodiment, the cell population is a tumor cell population or a cancer cell population.
The present invention further relates to a method of treating and/or modulating the growth of and/or prophylaxis of tumor cells in humans or animals, wherein the binding agent according to according one or more embodiments of the first or second aspect or the pharmaceutical composition according to according one or more embodiments of the invention is administered to a human or animal in an effective amount.
In an embodiment, the tumor cells are selected from the group consisting of leukemia cells, lymphoma cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, head-and-neck cancer cells, multidrug resistant cancer cells, and testicular cancer cells.
The embodiments of the invention described hereinbefore may be used in any combination with each other. Several of the embodiments may be combined together to form a further embodiment of the invention. A product, a use or a method to which the invention is related may comprise at least one of the embodiments of the invention described hereinbefore.
The binding according to one or more embodiments of the first or second aspect has a number of advantageous properties.
The binding agent is preferentially internalized by tumor or cancer cells. The binding agent has a good internalization efficiency.
The presence of two binding components improves capability and specificity of the binding of the binding agent to tumor or cancer cells.
The binding agent according to the first aspect allows for conjugating a relatively large number of payload molecules to the binding agent. The binding agent has low immunogenicity; yet it is well soluble in aqueous solutions.
EXAMPLES
In the following, the present invention will be described in more detail. Reference will now be made in detail to the embodiments of the present invention, examples of which
are illustrated in the accompanying drawings. The description below discloses some embodiments of the invention in such detail that a person skilled in the art is able to utilize the invention based on the disclosure. Not all steps of the embodiments are discussed in detail, as many of the steps will be obvious for the person skilled in the art based on this specification .
Example 1. 2G12 antibodies and toxin conjugates
2G12-antibody (human IgG; Polymun Scientific, Austria) was subjected to galactosylation and sialylation using UDP- galactose and CMP- 9-azido-N-acetyl-neuraminic as in Example 5. Fc-fragments were released from a small aliquot of reaction mixture with Fabricator enzyme and recovered using Poros Rl tips. MALDI-TOF MS analysis of purified Fc revealed major signal at m/z 25873 corresponding to Fc with 9-azido-NeuNAc-G2F .
9-azido-sialylated antibody was purified with Protein G as in Example 5 and DM1-DBCO was conjugated to 9-azido- sialylated 2G12 as in Example 5. Fabricator analysis of conjugated antibody was done as described below. MALDI-TOF MS of purified Fc revealed major signal at m/z 26927 corresponding to Fc chain carrying DMl-DBCO-9-azido-NeuNAc-G2F. A minor signal was detected at m/z 28299 corresponding to (DMl-DBCO-9-azido- NeuNAc) 2-G2F . Based on the peak intensities, approximately 2.3 toxins were conjugated to 2G12 antibody.
Synthesis of 2G12-drug conjugates by copper (I) catalyzed click reaction
To 300 yg (2 nmol) of 2G12 antibody in PBS - 5 % mannitol - 0.1 % Tween20 solution (80 μΐ) was added lOx molar excess of NHS-PEG4-N3 dissolved in DMSO (1 or 4 μΐ) and the reaction was allowed to proceed for 3 hours at room temperature.
To minimize loss of antibody, the reaction was conducted in an
Amicon Ultra centrifugal filter unit (30K, 0.5 ml) . Low molecular weight reagents were then removed by Amicon centrifugal filter with repeated addition of PBS - 5 % mannitol
- 0.1 % Tween20.
To prepare 2G12-drug conjugate (Scheme 1) , 50x molar excess of TGTA and sodium ascorbate in ¾0 (2 μΐ) , lOx molar
excess of CU S C in ¾0 (0.34 μΐ, final concentration 500 μΜ) and 20x molar excess of N- ( 6-propargyl-D-galactosyl ) -dolastatin 10 in DMSO (4 μΐ) were added into the solution of 2 nmol of 2G12- PEG4-N3 (40 μΐ) . The reactions were performed at room temperature for 45 minutes. The conjugated antibodies were purified by Amicon centrifugal filter as above.
The DAR of the 2G12-drug conjugate was estimated to be about 2, by isolating the Fc-fragments and light chains followed by MALDI-TOF MS analysis.
Scheme 1. Structure of (N-galactosyl ) -Modo-triazole-PEG-2G12 conjugate.
2G12 variantl
2G12 light chain encoding sequence is ordered as a synthetic gene from a supplier and cloned into e.g. a CHO expression vector.
2G12 heavy chain variantl is assembled by overlap PCR from two sequences. Sequence encoding amino acids 1-220 is ordered as a synthetic gene from a supplier, sequence encoding amino acids 221-453 is PCR amplified from GCM012 expression vector.
For transient expression, subsequent cloning of light and heavy chains are made as described with GCM005 below, and for stable expression as described for GCM023 below. 2G12 variant2 (2G12 variantl+I19N)
Heavy chain mutation I19N is generated to 2G12 variantl backbone by PCR overlap, using overlapping oligos containing the mutated site. Full length heavy chain is assembled from two pieces essentially as described for GCM023.
GCM020 (2G12 variantl+I19N+F78S)
Heavy chain mutation F78S is generated to 2G12 variantl or 2G12 variant2 heavy chain backbone by PCR overlap, using overlapping oligos containing the mutated site. Full length heavy chain is assembled from two pieces essentially as described for GCM023.
EXAMPLE 2. Generation of GCM005 (cetuximab heavy chain fused to 2G12 scFv)
Cetuximab light chain fragment was amplified by PCR from a plasmid having a CHO codon optimized light chain DNA sequence using primers enabling cloning into the transient expression vector pCEP4.
Cetuximab heavy chain and 2G12 scFv fragments were PCR amplified separately (cetuximab heavy chain from a plasmid having CHO codon optimized heavy chain; 2G12 scFv from a plasmid having CHO codon optimized 2G12 scFv) . PCR fragments were purified from agarose gel and joined by overlap extension PCR. The whole 2220 bp join product was amplified, cut with restriction enzymes, and ligated to transient expression vector pCEP4. All antibodies produced in the Examples used signal peptides of SEQ ID NO: 40 (for heavy chains) or SEQ ID NO: 41 (for light chains) .
Transient transfection and production of GCM005 antibody in CHO- s cells
Transfection was carried out according to Freedom CHO-S Kit protocol (Life Technologies) . 22,5 μg of Cetuximab light chain containing plasmid and 22,5 μg of cetuximab heavy chain + 2G12 scFV containing plasmid was used for transfection of 30 x 10s CHO-S cells. After 4 days of culture supernatant was collected by pelleting cells at 350 x g for 5 minutes at room temperature and the antibody was purified from culture supernatant by Protein A column (High Trap MAb Select Sure; 5 ml; GE Healthcare) and AKTA purifier instrument (GE Healthcare) as described in purification of GCM023.
Synthesis of GCM005-drug conjugate by copper (I) catalyzed click reaction
Synthesis of 6-0-propargyl-D-galactose
Scheme 2. Synthesis of 6-0-propargyl-D-galactose. i) NaH, propargyl bromide, DMF, RT, 3 h, 91%; ii) 60% TFA, 50°C, 1 h, quantitative.
1 , 2 ; 3 , 4-di-O-isopropylidene- 6-O-propargyl- -D- galactopyranose (compound 3 in Scheme 2) . To a solution containing 0.27g (l.Ommol) compound 1 in 5ml dry DMF (under an argon atmosphere) was added 75mg (2.0 equiv.) NaH at 0°C. The resulting mixture was stirred for 20 min. and 171μ1 (1.5 equiv.) of propargyl bromide was added. After 20 min. the mixture was brought to RT and stirred for an additional 2.5 hours. The mixture was cooled on an ice bath and quenched by the addition of MeOH (0.5ml) . The reaction mixture was brought to RT, diluted with 20ml CH2C I 2 and washed with 20ml saturated NaHC03-solution . The water phase was extracted with 20ml CH2C I 2 . The combined organic phase was washed with 20ml ¾0, dried over a2 S04 , filtered and concentrated. The crude product was purified by column chromatography (Hexane : EtOAc 2:1) to give compound 2 as a white solid (0.27g, 91%). TLC: Rf = 0.77 (Hexane : EtOAc 1:1). XH NMR (600 MHz, CDC13, 22° C ) : δ = 5.54 (d, 1 H, Ji , 2 = 5.1 Hz, H-l), 4.61 (dd, 1 H, J3 , 2 = 2.5, J3,4 = 8.0 Hz, H-3), 4.32 (dd, 1 H, H- 2), 4.26 (dd, 1 H, J4,5 = 1.9 Hz, H-4), 4.25 (dd, 1 H, JCH2a,≡cH = 2.4, JCH2a,cH2b = "15.9 Hz, C¾aC≡CH), 4.20 (dd, 1 H, JCH2b,≡cH = 2.4 Hz, CH2bC≡CH) , 4.00 (ddd, 1 H, J5,6a = 5.4, J5,6b = 7.1 Hz, H-5), 3.78 (dd, 1 H, J6a,6b = -10.1 Hz, H-6a), 3.67 (dd, 1 H, H-6b) , 2.43 (dd, 1 H, CH2C≡CH) , 1.55, 1.45, 1.34 and 1.33 (each s, each 3 H, 02C(CH3)2) ppm.
Synthesis of 6-0- propargyl-D-galactose (Scheme 2, compound 3) . 25mg (0.08mmol) of compound 2 was dissolved in 3ml 60% TFA and the resulting mixture was stirred at 50°C for 1 hour. The mixture was then diluted with water and concentrated to give 6-O-propargyl-D-galactose as a colorless oil (18mg, quantitative, furanose : pyranose 3:97, alphaPyranose : betaPyranose 35:65). Selected NMR-data: XH NMR (600 MHz, D20, 22°C): δ = 5.26 (d, 1 H, Ji,2 = 4.7 Hz, H-lfuranose) , 5.23 (d, 1 H, Ji,2 = 3.8 Hz, H- lapyranose) , 5.20 (d, 1 H, Ji,2 = 3.5 Hz, H-lfuranose ), 4.55 (d, 1 H, Ji , 2 = 7.9 Hz, Η-1βργΓ¾η03θ) .
Synthesis of N- (6-O-propargyl-D-galactosyl) -dolastatin 10
Sodium cyanoborohydride (200ymol) and 6-O-propargyl-D- galactose (45ymol) were added to the solution of monomethyldolastatin 10 (2.5ymol) (Concortis Biosystems) in DMSO (0.7ml) . The mixture was stirred at 60°C for three days. The title compound was isolated by reversed-phase chromatography on a column of Gemini-NX-5u C-18 (Phenomenex) . Synthesis of Cu(I) chelator TGTA (tris { [1- (6-D-galactosyl) -1H- 1 , 2, 3-triazol-4-ylJmethyl}amine)
Scheme 3. i) Tripropargylamine, CUSO4, sodium ascorbate, DMF:H20 3:1, RT, 40h, quantitative; ii) 60% TFA H20) , 60°C, 2.5h, quantitative.
Protected TGTA (2 in Scheme 3) : To a solution containing 43mg of 1 (0.15mmol, 5 equiv.) and 4.3μ1 tripropargylamine (0.03mmol, 1 equiv.) in 2ml of DMF:H20 (3:1) was added 2.4mg CuS04 (0.015mmol, 0.5 equiv.) and 6.4mg sodium L- ascorbate (0.03mmol, 1 equiv.) . The resulting mixture was stirred at RT for 40h (during this time a white solid precipitated from the reaction mixture) . After 40h, the reaction mixture was diluted with 20ml EtOAc transferred to a separatory funnel and washed with 5ml NH4Cl-solut ion (prepared by dissolving a saturated NH4Cl-solution with equal amount of water 1:1 v/v) and 15ml brine. The organic phase was dried with Na2S04, filtered and concentrated to give the crude product. The crude product was purified by column chromatography (EtOAc→EtOAc : MeOH 3:1) to give 2 as a colorless oil (30mg, quantitative) . TLC: Rf = 0.22 (EtOAc) . XH NMR (600MHz, CDCI3 , 25°C) : δ = 8.56 (s, 3 H, triazole-H) , 5.48 (d, 3 H, Ji,2 = 5.0Hz, H-l), 4.67 (dd, 3 H, J6a,5 = 3.1, J6a,6b = 14.1Hz, H-6a), 4.65 (dd, 3 H, J3,2 = 2.5, J3,4 = 8.1, H-3), 4.58 (dd, 3 H, J6b,5 = 9.0Hz, H-6b) , 4.41 and 4.33 (each d, each 3 H. JNCH2a,NCH2b = 14.1Hz, N(C¾)3), 4.32 (dd, 3 H, H-2), 4.25 (dd, 3 H, J4,5 = 1.4Hz, H-4), 4.17 (ddd, 3 H, H-5) , 1.50, 1.39, 1.37 and 1.25 (each s, each 9 H, 02C(C¾)2) ppm. HRMS : calcd. for C45H66 ioOi5 a [M+Na]+ 1009.46; found 1009.40.
TGTA (3) : 33mg of 2 (0.034mmol) was dissolved in 3ml 60% TFA (in H20) and stirred at 50°C for 1.5 hours. The reaction mixture was then diluted with water, concentrated and dried under vacuum to give 3 as a white solid (25mg, quantitative, :β 2:3) . Selected NMR-data; XH NMR (600MHz, D20, 25°C) : δ = 8.32 (s, 6 H (a and β, 3 H each), triazole-H), 5.21 (d, 3 H, J1/2 = 3.9Hz, H-lo , 4.59 (s, 12 H (a and β , 6 H each), N(C¾)3), 4.50 (d, 3 H, Ji, 2 = 8.1Hz, H-Ιβ) . HRMS: calcd. for C27H42 10Oi5 a [M+Na]+ 769.27; found 769.23.
Synthesis of GCM005-drug conjugate
To 100 yg of GCM005 antibody in PBS - 5 % mannitol - 0.1 % Tween20 solution (150 μΐ) was added lOx molar excess of NHS-PEG4-N3 dissolved in DMSO and the reaction was allowed to proceed for 2 hours at room temperature. To minimize loss of antibody, the reaction was conducted in an Amicon Ultra centrifugal filter unit (30K, 0.5 ml) . Low molecular weight
reagents were then removed by Amicon centrifugal filter with repeated addition of PBS - 5 % mannitol - 0.1 % Tween20.
To prepare GCM005-drug conjugate (Scheme 4), 50x molar excess of TGTA and sodium ascorbate in ¾0, lOx molar excess of CUSO4 in H20 (final concentration 500 μΜ) and 20x molar excess of N- ( 6-propargyl-D-galactosyl ) -dolastatin 10 in DMSO were added into the solution of GCM005-PEG4-N3. The reactions were performed at room temperature for 45 minutes. The conjugated antibody were purified by Amicon centrifugal filter as above.
Scheme 4. Structure of (N-galactosyl) -Modo-triazole-PEG-GCM005 conj ugate .
EXAMPLE 3. Generation of GCM012 (an anti-EGFRl antibody)
An expression vector with coding sequences for GCM012 heavy- and light chains was constructed to pCHOl .0 backbone. Coding sequence for entire light chain was ordered as a synthetic CHO codon optimized sequence and cloned to pCHOl .0 with AvrII/Bstll07I . Coding sequence for heavy chain was constructed by PCR overlap from two pieces, synthetic sequence for heavy chain variable region and PCR amplified sequence for heavy chain constant region. Full-length PCR product was cloned to the pCHOl.O - GCM012 light chain backbone with EcoRV/PacI. The resulting vector was verified by sequencing and used for transient expression in CHO-S cells.
GCM012 was produced by transfecting CHO-S cells transiently using FreeStyleTM MAX CHO Expression system (Life technologies) according to the manufacturer's instructions. The transfected cell cultures were grown for four days before the culture supernatants were collected by centrifugating at 350 x g for 5 minutes at RT . GCM012 was purified from culture supernatant by Protein A column (High Trap MAb Select Sure; 5
ml; GE Healthcare) and AKTA purifier instrument (GE
Healthcare) as described in purification of GCM023. GCM012 comprises sequences set forth in SEQ ID NOs : 39 and 42. EXAMPLE 4. Generation of GCM014 (GCM012 heavy chain fused to 2G12 scFv variant with additional cysteines)
A vector with CHO optimized coding sequences for GCM014 heavy- and light chain was constructed to a plasmid backbone.
Sequence encoding the C-terminal part (2G12 scFv) of the GCM014 heavy chain was ordered as a synthetic gene, N- terminal part of the GCM014 heavy chain (GCM012) was made as a PCR fragment from the plasmid described in the previous example. Sequences were combined by overlap PCR into EcoRV/PacI site replacing the GCM012 heavy chain and resulting vector was verified by sequencing and used for transient expression in CHO- S cells. The 2G12 scFv part of the GCM014 has two additional cysteines corresponding to G44C in the heavy chain and G100C in the light chain to stabilize the bispecific antibody. Transfecting CHO-S cells for transient GCM014 expression
GCM014 was produced by transfecting CHO-S cells transiently using Freestyle™ MAX CHO Expression system (Life technologies) according to the manufacturer's instructions. The transfected cell cultures were grown for four days before the culture supernatants were collected by centrifugating at 350 x g for 5 minutes at RT .
Glycan analysis of GCM014
N-glycans of GCM014 were analysed from total antibody and Fc fragment. N-glycans were released from SDS denatured GCM014 using PNGase F (ProZyme Inc.) in 20 mM sodium phosphate buffer, pH 7.3, in overnight reaction at +37°C. The released N- glycans were purified with Hypersep C18 and Hypersep Hypercarb (Thermo Scientific) and analysed with MALDI-TOF MS.
In total antibody and Fc fragment the main glycoform was FG0. The MALDI-TOF image of N-glycans released from GCM014 is shown in Figure 1.
For the light chain analysis the domain structure of the antibody was first denatured with guanidine-HCl and the
disulphide bonds were reduced with dithiotreitol . Free light chains were then purified with Poros Rl and analyzed by MALDI- TOF. MALDI analysis implicated that sialylated N-glycan SFG2 is the most abundant structure (m/z 26171, Figure 2) . 97% of LCs are glycosylated.
Conjugation of aminooxybutynylacetamide- monomethyldolastatin 10 (ABAA-MODO) to 7-aldehydo-NeuNAc-GCM014
To oxidize the sialic acids in GCM014, the antibody was incubated with 3 mM sodium periodate in 0.1M sodium acetate, pH 4.2. and the 7-aldehydo-NeuNAc-GCM014 thus obtained was purified by ultrafiltration on Amicon centrifugal filter. The outcome of the oxidation reaction was analyzed by liberating the glycosylated light chains and subsequent MALDI-MS analysis as described in Example 5. The mass spectrum showed two major peaks, m/z 26116 and m/z 26351, which were assigned to light chains carrying glycans 7-aldehydo-NeuNAc-G2F and (7-aldehydo- NeuNAc) 2 _G2F, respectively. Synthesis of 6-azido-6-deoxy-D-galactose
Scheme 5 . Synthesis of 6-azido- 6-deoxy-D-galactose . i) TsCl, pyridine, RT, 22h, 81%; ii) NaN3, DMF, 120°C, 68%; iii) 60% TFA, 50°C, lh, quantitative.
Synthesis of 1 , 2 ; 3 , 4-di-O-isopropylidene- 6-O-tosyl- -D- galactopyranose (Scheme 5, compound 2): 0.39g (1.5mmol) of compound 1 was dissolved in 5ml of dry pyridine under an argon atmosphere. The reaction mixture was cooled on an ice bath and 0.88g (3.1 equiv.) of TsCl was added. The reaction was slowly warmed to RT and stirred overnight. After 22 hours the reaction was diluted with 30ml of CH2CI2 and washed with 30ml of ice-cold water. The organic phase was washed with 20ml of 10% (w/v) aqueous CuSC^-solution, 20ml of saturated NaHC03-solution and 20ml H2O . The organic phase was separated, dried over a2S04, filtered and concentrated. The crude product was purified by
column chromatography (Hexane : EtOAc 1:1) to give compound 2 as a yellowish oil (0.49g, 81%). TLC: Rf = 0.74 (Hexane :EtOAc 1:1). XH NMR (600 MHz, CDC13, 22°C): δ = 7.81-7.32 (m, 4 H, CH3C6H4SO2), 5.45 (d, 1 H, Ji , 2 = 4.9 Hz, H-l), 4.59 (dd, 1 H, J3 , 2 = 2.5, J3,4 = 7.9 Hz, H-3), 4.29 (dd, 1 H, H-2), 4.22- 4.18 (m, 2 H, H-6a, H-4), 4.09 (dd, 1 H, J6b,5 = 6.9, J6b,6a = -10.3 Hz, H-6b), 4.05 (ddd, 1 H, J5,4 = 1.9, J5,6a = 6.2 Hz, H-5) , 2.44 (s, 3 H, CH3C 6H4 S O2 ) , 1.50, 1.34, 1.31 and 1.28 (each s, each 3 H, 02C(CH3)2) ppm.
Synthesis of 1 , 2 ; 3 , 4-di-O-isopropylidene- 6-deoxy- 6- azido-a-D-galactopyranose (Scheme 5, compound 3) . To a solution containing 1.5g (3.7mmol) of compound 2 in 20ml dry DMF (under an argon atmosphere) was added 1.7g (7 equiv.) NaN3 and the resulting mixture was stirred at 120°C overnight. After 18 hours, the reaction mixture was brought to RT, diluted with 20ml CHCI3, filtered and concentrated. The crude product was purified by column chromatography (Hexane : EtOAc 3:1) to give compound 3 as a colorless oil (0.7g, 68%). TLC: Rf = 0.52 (Hexane : EtOAc 3:1). 1 NMR (600 MHz, CDC13, 22°C): δ = 5.55 (d, 1 H, Ji , 2 = 5.1 Hz, H-l), 4.63 (dd, 1 H, J3,2 = 2.5, J3,4 = 8.1 Hz, H-3), 4.33 (dd, 1H, H-2), 4.19 (dd, 1 H, J4,5 = 2.0 Hz, H-4), 3.92 (ddd, 1 H, J5,6b = 5.3, J5,6a = 7.8 Hz, H-5), 3.51 (dd, 1 H, J6a,6b = -12.9 Hz, H- 6a), 3.36 (dd, 1 H, H-6b) , 1.55, 1.46, 1.35 and 1.34 (each s, each 3 H, 02C(CH3)2) ppm.
Synthesis of 6-azido- 6-deoxy-D-galactose (Scheme 5, compound 4) . 80mg (0.3mmol) of compound 3 was dissolved in 3ml 60% TFA and the resulting mixture was stirred at 50°C for 1 hour. The mixture was then diluted with water and concentrated to give 6-azido- 6-deoxy-D-galactose as a colorless oil (60mg, quantitative, furanose : pyranose 3:97, alphaPyranose : betaPyranose 35:65). Selected NMR-data: 1 NMR (600 MHz, D20, 22°C): δ = 5.28 (d, 1 H, Ji , 2 = 4.7 Hz, H-lfuranose) , 5.26 (d, 1 H , Ji , 2 = 3.9 Hz, H- lOipyranose) , 5.22 (d, 1 H, Ji , 2 = 3.4 Hz, H"lfuranose ), 4.60 (d, 1 H,
Ji , 2 = 7.8 Hz, Η-1βργΓ¾η03θ) .
Synthesis of N- (6-azido-6-deoxy-D-galactosyl) -dolastatin 10
Sodium cyanoborohydride (160ymol) and 6-azido- 6-deoxy- D-galactose (95ymol) were added to the solution of monomethyldolastatin 10 (MODO) (2.5ymol) in DMSO (0.6ml). The
mixture was stirred at 60 °C for three days. The title compound (N- ( 6-N3-Gal ) -MODO) was isolated by reversed-phase chromatography on a column of Gemini-NX-5u C-18 (Phenomenex) . Dolastatin derivative carrying an aminooxy-functionality
2- [N- (tert-butoxycarbonyl) aminooxy] -N- (butynyl) acetamide (Boc-ABAA) was prepared as follows: Boc-aminooxyacetic acid (Novabiochem) (0.41 g, 2.1 mmol) was dissolved in 7 ml dry THF (under argon atmosphere) and the mixture was cooled on an ice bath. 0.24 ml (2.1 mmol, 1 equiv.) NMM and 0.28 ml (2.1 mmol, 1 equiv.) IBCF were added and the reaction mixture was stirred for 0.5 h at 0 °C . 0.18 ml (2.1 mmol, 1 equiv.) of 1- amino-3-butyne was added and the resulting mixture was brought to RT and stirred for an additional 1.5 h. The mixture was then filtered and concentrated and the crude product was dissolved in 20 ml Et20 and washed with 10 ml 0.1 M NaOH, 10 ml 1 M HC1 and 10 ml brine. The organic phase was dried with a2S04, filtered and concentrated. The crude product was purified by column chromatography (hexane : EtOAc 1:2) to give the title compound as a white solid. TLC : Rf = 0.34 (in hexane:EtOAc 1:2). Gal XH NMR (600 MHz, CDC13, 22 °C) : δ 8.25 (br s, 1 H, NH) , 7.48 (s, 1 H, NH) , 4.33 (s, 2 H, OC¾CO) , 3.49 (ap q, 2 H, J = 6.8 Hz, NHC¾CH2C≡CH) , 2.44 (ap td, 2 H, J = 2.6, 6.8 Hz, NHCH2C¾C≡CH) , 1.99 (ap t, 1 H, J = 2.6 Hz, NHCH2CH2C≡CH) and 1.49 (s, 9 H, OC(CH3)3) ppm.
Boc-ABAA was conjugated to N- ( 6-N3-Gal ) -MODO by copper (I) catalyzed azide-alkyne cycloaddition reaction: The reaction contained 2.5 ymol N- ( 6-N3-Gal ) -MODO, 6,3 ymol Boc-ABAA (2,5 x molar excess to N- ( 6-N3-Gal ) -MODO) , 25 ymol Na-ascorbate (10 x molar excess to N- ( 6-N3-Gal ) -MODO) and 5 ymol of CuS04 (2 x molar excess to N- ( 6-N3-Gal ) -MODO) . Boc-ABAA and N- ( 6-N3-Gal) - MODO were dissolved in DMSO and Na-ascorbate and CuS04 in MilliQ- H20 before adding to the reaction. Total volume of the reaction was 117 μΐ containing 64% DMSO. Reaction was carried out for 1.5 hours at RT . The conjugation was stopped with 40 μΐ of 0,5M EDTA pH 8 (20 μιηοΐ EDTA) . Progress of the reaction was analyzed with MALDI-TOF MS using 2 , 5-dihydroxybenzoic acid matrix in the positive ion reflector mode. Major signal was observed at m/ z 1224.6, which corresponds to [M+Na]+ ion of the expected click-
reaction product Modo-Boc- aminooxybutynylacetamide (Boc-
ABAA-MODO) .
Boc-ABAA-MODO was purified by solid-phase extraction on Bond-Elut C18 extraction cartridge. To obtain unprotected aminooxy drug, ABAA-MODO, the Boc-protecting group was removed by incubating in dichloromethane-TFA (12.5:1), and the product MODO-ABAA was isolated by reversed-phase chromatography using Gemini NX C18 column (Phenomenex) using a acetonitrile gradient in 20 mM ammonium acetate, pH 5.6.
Conjugation of ABAA-MODO to 7-aldehydo-NeuNAc-GCM014
ABAA-MODO was conjugated to 7-aldehydo-NeuNAc-GCM014 in an oxime ligation reaction by incubating 500 yg of antibody with 34 nmol of ABAA-MODO in 0.08M sodium acetate, pH 4.2. The conjugate (Scheme 6) was purified by ultrafiltration and light chains were isolated as above to analyze the reaction outcome. MS analysis showed a major signal at m/z 28271, which was assigned to (7- aldehydo-NeuNAc) 2-G2F-LC carrying two oxime linked ABAA-MODO units .
Scheme 6. Structure of MODO-ABAA-GCM014. For clarity, only sialic acid and galactose residues of the N-glycan are shown.
EXAMPLE 5. Generation of GCM023 (GCM012 heavy chain fused to 2G12 scFv variant [additional cysteines in scFv and I19N and F78S in heavy chain] )
I506N and F565S mutations (corresponding to I19N and
F78S in 2G12 heavy chain) were made by overlapping PCR, amplifying Ascl-Pacl fragment of GCM012 heavy chain as three
overlapping parts, and assembling the final plasmid comprising also GCM012 light chain sequence.
IRES2-eGFP fragment was added to the construct to aid the identification of high-expressing clones. IRES2-eGFP sequence was cut from helper plasmid as Eco32I-fragment and cloned into Bstll07I-site right after light chain.
Transfecting CHO-S cells for stable GCM023 expression using Freestyle MAX reagent
GCM023 (cloned in an IRES-eGFP vector) was transfected into CHO-S cells to develop stable cell pools for GCM023 production using Freedom CHO-S kit (Life Technologies) according to the manufacturer's instructions. Negative controls (no Freestyle MAX reagent, no DNA) as well as the expression vector (pCHOl.O) alone were included. GCM023 plasmid and the expression vector were linearized using Ndel prior to transfection to improve the transfection efficiency. Two transfections with the GCM023 plasmid were performed. Selecting stable transfectants for GCM023 expression
Selection phase 1
Selection phase 1 was conducted after transfection according to the manufacturer's instructions using selection reagents puromycin (Invitrogen) and methotrexate (Sigma) to select the stable transfectants . For each transfection two flasks (125 ml Erlenmeyer flask, Corning) were seeded having different selection reagent concentrations. Negative controls (no Freestyle MAX reagent, no DNA) were discarded on day 14 of selection phase 1 (almost no live cells) . Selection phase 1 was completed when the viability of the samples exceeded 85% and pools of each sample were cryopreserved .
Selection phase 2
In the beginning of selection phase 2 each sample flask was further divided into two having increased selection reagent concentrations according to the Freedom CHO-S Kit manual. Selection was complete when the viability exceeded 90 % and pools of each sample were again cryopreserved.
Analysing the selections phase 2 cell pools for eGFP expression using flow cytometry
At the end of selection phase 2 the cell pools were analysed for eGFP expression, which correlated with the level of GCM023 produced. The eGFP expression of the cell pools was analysed by flow cytometry (FACSAria II, BD Biosciences) and the data analysis was done by FACSDiva software. About 1 x 10s cells were taken from each sample, the cells were centrifuged at 200 x g for 5 minutes and the cells were suspended in 0.5 ml Complete CD FortiCHO™ medium (Life technologies) . The cells were filtered through cell strainer caps (35 ym nylon mesh, BD Falcon) and 10 000 events were recorded from each sample. The sample having only the expression vector transfected was used as a negative control in the analysis. The amount of eGFP-positive cells was about 3-100 % in the samples.
Sorting
Based on the flow cytometry analysis of selection phase 2 cell pools, a sample (99.9 % eGFP - positive) was chosen to be used in sorting. The most eGFP -positive cells (15.5~6 ) were sorted using 2-way purity method aiming to get a cell pool with enhanced GCM023 producing capability. The sorted cells were collected into 15 ml Falcon tube having 0.5 ml Complete CD FortiCHO™ medium. About 6.5 x 10s cells were sorted in total. The sorted cells were centrifuged (300 x g, 5 min, RT) and suspended in 20 ml Complete CD FortiCHO™ medium including the selection reagents (50 yg/ml Puromycin; 1000 nM methotrexate) and penicillin/streptomycin. Culture of GCM023 producing cells
Sorted cells or the high expressing cell pool were grown for six days in Complete CD FortiCHO™ medium, 0.3 x 10s cells/ml; V=30 ml. On day five a 3 ml of CHO CD Efficient Feed B (Life technologies) was added to each flask (125 ml Erlenmeyer flask, Corning) . The culture medium was collected at day 6 by centrifugating at 350 x g, 5 min, RT .
Purification of GCM023 from culture supernatant using Protein A column
The culture medium was filtered (HPF Millex HV PVDF filter; 0.45 ym) and NaCl was added to the medium to a final concentration of 150 mM. The GCM023 antibody was purified using Protein A column (High Trap MAb Select Sure; 5 ml; GE Healthcare) and AKTA purifier instrument (GE Healthcare) . The column was equilibrated with 20 mM Na-phosphate - 150 mM NaCl, pH 7.3 before sample application. The unbound material was washed with 50 mM Tris - 250 mM arginine-HCl - 1M NaCl, pH 9 and with 20 mM Na-phosphate - 150 mM NaCl, pH 7.3. GCM023 was eluted with 0.1M Na-citrate, pH 3. GCM023 containing fractions were collected, neutralized with 2M Tris-HCl, pH 9 and pooled. The pooled fractions were concentrated using Amicon Ultra-4 Centrifugal filter unit, 30K (Millipore) . The GCM023 concentration was determined by using NanoDrop 1000 (Thermo Scientific) .
SDS-PAGE
GCM023 produced from high expressing cell pool was ran in SDS-PAGE (4-15 % Mini-Protean TGX gel; BioRad) , in the presence of reducing (Figure 3, lane 1) and non-reducing (Figure 3, lane 2) sample buffer. The size of the light chain is about 37 kDa and that of heavy chain about 100 kDa . The non-reduced protein moves around the place of the 260 kDa molecular marker.
N-glycans were released from GCM023 and purified as described above. The main glycoform in the GCM023 heavy chain is FG0 (m/z 1485, Figure 4) .
The N-glycosylation of light chains was analysed as described above. MALDI analysis implied sialylated N-glycans in the light chains SFG2 being the most abundant structure (Figure 5) . 94% of LCs were glycosylated.
30 yg of antibody was digested with 30 U of FabRICATOR (Genovis) , +37°C, 60 min, producing F(ab')2 fragment and two Fc- scFv fragments. Digested samples were purified using Poros Rl filter plate (Glyken corp.) and the Fc-scFv fragments were analysed using MALDI-TOF MS. According to the analysis, at least over 94% of the scFv glycosylation site (2G12, HC:I19N) in the Fc-scFv fragment was glycosylated (Figure 6) .
Conjugating DMl-DBCO to GCM023
Galactosylation and 9-azido- sialylation of GCM023
Terminal galactose-residues in GCM023 N-glycans were sialylated with a-2, 6 sialyltransferase : 100 μΜ antibody, 30 mM CMP-NeuNAc and 0,05 yg/μΐ ST6Gal-l (hum rec, Roche Diagnostics) in 50 mM MOPS pH 7,2 were incubated o/n at +37°C. To analyze the reaction progress, Fc-ScFv-fragments were released from a small aliquot of the reaction mixture with Fabricator enzyme and recovered using reversed-phase extraction on hand¬ made Poros Rl tips. Light chains were released by treatment with 6M guanidine-HCl and dithiothreitol , and recovered using Poros Rl tips. MALDI-TOF MS analysis of purified Fc-ScFv revealed major signal at m/z 27210, which was assigned to doubly-charged (z=2) ion of Fc-ScFv corresponding to GOF in Fc-N-glycans and SGIF in ScFv. Another signal at m/z 27438 (z=2) was revealed corresponding to GOF in Fc-N-glycans and S2G2F in ScFv. A minor signal at m/z 27291 (z=2) was also detected corresponding to GOF in Fc-N-glycans and SG2F in ScFv. MALDI-TOF MS analysis of purified LC revealed major signal at m/z 26466 corresponding to LC with S2G2F glycan. Minor signals at 26012 and 26177 corresponded to LC with SGIF and SG2F.
Sialylated GCM023 was purified with HiTrap Protein G column (GE Healthcare) using 0.02 M Na-phosphate pH 7.0 as the binding buffer and 0.1 M citric acid pH 2.6 as the elution buffer. Purified antibody was subjected to galactosylation and sialylation using UDP-galactose and CMP- 9-azido-N-acetyl- neuraminic acid as the donor substrates. β-1,4- galactosyltransferase- and a-2 , 6-sialyltransferase-reactions were done in succession without removal of the galactosylation components. In short, 100 μΜ antibody, 20 mM UDP-Gal, 4 mU/μΙ β- 1,4-GalT (bovine milk, Sigma), 10 mM MnCl2 in 50 mM MOPS pH 7,2 were incubated o/n, after which CMP- 9-azido-NeuNAc and ST6Gall (hum rec, Roche Diagnostics) were added to final concentrations of 15 mM and 0,05 μg/μl. Incubation was continued o/n at +37°C. Fc-ScFv-fragments were released from small aliquot of reaction mixture with Fabricator enzyme and recovered using Poros Rl tips. Light chains were released from a small aliquot by treatment with 6M guanidine-HCl and dithiothreitol, and recovered using Poros Rl tips. MALDI-TOF MS analysis of purified Fc-ScFv revealed major signal at m/z 27761, which was assigned
to doubly-charged ion of Fc- ScFv carrying 9-azido-NeuNAc- G2F in Fc-N-glycans + S2G2F in ScFv, and Fc-ScFv carrying 9- azido-NeuNAc-G2F in Fc-N-glycans and 9-azido-NeuNAc-SG2F in ScFV. The galactosylated/ 9-azido-sialylated antibody was purified with Protein G as above.
Synthesis of DMl-DBCO
3.9 ymol DM1, 2.5 molar excess of iodoacetic acid in DMF (33 μΐ), 67 μΐ DMF and 90 μΐ 200 mM NH4HCO3 were stirred at RT for one hour. The crude reaction mixture was analysed by MALDI-TOF mass spectra using 2 , 5-dihydroxybenzoic acid matrix, showing expected mass for DMl-S-CH2COOH (m/z 818 [M+Na]+). The crude DMl-S-CH2COOH, 3.5 molar excess of DBCO-NH2 (Sigma) in DMF (200 μΐ) and 26 mg (95 μιηοΐ) DMT-MM in DMF (500 μΐ) were stirred at RT for overnight. The crude reaction mixture was analysed by MALDI-TOF mass spectra using 2 , 5-dihydroxybenzoic acid matrix, showing expected mass for DMl-DBCO (m/z 1076 [M+Na]+). DMl-DBCO was purified by reversed-phase chromatography on a column of Gemini-NX-5u C-18 (Phenomenex) .
Conjugation of DMl-DBCO and azido-sialylated GCM023
DMl-DBCO was conjugated to galactosylated and 9-azido- sialylated GCM023 as follows: 20 μΜ antibody in 4 "6 mannitol , 0,1 % Tween, PBS was incubated with 400 μΜ DMl-DBCO in the presence of 20% propylene glycol and 6% DMSO. Reaction was allowed to proceed 16 h at room temperature after which unbound DMl-DBCO was removed by repeated additions of 5 % mannitol, 0,1 % Tween, PBS and centrifugations through Amicon Ultracel 30 k centrifugal filter. DMl-DBCO-linked antibody (Scheme 7) was recovered from the concentrator and a small sample was taken for Fc-analysis, which revealed major signals at m/z 28275 and 28815. The signal m/z 28275 was assigned to DMl-DBCO-9-azido- NeuNAc-G2F in Fc N-glycans and S2G2F in ScFv N-glycans. m/z 28815 was assigned to DMl-DBCO-9-azido-NeuNAc-G2F in Fc N- glycans and DMl-DBCO-9-azido-NeuNAc-SG2F in ScFv N-glycans.
Scheme 7. Structure DMl-DBCO-9-azido-NeuNAc-GCM023. For clarity, only sialic acid and galactose residues of the N-glycan are shown.
Considering that light chain was free of 9-azido-sialic acids, and thus unreactive with DM1-DBCO, the antibody-drug- conjugate was thus a mixture of antibodies having either 2 (DAR2) or 4 (DAR4) attached drugs.
Synthesis of DM1-DBCO-GCM023 conjugate
GCM023-PEG4-N3 was prepared as described in Example 2. To prepare GCM023-DM1 conjugate (Scheme 8), lOx molar excess per azido group of DM1-DBCO (Example 5) in DMSO was added into the solution of GCMO23-PEG4-N3. The reaction was performed at room temperature for 2 hours. The conjugated antibody was purified by Amicon centrifugal filter as above.
To analyze the reaction progress, light chains were isolated as described in Example 5. The analysis revealed a major signal at m/z 27500, corresponding to light chain carrying one DM1-DBCO unit.
Scheme 8. Structure of DM1-DBCO-GCM023 conjugate. Synthesis of DBCO-Val-Cit-PAB-MODO-GCM023 conjugate
Synthesis of Val-Cit-PAB-MODO
6.5 mg (8 ymol) monomethyldolastatin (Modo) in DMF (200 μΐ) , 2 molar excess of Fmoc-Val-Cit-PAB-pnp (Concortis Biosystems) , 0.3 mg (2 ymol) HOBt in DMF (28 μΐ), 7 μΐ (40 μιηοΐ) diisopropylethylamine and 65 μΐ DMF were stirred for two days at room temperature. The crude reaction mixture was analysed by MALDI-TOF mass spectra using 2 , 5-dihydroxybenzoic acid matrix, showing expected mass for Fmoc-Val-Cit-PAB-MODO (m/z 1420 [M+Na] +) .
Fmoc removal was carried out by adding 150 μΐ of diethylamine and by stirring at room temperature overnight. MALDI-TOF mass analysis using 2 , 5-dihydroxybenzoic acid matrix showed the generation of expected deprotected product (m/z 1198 [M+Na] +) .
Val-Cit-PAB-MODO was purified by Akta purifier (GE
Healthcare) HPLC instrument with Gemini 5 μιη NX-C18 reverse phase column (21.1 x 250 mm, 110 A, AXIA (Phenomenex) ) eluted with ACN gradient in aqueous ammonium acetate. Synthesis of DBCO-Val-Cit-PAB-MODO
~2 μιηοΐ Val-Cit-PAB-MODO, ~5 molar excess of DBCO-NHS ester in DMF (126 μΐ) and 3.5 μΐ diisopropylethylamine were
stirred at RT for three hours. The crude reaction mixture was analysed by MALDI-TOF mass spectra using 2 , 5-dihydroxybenzoic acid matrix, showing expected mass for MODO-Val-Cit-PAB-DBCO (m/z 1485 [M+Na] +) .
MODO-Val-Cit-PAB-DBCO was purified by reversed-phase chromatography as described above.
Conjugation of DBCO-Val-Cit-PAB-MODO with GCM023-PEG4-N3
GCM023-PEG4-N3 was prepared as described in Example 2. To prepare GCM023-drug conjugate (Scheme 9) , lOx molar excess per azido group of DBCO-Val-Cit-PAB-MODO in DMSO was added into the solution of GCMO23-PEG4-N3. The reaction was performed at room temperature for 2 hours. The conjugated antibody was purified by Amicon centrifugal filter as above.
To analyze the reaction progress, light chains were isolated as described in Example 5. The analysis revealed a major signal at m/z 27906, corresponding to light chain carrying one DBCO-Val-Cit-PAB-MODO unit.
Scheme 9. Structure of GCM023-DBCO-Val-Cit-PAB-MODO conjugate.
Synthesis of MODO- REA-DBCO-GCMO23 conjugate
Synthesis of MODO-TREA (1- [MODO-Gal] -1 , 2, 3-triazol-4-ethylamine)
12 ymol N- ( 6-N3-Gal ) -MODO (Example 4) in DMSO (40 μΐ) , 2x molar excess of l-amino-3-butyne in DMSO (20 μΐ) , 3.1 mg (19 mmol) CuS04 in MQ (50 μΐ) , 19.2 mg Na-ascorbate in MQ (50 μΐ) , 90 μΐ DMSO and 400 μΐ MQ were stirred at RT for 2.5 hours. The crude reaction mixture was analysed by MALDI-TOF mass spectra using 2 , 5-dihydroxybenzoic acid matrix, showing expected mass for MODO-TREA (m/z 1051 [M+Na]).
MODO-TREA was purified by Akta purifier (GE Healthcare) HPLC instrument with Gemini 5 μιη NX-AXIA-C18 reversed phase
column (21.2 x 250 mm, 110 A (Phenomenex) ) eluted with ACN gradient in aqueous ammonium acetate.
Synthesis of MODO-TREA-DBCO
8 ymol MODO-TREA, 5x molar excess of DBCO-NHS ester
(Jena Bioscience) in DMF (1 ml) and 16 μΐ diisopropylethylamine were stirred at RT for three hours. The crude reaction mixture was analysed by MALDI-TOF mass spectra using 2,5- dihydroxybenzoic acid matrix, showing expected mass for MODO- TREA-DBCO (m/z 1338 [M+Na] ) .
MODO-TREA-DBCO was purified by Akta purifier (GE Healthcare) HPLC instrument with Gemini 5 ym NX-AXIA-C18 reversed phase column (21.2 x 250 mm, 110 A (Phenomenex)) eluted with ACN gradient in aqueous ammonium acetate.
Conjugation of MODO-TREA-DBCO with GCM023-PEG4-N3
GCM023-PEG4-N3 was prepared as described in Example 2.
To prepare GCM023-MODO-TREA-DBCO (Scheme 10), lOx molar excess per azido group of MODO-TREA-DBCO in DMSO was added into the solution of GCMO23-PEG4-N3. The reaction was performed at room temperature for 2 hours. The conjugated antibody was purified by
Amicon centrifugal filter as above.
To analyze the reaction progress, light chains were isolated as described in Example 5. The analysis revealed a major signal at m/z 27770, corresponding to light chain carrying one MODO-TREA-DBCO unit.
Scheme 10. Structure of MODO-TREA-DBCO-GCM023 conjugate.
EXAMPLE 6. Conjugation of aminooxy functionalized MMAF to 7- aldehydo-NeuAc-cetuximab
10 mg monomethylauristatin F (Concortis) was dissolved in acetonitrile (2.5 ml). lOx molar excess of Boc-aminooxyacetic
acid (Novabiochem) and DMT-MM were added. 25 μΐ of diisopropylethylamine was added and the reaction mixtures were stirred overnight at room temperature. MALDI-TOF MS analysis showed the formation of the expected product, monomethylauristatin-boc-aminooxyacetic acid amide, (MMAF-ABAA) m/z=927 [M+Na] . Boc-protecting group was removed as described in Example 4, and the deprotected product was purified by reversed- phase chromatography on a column of Gemini-NX-5u C-18.
7-aldehydo-NeuAc-cetuximab was prepared as described in Example 4, and was conjugated with 300x molar excess of MMAF- AOAA in 0.1 M sodium acetate buffer pH 5.5.
The Fc-fragment of MMAF-AOAA-Cetuximab conjugate (Scheme 11) was isolated as described in Example 5 and analyzed by MALDI-TOF MS. The spectrum of Fc-fragment showed a major signal at m/z 26614, corresponding to MMAF-AOAA-Cetuximab conj ugate .
Scheme 11. Structure of MMAF-AOAA-Cetuximab conjugate. For clarity, only sialic acid and galactose residues are shown.
EXAMPLE 7. Antibody binding to cells and internalization
Cells were suspended in 0.1% BSA-PBS-buffer at 5-10 x
10s cells/ml concentration and 100 μΐ was used for staining. Primary antibody was used at 20 μg/ml and secondary antibody when needed at 2 μg/ml concentration and staining was carried out for 30 minutes on ice. Cells were analysed with LSRII flow cytometer (Becton Dickinson) and FACSDiva 6.2 software (see Table 1)
For 2G12 and GCM005 antibody analysis HEK-cells were cultured in the presence of kifunensine (a mannosidase inhibitor) . After 3 days culture with kifunensine (Cayman Chemical) at 12 μg/ml concentration high-mannose glycans appear on the cell surface. Cetuximab and GCM012 were used as a control.
Table 1. Percentage of stained cells.
Internalization assays FACS analysis
HSC-2, FaDu, Skov-3 and HEK cells (2xl05) were seeded on a 24-well plate and allowed to grow for 24h. Thereafter the cells were incubated 3h either at +37°C or at +4°C in 300μ1 media containing 2 yg/ml AlexaFluor488 labeled 2G12, cetuximab, or GCM005. The cells were washed two times with PBS, detached by incubating with ΙΟΟμΙ Trypsin-EDTA, lOmin at +37°C, neutralized with 300 μΐ media, resuspended in PBS, and analyzed in a flow cytometer (FACS LRS II) . The mean fluorescence intensity of each samples were calculated by the software (FACS Diva) . Table 2 shows the results of the internalization assay (measured as mean of all fluorescent events) . Table 3 shows an "internalization efficiency" measured as a fold change of fluorescent intensity to +4C value (= ratio +37C/+4C) . Table 4 shows fold increase of internalization of the bispecific antibody GCM005 compared to its components 2G12 or cetuximab.
Table 2. Mean fluorescent intensity of antibodies at +4°C (cell surface bound) and +37°C (internalized) .
HEK HEK Fadu Fadu HSC2 HSC2 SKOV- SKOV-3
3
( +4C) (+37C) ( +4C) (+37C) ( +4C) (+37C) ( +4C) (+37C)
2G12 82 414 127 887 387 3457 236 867 cetuximab 170 158 3877 6906 49990 82296 1810 2746
GCM005 215 1551 4246 12228 54667 107697 1849 5255
Table 3. Fold change of an antibody internalization as a ratio of +37°C to +4°C.
Microscope analysis
HSC-2 cells (5xl04) were seeded on a chamber slides and allowed to grow for 24h. Thereafter the cells were incubated 3h either at +37°C or at +4°C in ΙΟΟμΙ media containing 5 yg/ml AlexaFluor488 labeled GCM005. The cells were washed two times with PBS and fixed with 4% paraformaldehyde for 20 min. The cells were mounted (Prolong Gold antifade reagent with DAPI) and photographed with fluorescence microscopy (Zeiss Axio Scope Al) . GCM005 binds to cell surface at 4°C but after incubation at 37°C, antibody was internalized and most staining was seen inside the cells (Figure 7) .
In vitro cell assay
Toxicity of antibody drug conjugates (ADC) was tested by in vitro cell assay. Appropriate amount of cells was plated the day before on 96-well plate. ADCs were diluted in cell culture medium and sterile filtered with a syringe and a 0.22 μιη
filter. Logarithmic dilution series from ADC was prepared and applied to cells in triplicate. Cells with ADC were cultured for three to four days at +37°C and 5% CO2. Cell proliferation and viability was evaluated using PrestoBlue Cell Viability reagent (Life Technologies) according to the manufacturer's protocol. Cell culture medium was used as a background control. Viability of ADC treated cells was compared to untreated (normal) cells (= percentage of living cells) (see Tables 5-7) . Table 5.
Table 6.
Table 7.
HEKa Percentage of untreated
ADC 1 pM 10 pM 100 1 nM 10 nM 100
pM nM
2G12-N3NeuNAc-DMl- 88, 9 91, 4 87,1 22,2 18,8 19, 3
DBCO
GCM023-N3NeuNAc- 104,2 88, 6 92, 0 34, 7 29, 1 34, 0
DM1-DBCO
As is clear for a person skilled in the art, the invention is not limited to the examples and embodiments described above, but the embodiments can freely vary within the scope of the claims.
Claims
1. A binding agent comprising a payload molecule and a first binding component comprising the complementarity determining regions of an antibody, wherein said antibody is capable of binding a high-mannose N-glycan.
2. A binding agent comprising a first binding component comprising the complementarity determining regions of an antibody, wherein said antibody is capable of binding a high- mannose N-glycan; and a second binding component capable of binding an antigen other than the antigen which the first binding component is capable of binding.
3. The binding agent according to claim 1 or 2, wherein said antibody is capable of binding an oligosaccharide structure comprising the structure according to formula I
Formula \
wherein
(β-Ν-Asn) = β-Ν linkage to asparagine;
Rl = absent or Man 2nMan 6, wherein n = 0 or 1 ; R2 = absent or Man 2mMan 3, wherein m = 0 or 1 ;
R3 = Man 2kMan 3, wherein k = 0, 1 or 2 ; with the proviso that at least two substituent groups selected from the group consisting of Rl, R2 and R3 comprise at least two Man residues.
4. The binding agent according to any one of claims 1 -
3, wherein the first binding component comprises the heavy chain complementarity determining regions 1-3 having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity as compared to the heavy chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10, and the light chain complementarity determining regions 1-3 of PGT125, PGT126, PGT127, PGT128, PGT130 or TM10 or light chain complementarity determining regions 1-3 having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity as compared to light chain
complementarity determining regions 1-3 of PGT125, PGT126,
PGT127, PGT128, PGT130 or TM10.
5. The binding agent according to any one of claims 1 -
4, wherein the first binding component comprises heavy chain complementarity determining regions 1-3 and/or light chain complementarity determining regions having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NOs : 1 - 4, amino acid sequence KAS and SEQ ID NO: 6.
6. The binding agent according to any one of claims 1 -
5, wherein the first binding component comprises the heavy chain complementarity determining regions HCDR1 (SEQ ID NO: 1), HCDR2 (SEQ ID NO: 2) and HCDR3 (SEQ ID NO: 3) and the light chain complementarity determining regions LCDR1 (SEQ ID NO: 4), LCDR2 (amino acid sequence KAS) and LCDR3 (SEQ ID NO: 6) of the antibody 2G12.
7. The binding agent according to any one of claims 1 -
6, wherein the first binding component is a scFv, a single domain antibody, an Fv, a VHH antibody, a diabody, a tandem diabody, a Fab, a Fab', or a F(ab)2.
8. The binding agent according to any one of claims 1 -
7, wherein the first binding component is a scFv comprising the sequence set forth in SEQ ID NO: 7 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 7.
9. The binding agent according to any one of claims 1 -
8, wherein the first binding component comprises a heavy chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11 and a light chain variable region of the antibody 2G12 comprising a sequence set forth in SEQ ID NO: 12 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 12, and optionally the light chain constant domain of the antibody 2G12 and/or one or more heavy chain constant domains of the antibody 2G12 selected from the group consisting of CHI, CH2 and CH3 of the antibody 2G12.
10. The binding agent according to any one of claims 1 - 9, wherein the first binding component or the antibody 2G12 comprises a heavy chain variable region comprising a sequence set forth in SEQ ID NO: 11 or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 11 and a light chain variable region comprising a sequence set forth in SEQ ID NO: 12 or a sequence having at least about 80 90 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 12.
11. The binding agent according to any one of claims 1 - 10, wherein the first binding component comprises one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the light chain of an Ig molecule; and/or one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the heavy chain of an Ig molecule; wherein the first binding component comprises one or more introduced N-glycosylation sites in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the light chain, and/or one or more introduced N-glycosylation sites in any region or domain in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the heavy chain .
12. The binding agent according to any one of claims 1
11, wherein the first binding component comprises the 2G12 heavy chain having a sequence set forth in SEQ ID NO: 13, wherein one or more amino acid residues are substituted by substitutions selected from the group consisting of I19N, F78S, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 13.
13. The binding agent according to any one of claims 1
12, wherein the first binding component comprises the 2G12 light chain having a sequence set forth in in SEQ ID NO: 14,
wherein one or more amino acid residues are substituted by substitutions selected from the group consisting of T18N, L154S, Q160N S174N and T180N as compared to SEQ ID NO: 14.
14. The binding agent according to any one of claims 1 - 13, wherein the binding agent comprises a detection-enabling molecule .
15. The binding agent according to any one of claims 1 or 3 - 14, wherein the binding agent comprises a second binding component capable of binding an antigen other than the antigen which the first binding component is capable of binding.
16. The binding agent according to any one of claims 2 - 15, wherein the first binding component and the second binding component are fused or chemically cross-linked.
17. The binding agent according to any one of claims 2 - 16, wherein the second binding component is capable of binding human EGFR1 or human ERBB2/HER2.
18. The binding agent according to any one of claims 2
17, wherein the second binding component comprises i) the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of an anti-EGFRl antibody, or ii) the heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and the light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of an anti-ERBB2 /HER2 antibody.
19. The binding agent according to any one of claims 2
18, wherein the second binding component is an anti-EGFRl antibody or an EGFR1 binding fragment thereof or an anti- ERBB2/HER2 antibody or an ERBB2/HER2 binding fragment thereof.
20. The binding agent according to any one of claims 2 - 19, wherein the second binding component comprises a heavy chain variable region and a light chain variable region of the anti-EGFRl antibody or a heavy chain variable region and a light chain variable region of the anti-ERBB2 /HER2 antibody.
21. The binding agent according to any one of claims 18 - 20, wherein the anti-EGFRl antibody is selected from the group consisting of cetuximab, imgatuzumab, matuzumab, nimotuzumab, necitumumab, panitumumab, and zalutumumab, or wherein the anti- ERBB2/HER2 antibody is selected from the group consisting of trastuzumab, ertumaxomab, margetuximab, and pertuzumab.
22. The binding agent according to any one of claims 18 - 21, wherein the anti-EGFRl antibody or its EGFRl binding fragment comprises one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the light chain of an anti-EGFRl Ig molecule; and/or one or more regions or domains selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of a sequence corresponding to the heavy chain of an anti-EGFRl Ig molecule; wherein the anti-EGFRl antibody or its EGFRl binding fragment comprises one or more introduced N-glycosylation sites in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the light chain; and/or one or more introduced N-glycosylation sites in any region or domain in any region or domain selected from the group consisting of the complementarity determining regions, framework regions, variable region, and constant domains of the heavy chain.
23. The binding agent according to any one of claims 2 - 22, wherein the first binding component is a scFv derived from 2G12 comprising the sequence set forth in SEQ ID NO: 7, 8, 9 or 10, or a sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher sequence identity as compared to SEQ ID NO: 7, 8, 9 or 10; and the second binding component comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3 and light chain complementarity determining regions LCDR1, LCDR2, and LCDR3 of an anti-EGFRl antibody.
24. The binding agent according to claim 23, wherein the scFv derived from 2G12 is fused to the C-terminus of an anti-EGFRl antibody or an EGFRl binding fragment thereof.
25. The binding agent according to any one of claims 2 - 24, wherein the second binding component comprises at least one of the following:
(i) the cetuximab heavy chain having a sequence set forth in SEQ ID NO: 18, wherein one or more amino acid residues are substituted by a substitution selected from the group
consisting of G161S, Q177N, L184N, S192N and L195N as compared to SEQ ID NO: 18;
(ii) imgatuzumab heavy chain having a sequence set forth in SEQ ID NO: 20, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E80N, G164S, Q178N, L185N, S193N, and L196N as compared to SEQ ID NO: 20;
(iii) matuzumab heavy chain having a sequence set forth in SEQ ID NO: 22, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 22;
(iv) nimotuzumab heavy chain having a sequence set forth in SEQ ID NO: 24, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E74N, E89N, G165S, Q181N, L188N, S196N, and L199N as compared to SEQ ID NO: 24;
(v) necitumumab heavy chain having a sequence set forth in SEQ ID NO: 26, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of A89N, G165S, Q179N, L186N, S194N, and L197N as compared to SEQ ID NO: 26;
(vi) panitumumab heavy chain, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E to N substitution at about amino acid 91, G to S substitution at about amino acid 161 (in sequence NSG) , Q to N at about amino acid 177 (in sequence QSS), L to N at about amino acid 184 (in sequence LSS), S to N at about amino acid 192 (in sequence SSS) , and L to N at about amino acid 195 (in sequence LGT) as compared to the panitumumab heavy chain sequence; or
(vii) zalutumumab heavy chain having a sequence set forth in in SEQ ID NO: 28, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of E89N, G169S, Q183N, L190N, S198N, and L201N as compared to SEQ ID NO: 28.
26. The binding agent according to any one of claims 2 - 25, wherein the second binding component comprises at least one of the following:
(i) the cetuximab light chain having a sequence set forth in in SEQ ID NO: 19, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L154S, Q160N, S174N, and T180N as compared to SEQ ID NO: 19;
(ii) the imgatuzumab light chain having a sequence set forth in in SEQ ID NO: 21, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 21;
(iii) the matuzumab light chain having a sequence set forth in in SEQ ID NO: 23, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 23;
(iv) the nimotuzumab light chain having a sequence set forth in in SEQ ID NO: 25, comprises one or more substitutions selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 25;
(v) the necitumumab light chain having a sequence set forth in in SEQ ID NO: 27, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 27;
(vi) the panitumumab light chain wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R to N substitution at about amino acid 18, L to S substitution at about amino acid 154 (in sequence NAL) , Q to N substitution at about amino acid 160 (in sequence QES) , S to N substitution at about amino acid 174 (sequence SLS -> NLS) , and T to N substitution at about amino acid 180 (in sequence TLS) as compared to the panitumumab light chain sequence; or
(vii) the zalutumumab light chain having a sequence set forth in in SEQ ID NO: 29, wherein one or more amino acid residues are substituted by a substitution selected from the group consisting of R18N, L159S, Q165N, S179N, and T185N as compared to SEQ ID NO: 29.
27. The binding agent according to any one of claims 1 - 26, wherein the first binding component and/or the second binding component comprises one or more additional stabilizing amino acid substitutions, such as an additional cysteine residues in the scFv.
28. The binding agent according to any one of claims 1 - 27, wherein the binding agent comprises a fusion polypeptide having a sequence selected from the group consisting of the sequences set forth in SEQ ID NO: 36, SEQ ID NO: 37 and NO: 38.
29. The binding agent according to any one of claims 1
28, wherein the binding agent comprises the sequences set forth in SEQ ID NOs : 36 and 39, the sequences set forth in SEQ ID NOs: 37 and 39, or the sequences set forth in SEQ ID NOs: 38 and 19.
30. The binding agent according to any one of claims 1 or 3 - 29, wherein the payload molecule is a toxic payload molecule selected from the group consisting of a dolastatin, auristatin, doxorubicin, maytansinoid, epirubicin, duocarmycin, or any analogue or derivative thereof.
31. The binding agent according to any one of claims 1 or 3 - 30, wherein the binding agent comprises a molecule represented by formula II
[D-L]n-P
Formula II wherein P is the first binding component or the second binding component;
n is at least 1 ;
L is a linker group covalently joining P to D; and
D is the payload molecule.
32. The binding agent according to any one of claims 1 or 3 - 31, wherein the binding agent comprises a molecule represented by formula III
[D-L-G]n-P
Formula III
wherein P is the first binding component or the second binding component comprising an N-glycan, wherein the N-glycan comprises a GlcNAc residue bound by a β-Ν linkage to an asparagine ;
n is at least 1 ;
D is the payload molecule;
L is a linker group covalently joining G to D; and
G is a saccharide structure represented by formula IV
R is a glycosidic bond to the N-glycan or a glycosidic bond to the GlcNAc residue bound by a β-Ν linkage to an asparagine;
X1 is H or carboxyl;
X2, X3 and X4 are each independently OH, H, amino, C2-C6 acylamide, phosphate or sulphate ester, or a bond to L;
X5 is CH2OH, carboxyl, CH3, H, C1-C3 alkyl or substituted C1-C3 alkyl, or a bond to L;
with the proviso that one substituent selected from X2,
X3, X4 and X5 is a bond to L or bonded via a bond to L; and
with the proviso that when X 1 is carboxyl, then X? is H,
X3 is OH, X5 is C1-C3 alkyl or substituted C1-C3 alkyl; R is a glycosidic bond to the N-glycan; and X4 is a bond to L or X5 is bonded via a bond to L; or
when X1 is H, then R is a glycosidic bond to the N- glycan or to the GlcNAc residue bound by a β-Ν linkage to an asparagine .
33. The binding agent according to claim 31 or 32, wherein L is a linker group represented by formula VII
Formula VII wherein
Y is an oxygen, sulphur, amine, amide, peptide or absent, wherein the peptide is an E1-P-E2 unit in which Ei and E2 are independently C=0, 0 or NRP, wherein Rp is H, C1-C6 alkyl or substituted C1-C6 alkyl, P is a peptide unit from 2 to 5 amino acids in length, and Ei and E2 can independently be linked to the peptide through the terminal nitrogen, terminal carbon or through a side chain of one of the amino acids of the peptide;
Z is a saccharide or absent;
D' is the payload molecule, wherein the payload molecule comprises an amine moiety, through which the payload molecule is bound so as to form a secondary or tertiary amine;
Ri, R2, R3, R4, R5,
R7, e and R9 are each independently H, OH, amine, C2-C6 acylamide, carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
W is H, CH2OH, CH3, carboxyl, substituted carboxyl, C1-C6 alkyl or substituted C1-C6 alkyl;
a is an integer from 0 to 6;
b is 0 or 1;
c and e are each independently an integer from 0 to 7; d is an integer from 1 to 7;
Q is E'-F'-E, wherein F' is an amine, amide, disulfide, thioether, thioester, hydrazone, Schiff base, oxime, olefin metathesis reaction product, triazole or phosphine group, or
other group generated by the reaction of the functional group F-E and the functional group F' , wherein F is a functional group that can react with an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine, and F' is an amine, thiol, azide, alkene, alkyne, aldehyde, ketone, carboxylic acid or hydroxylamine; and E is absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and E and E' are each independently absent or a polyethyleneoxy unit of formula ( CH2CH20 ) P , wherein p is an integer from 2 to about 20; and
Q is bound via a bond to G.
34. The binding agent according to any one of claims 1
- 33, wherein the binding agent is preferentially internalized by a tumor cell or a cancer cell.
35. A pharmaceutical composition comprising the binding agent according to any one of claims 1 - 34.
36. An isolated nucleic acid encoding the protein moiety of the binding agent according to any one of claims 1 -
34 or the binding agent according to any one of claims 2 - 34.
37. A recombinant expression vector comprising the nucleic acid according to claim 36.
38. A host cell comprising the recombinant expression vector according to claim 37.
39. The binding agent according to any one of claims 1 - 34 or the pharmaceutical composition according to claim 35 for use as a medicament.
40. The binding agent according to any one of claims 1
- 34 or the pharmaceutical composition according to claim 35 for use in the treatment of cancer, autoimmune disease, inflammatory disorder or infection.
41. A method of treating cancer, autoimmune disease, inflammatory disorder or infection, wherein the binding agent according to any one of claims 1 - 34 or the pharmaceutical composition according to claim 35 is administered to a human in an effective amount.
42. The method according to claim 41, wherein the cancer is an leukemia, lymphoma, breast cancer, prostate cancer, ovarian cancer, colorectal cancer, gastric cancer, squamous
cancer, small-cell lung cancer, head-and-neck cancer, multidrug resistant cancer, glioma, melanoma and testicular cancer.
43. A method for modulating growth of a cell population, wherein the method comprises contacting the binding agent according to any one of claims 1 - 34 or the pharmaceutical composition according to claim 35 with the cell population .
44. The method according to claim 43, wherein the cell population is a tumor cell population or a cancer cell population.
45. A method of treating and/or modulating the growth of and/or prophylaxis of tumor cells in humans or animals, wherein the binding agent according to any one of claims 1 - 34 or the pharmaceutical composition according to claim 35 is administered to a human or animal in an effective amount.
46. The method according to claim 45, wherein the tumor cells are selected from the group consisting of leukemia cells, lymphoma cells, breast cancer cells, prostate cancer cells, ovarian cancer cells, colorectal cancer cells, gastric cancer cells, squamous cancer cells, small-cell lung cancer cells, head-and-neck cancer cells, multidrug resistant cancer cells, and testicular cancer cells.
47. A binding agent comprising a sequence selected from the group consisting of SEQ ID NOs: 17, 36, 37 and 38.
48. A binding agent comprising the sequences set forth in SEQ ID NOs: 17 and SEQ ID NO: 12; or SEQ ID NOs: 17 and SEQ ID NO: 14; or SEQ ID NOs: 36 and 39; or SEQ ID NOs: 37 and 39; or SEQ ID NOs: 38 and 19.
49. The binding agent according to claim 47 or 48 further comprising a payload molecule.
50. A pharmaceutical composition comprising the binding agent according to any one of claims 47 - 49.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20145616 | 2014-06-25 | ||
FI20145616 | 2014-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015197919A1 true WO2015197919A1 (en) | 2015-12-30 |
Family
ID=53718028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2015/050466 WO2015197919A1 (en) | 2014-06-25 | 2015-06-24 | Antibody drug conjugates binding to high-mannose n-glycan |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015197919A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
WO2022049211A1 (en) * | 2020-09-02 | 2022-03-10 | Synaffix B.V. | Methods for the preparation of bioconjugates |
WO2022159413A1 (en) * | 2021-01-19 | 2022-07-28 | University Of Louisville Research Foundation, Inc. | Actinohivin variant polypeptides and related methods |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015769A1 (en) | 1993-12-08 | 1995-06-15 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
WO1997034632A1 (en) | 1996-03-20 | 1997-09-25 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
US5911989A (en) | 1995-04-19 | 1999-06-15 | Polynum Scientific Immunbiologische Forschung Gmbh | HIV-vaccines |
US20050003347A1 (en) | 2003-05-06 | 2005-01-06 | Daniel Calarese | Domain-exchanged binding molecules, methods of use and methods of production |
US20060022925A1 (en) | 2004-07-27 | 2006-02-02 | Seiko Epson Corporation | Grayscale voltage generation circuit, driver circuit, and electro-optical device |
US20060074008A1 (en) | 2002-07-31 | 2006-04-06 | Senter Peter D | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2011035205A2 (en) * | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
WO2014096551A1 (en) * | 2012-12-21 | 2014-06-26 | Glykos Finland Oy | Linker-payload molecule conjugates |
WO2014177771A1 (en) * | 2013-05-02 | 2014-11-06 | Glykos Finland Oy | Conjugates of a glycoprotein or a glycan with a toxic payload |
-
2015
- 2015-06-24 WO PCT/FI2015/050466 patent/WO2015197919A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
WO1995015769A1 (en) | 1993-12-08 | 1995-06-15 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
US5911989A (en) | 1995-04-19 | 1999-06-15 | Polynum Scientific Immunbiologische Forschung Gmbh | HIV-vaccines |
WO1997034632A1 (en) | 1996-03-20 | 1997-09-25 | Immunomedics, Inc. | Glycosylated humanized b-cell specific antibodies |
US20060074008A1 (en) | 2002-07-31 | 2006-04-06 | Senter Peter D | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US20050003347A1 (en) | 2003-05-06 | 2005-01-06 | Daniel Calarese | Domain-exchanged binding molecules, methods of use and methods of production |
US20060022925A1 (en) | 2004-07-27 | 2006-02-02 | Seiko Epson Corporation | Grayscale voltage generation circuit, driver circuit, and electro-optical device |
WO2011035205A2 (en) * | 2009-09-18 | 2011-03-24 | Calmune Corporation | Antibodies against candida, collections thereof and methods of use |
WO2014096551A1 (en) * | 2012-12-21 | 2014-06-26 | Glykos Finland Oy | Linker-payload molecule conjugates |
WO2014177771A1 (en) * | 2013-05-02 | 2014-11-06 | Glykos Finland Oy | Conjugates of a glycoprotein or a glycan with a toxic payload |
Non-Patent Citations (22)
Title |
---|
BAI ET AL., MOL. PHARMACOL., vol. 75, 2009, pages 218 - 26 |
BARBAS, BURTON, SCOTT & SILVERMAN;: "Phage Display: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
BUCHACHER ET AL., AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 10, no. 4, 1994, pages 359 - 369 |
CALARESE ET AL., SCIENCE, vol. 300, 2003, pages 2065 - 2071 |
CARBOHYDRATE RES., vol. 297, 1997, pages 1 |
CARBOHYDRATE RES., vol. 312, 1998, pages 167 |
CARTER ET AL., CANCER J., vol. 14, no. 3, 2008, pages 154 |
DOSIO ET AL., TOXINS, vol. 3, 2011, pages 848 - 883 |
DUCRY ET AL., BIOCONJUGATE CHEM., vol. 21, 2010, pages 5 - 13 |
EUR. J. BIOCHEM., vol. 257, 1998, pages 293 |
INT. J. ONCOL., vol. 15, 1999, pages 367 - 72 |
KONTERMANN RE: "Dual targeting strategies with bispecific antibodies", MABS, vol. 4, 2012, pages 182 - 197 |
LAURA M WALKER ET AL: "Broad neutralization coverage of HIV by multiple highly potent antibodies", vol. 477, no. 7365, 22 September 2011 (2011-09-22), pages 466 - 470, XP002711539, ISSN: 0028-0836, Retrieved from the Internet <URL:http://www.nature.com/nature/journal/v477/n7365/full/nature10373.html> [retrieved on 20110817], DOI: 10.1038/NATURE10373 * |
MOL. CANCER THER., vol. 3, 2004, pages 921 - 32 |
NEWSOM-DAVIS ET AL., CANCER RES., vol. 69, 2009, pages 2018 - 25 |
PETTIT, G.R. ET AL., J. NAT. PROD., vol. 74, 2011, pages 962 - 8 |
SAMMET ET AL., PHARM. PAT. ANALYST, vol. 1, no. 1, 2012, pages 2046 - 8954 |
SCHRAMA D ET AL: "Antibody targeted drugs as cancer therapeutics", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, GB, vol. 5, no. 2, 1 February 2006 (2006-02-01), pages 147 - 159, XP002566323, ISSN: 1474-1776, [retrieved on 20060120], DOI: 10.1038/NRD1957 * |
SENTER, CURRENT OPIN. CHEM. BIOL., vol. 13, 2009, pages 235 - 244 |
TRKOLA ET AL., JOURNAL OF VIROLOGY, vol. 70, no. 2, 1996, pages 1100 - 1108 |
VARKI, CUMMINGS, ESKO, FREEZE, STANLEY, BERTOZZI, HART & ETZLER;: "Essentials of Glycobiology, 2nd edition,", 2009, COLD SPRING HARBOR LABORATORY PRESS |
WALKER ET AL., NATURE, vol. 477, 2011, pages 466 - 471 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
WO2022049211A1 (en) * | 2020-09-02 | 2022-03-10 | Synaffix B.V. | Methods for the preparation of bioconjugates |
NL2026400B1 (en) * | 2020-09-02 | 2022-05-04 | Synaffix Bv | Methods for the preparation of bioconjugates |
WO2022159413A1 (en) * | 2021-01-19 | 2022-07-28 | University Of Louisville Research Foundation, Inc. | Actinohivin variant polypeptides and related methods |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210252158A1 (en) | Conjugates of a glycoprotein or a glycan with a toxic payload | |
US20200289662A1 (en) | Antibody-active agent conjugates and methods of use | |
US20210106689A1 (en) | Saccharide Derivative of a Toxic Payload and Antibody Conjugates Thereof | |
US20210106692A1 (en) | Payload-Polymer-Protein Conjugates | |
AU2020294201A1 (en) | Site-specific glycoengineering of targeting moieties | |
KR101854443B1 (en) | Anti-her2 antibody and conjugate thereof | |
KR20210038904A (en) | Effective method for preparing antibody-drug conjugates | |
EP2621954A1 (en) | Anti-rori antibodies | |
JP2020525404A (en) | Hydrophilic linker and conjugate thereof | |
AU2015243512A1 (en) | Site-specific antibody-drug glycoconjugates and methods | |
US20180028680A1 (en) | Glycooptimized antibody drug conjugates | |
WO2015197919A1 (en) | Antibody drug conjugates binding to high-mannose n-glycan | |
JP7276855B2 (en) | Anti-sulfated glycosaminoglycan antibody | |
AU2009270181A1 (en) | Pharmaceutical composition for treatment and prevention of cancer | |
EP2470569A1 (en) | Antibodies against epha10 | |
JP2019206491A (en) | Antibody-drug complex for treatment of breast or gastric cancer | |
CN111132697A (en) | Pharmaceutical combination comprising anti-BST-1 antibodies and cytidine analogs | |
WO2023141855A1 (en) | Protein conjugates with multiple payloads and methods for making the same | |
WO2012012141A1 (en) | Scnn1a/tnfrsf1a fusion proteins in cancer | |
TW202333798A (en) | Antibody-drug conjugate targeting claudin 18.2 | |
Martin Killias | Designed ankyrin repeat proteins for targeted cancer therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15741234 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15741234 Country of ref document: EP Kind code of ref document: A1 |